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The cyclical disorder of mental and physical state known as
premenstrual tension or the premenstrual syndrome poses a considerable
management problem. Clinical trials involving various approaches to
therapy have yielded conflicting and largely negative results. There
is confusion in the literature about the exact definition and nature
of the problem. In the initial chapter of this thesis, the current
state of our knowledge of menstrual cycle symptomatology is reviewed,
examining the extent to which cyclical variations in mental and
physical symptoms should be regarded as normal and the factors
influencing their presence and severity. The different methods used
for measurement of mood and physical symptoms are described, together
with the methods selected for use in this thesis.
The initial study was a prospective assessment of 100 women who
presented with problems attributed to premenstrual tension. It
revealed that the physical symptoms of breast discomfort and swelling
were closely related to menstrual cycle phase in the majority of the
women. However the psychological symptoms were confined to the
premenstrual phase in only only one third of the group, being present
to a variable degree throughout the cycle in the remainder. In almost
half the women, they were maximal during menstruation. Those women
whose mental symptoms were incompletely relieved following
menstruation were significantly more likely to have a history of past
psychiatric problems or marital breakdown than those with substantial
postmenstrual relief. A classification of menstrual cycle related
mood disorders is proposed as a basis for clinical management and
further research.
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In the next section, the relationship between endogenous and exogenous
ovarian steroids, mood and physical symptoms is reviewed. There is no
convincing evidence to support an underlying disorder of ovarian
function in women with premenstrual tension. Studies with oral
contraceptive steroids have shown these to have no adverse effect on
mood, except in women with a past history of such problems. Overall,
they show a damping down effect on cyclical symptoms, suggesting that
ovulation suppression may be an appropriate therapy for premenstrual
tension. The second study tests this theory using two synthetic
progestogens, norethisterone (NET) and medroxyprogesterone acetate
(MPA), each compared with placebo, to suppress ovulation. MPA was
more effective than placebo in the relief of breast discomfort but
neither progestogen significantly improved the psychological
symptoms.
The third study explores the effect of a new synthetic agonist
analogue of LHRH, goserelin (Zoladex). Inhibition of pituitary-
ovarian activity and menstruation was associated with relief of
physical symptoms and significant but not complete, suppression of
mental symptoms. However return of ovulatory menstruation after
completion of therapy was associated with a prompt recurrence of
symptoms, supporting a link between these endocrine changes and mood.
In a final pilot study, a new oral opiate antagonist, nalmefene,
modified cyclical symptoms without altering plasma ovarian steroid
concentrations. The role of endogenous opioids and other central
neurotransmitters in the aetiology of the mental symptoms of
premenstrual tension is discussed.
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MOOD. PHYSICAL CHANGES AND THE MENSTRUAL CYCLE - LITERATURE REVIEW
1.1 - Introduction
From adolescence to middle age, women experience a regularly recurring
monthly sequence of hormonal and physical changes which comprise the
menstrual cycle. Menstruation is associated with the potential of
fertility as well as the reassurance or disappointment that conception
has not occurred. It is also a cause of physical discomfort and
inconvenience and, in some women, of morbidity which significantly
disrupts their social and professional lives. Negative aspects of the
menstrual cycle are not confined to menstruation itself. Physical
discomforts such as headaches and pelvic pain are frequently present
premenstrually and feelings of anticipation may be associated with the
lead up to menstruation with relief once the 'bad time' is over.
Mental and physical well-being may also be directly influenced by the
hormonal changes which underlie menstrual cyclicity.
It is unclear to what extent these various factors normally influence
mood and emotions and the way in which women cope with their day to
day lives. Women commonly seek medical help with problems related to
the menstrual cycle and in addition to menstrual disorders such as
excessive bleeding and pain, the premenstrual phase of the cycle has
become specifically associated with a group of adverse mental and
physical symptoms known as premenstrual tension or the premenstrual
tension syndrome.
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It is the problem of premenstrual tension which is the central theme
of this thesis. In this introductory chapter, the state of our
current knowledge will be reviewed, highlighting the deficiencies in
our understanding of the definition of the syndrome, its prevalence,
the extent to which cyclical fluctuation in mood and physical symptoms
is a normal phenomenon and possible influencing factors. Methods
currently used in the assessment and measurement of mood will be
discussed. Firstly the endocrine changes underlying menstrual
cyclicity will be described.
1.2 - The endocrine control of the menstrual cycle
The menstrual cycle is the consequence of a sequence of endocrine
events involving complex interactions between the ovaries, anterior
pituitary and hypothalamus. Cyclical production of ovarian steroid
hormones is under 'feedback' control by the anterior pituitary and
modulated by the hypothalamus. In turn, ovarian steroids exert
effects on target organs, in particular the uterus. As a basic
understanding of the mechanisms involved is fundamental to many of the
topics covered in this thesis, they will be briefly described below.
The literature on the subject is extensive and references will be
confined to a few recent reviews.
1.2.1 - The ovary and its steroid production
Reviews of ovarian follicular development and its regulation include
those by Baird (1983) and Erickson (1986). The ovary contains a very
large pool of follicles, several of which are able to respond to
rising levels of circulating follicle stimulating hormone (FSH) at the
onset of each menstrual cycle, resulting in their rapid growth and
9
development. Under normal circumstances the growth of a single
follicle predominates from about day seven of the cycle, the remainder
undergoing atresia (figure 1.2). The developing follicle comprises
the oocyte surrounded by granulosa cells which secrete fluid into a
central cavity, the antrum, and a compact layer of surrounding stromal
cells, the theca interna which is separated from the granulosa cells
by a basement membrane.
The principal ovarian steroid secreted by the developing follicle is
oestradiol, produced by the granulosa cells from androgenic
precursors, mainly androstenedione, synthesised in the thecal cells
(figure 1.1). Aromatisation of androgens to oestrogen is stimulated
by FSH but androgen production is dependent on the presence of
luteinising hormone (LH). FSH stimulated growth of the dominant
follicle is accompanied by the development of LH receptors on the
granulosa cells in preparation for the preovulatory LH surge. Rapidly
rising levels of circulating oestradiol initiates this LH surge by
'positive' feedback, following which the mature follicle ruptures,
releasing the oocyte.
Ovulation with extrusion of the oocyte is followed by collapse of the
follicle, loss of the basement membrane and invasion of the granulosa
layer by blood vessels to produce the so-called corpus luteum.
Cellular aspects of corpus luteum function have been reviewed by
Hillier & Wickings (1985). Production of the other principal ovarian
steroid, progesterone, increases rapidly after ovulation although
levels rise slightly prior to this in parallel with the LH surge.
Following ovulation, progesterone is secreted by the granulosa-lutein
10
Figure 1.1 - Structure and biosynthesis of ovarian steroids
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cells of the corpus luteum. This is accompanied by a parallel
secondary rise in oestradiol secretion, again derived from androgens
produced in theca-lutein cells. Steroid production from the corpus
luteum is dependent on the presence of LH and to a lesser extent FSH.
If conception does not occur, the corpus luteum regresses after 14
days, with a rapid fall in oestrogen and progesterone and this in turn
triggers a rise in pituitary FSH, and to a lesser extent LH secretion
by 'negative feedback' to initiate development of a fresh crop of
ovarian follicles. The function of the corpus luteum is thought to be
largely determined by the events preceding ovulation and various
luteal phase 'defects' have been described (Jones, 1976) although
their precise cause and significance remain to be determined.
1.2.2 - Hypothalamic control of the menstrual cycle
This subject has been reviewed by Bennett & Whitehead (1983) and
Reichlin (1985). Gonadotrophin secretion and release is dependent on
stimulation by a hypothalamic releasing factor, luteinising hormone
releasing hormone (LHRH) also called gonadotrophin releasing hormone
(GnRH) which is responsible for the initiation of pituitary-ovarian
activity at puberty and exerts a modulating effect throughout
reproductive life. This hypothalamic neurohormone is released into
the hypophyseal portal vessels from neurosecretory cells which
terminate in the median eminence (tuberoinfundibular system). Release
of LHRH is characteristically pulsatile, the rate and amplitude of the
pulses in part determining the pituitary response. Pituitary
secretion of FSH and LH is also pulsatile, their relative proportions
and pulsatile pattern varying throughout the menstrual cycle. Pulse





































































































































































phase, both progressively rising during the follicular phase to reach
a maximum prior to ovulation.
The feedback effects of circulating ovarian steroids are exerted at
the level of both the anterior pituitary and the hypothalamus,
modulating the response of the anterior pituitary to LHRH as well as
altering the frequency and amplitude of LHRH pulses. The rapidly
rising oestrogen levels in the late follicular phase stimulate
frequent high amplitude pulses of LHRH while increasing the
sensitivity of the anterior pituitary to this stimulus, resulting in
the initiation of the LH surge (figure 1.2). Falling levels in the
late luteal phase result in low amplitude pulses which favour FSH
secretion. Selective suppression of the latter in favour of LH as the
follicular phase advances may be in part due to the effect of inhibin,
a gonadal peptide secreted by the developing follicle although the
exact mechanisms remain to be clarified.
Various hypothalamic neurotransmitters, in particular dopamine and
noradrenaline may be involved as mediators in the control of LHRH
secretion. In addition, direct neural regulation may play an
important role via connections with the mid brain, forebrain and
limbic system. This is important in various animal species where
environmental factors, for example light, control patterns of oestrus.
Stress is known to influence ovarian cyclicity in humans and may act
via noradrenergic neurones arising from the locus coeruleus of the mid
brain. The possible role of endogenous opioid peptides in the
modulation of hypothalamic LHRH release is discussed in chapter 7.
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1.2.3 - Menstruation and its control
The histological changes which take place in the endometrium in
relation to changing steroid levels are well known although the
mechanisms underlying menstrual bleeding and its disorders have yet to
be fully clarified (Abel, 1985; Smith et al, 1985). Withdrawal of
steroids in the late luteal phase of the cycle results in shrinkage of
the endometrium with increased coiling of its spiral arterioles.
Resulting vascular stasis is then followed by a period of intense
vasoconstriction and finally by relaxation and active bleeding. It
has been proposed that prostaglandins produced locally are responsible
for the initiation and control of menstruation. Endometrium produces
mainly PGF2a and PGE2 although the former predominates in secretory
endometrium, being a powerful vasoconstrictor while the latter acts as
a vasodilator. Release of arachadonic acid, the main precursor of
prostaglandins occurs during the phase of vascular stasis and tissue
ischaemia. Resulting synthesis and release of PGF2a may be the factor
responsible for the vasoconstriction mentioned above and also for the
more intense myometrial contractions which characteristically occur at
the onset of menstruation (spasmodic dysmenorrhoea). Prostacyclin
(PGI2) is synthesised only by myometrium but acts as a vasodilator and
prevents platelet aggregation and it is possible that it is also
involved in the control of menstrual blood loss, acting together with
PGE2 to counterbalance the vasoconstrictive effect of PGF2a.
1.2.4 - Hormonal manipulation of the cycle
Understanding of the control of the menstrual cycle has led to the
development of synthetic steroids for use in contraception and for
management of menstrual and other gynaecological disorders.
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Oestrogen-progestogen combinations or high doses of progestogen alone
will inhibit follicular development and ovulation through negative
feedback. More recently, synthetic analogues of LHRH have been used
to suppress ovarian cyclicity by inhibition of gonadotrophin secretion
(see chapter 5).
1.2.5 - Steroid hormones and the central nervous system
Oestrogens, like testosterone, are transported in the circulation
bound to sex-hormone binding globulin (SHBG) (Anderson, 1974), while
progesterone binds to cortisol-binding globulin. Only the unbound
steroid is biologically active and an equilibrium exists between free
and bound steroid. Steroid hormones are lipid soluble and readily
cross the blood-brain barrier where they act via specific receptors in
the central nervous system. In addition to their feedback control of
gonadotrophin and LHRH secretion they influence sexual differentiation
and play an important role in the control of sexual behaviour in
animal species. Observations of mood change in relation to the
menstrual cycle, childbirth, the menopause and oral contraceptive
therapy in women suggest that ovarian steroids have direct behavioural
effects although interpretation is made difficult because of the
profound influence of learning and social conditioning. Possible
endocrine mechanisms underlying disorders of mood related to the
menstrual cycle and the response to hormonal manipulation will be
considered in detail in later chapters of this thesis. Firstly the
nature and prevalence of such problems will be reviewed, followed by a
brief consideration of some of the physiological changes associated
with the menstrual cycle and their relevance to symptomatology.
16
1.3 - The definition of premenstrual tension
The concept of psychological morbidity related to the menstrual cycle
is not new but a distinct pathological condition described as
'premenstrual tension' was first described in the medical literature
by Frank in 1931. He described fifteen women in whom 'grave systemic
disorders manifest themselves predominantly during the premenstrual
period'. Dramatic relief was seen within a few hours of the onset of
the menstrual flow. Israel (1938) described a further 14 cases, also
emphasising 'the sensation of indescribable tension, marked physical
unrest and constant irritability'. Both these authors referred to the
minor but unpleasant symptoms experienced by many women prior to
menstruation but made a clear distinction between these and the much
more extreme personality changes exhibited by those who suffered
symptoms of premenstrual tension.
Since then, the concept of premenstrual tension has been widened to
encompass a large cluster of adverse mental and physical symptoms
covered by the term 'premenstrual syndrome'. Greene & Dalton (1953)
published the first report based on British women. In an analysis of
84 cases, the commonest symptom was headache followed in decreasing
frequency by skin and mucosal changes, arthralgia, exacerbations of
asthma and epilepsy, nausea, irritability and depression, the latter
present ,in only two percent of the women. This is a rather different
picture from the descriptions of tension, depression, irritability,
abdominal bloating, nausea, appetite changes and breast discomfort
which have been characteristic of most of the later reports (e.g.
Rees, 1953; Dalton, 1977; Sutherland & Stewart, 1965; Coppen & Kessel,
1963; Sampson & Jenner, 1977). Moos (1968) devised a list of 47
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symptoms which he tested out on 839 healthy subjects, deriving eight
separate intercorrelated symptom clusters by factor analysis. These
symptom clusters, and the 'Menstrual Distress Questionnaire' which he
devised on the basis of these results have been used extensively in
subsequent research into the subject.
Most recent authors agree that it is the relationship of the symptoms
to menstruation, rather than the symptoms themselves, which are
critical to the diagnosis of the premenstrual syndrome. However,
beyond this there is lack of consensus. Dalton (1977) who has written
extensively on the subject, but performed no controlled studies, has
described three symptom patterns. Symptoms may be present only
premenstrually or may build up gradually from the time of ovulation.
In a third pattern, symptoms may be present around the time of
ovulation and then again premenstrually. In all three groups, symptom
relief should occur during menstruation, with a symptom-free spell of
at least a week thereafter. Reid & Yen (1981) agree with her
definition but recognise a fourth pattern where symptoms extend into
menstruation, gradually resolving towards its end. Kerr et al (1980)
state that subjects should be symptom free within 48 hours of the
onset of menstruation and O'Brien (1982) also maintains that symptoms
around ovulation and continuing into the early part of menstruation
are not indicative of the premenstrual syndrome. Dennerstein et al
(1984) distinguish between women with a discrete premenstrual
syndrome, relieved during menstruation and followed by a completely
symptom-free week and those with symptoms present throughout the
cycle, associated with diagnosable psychiatric problems. She
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identifies the latter group as suffering from 'menstrual distress'; a
term also used by Dalton (1977).
Sampson & Prescott (1981) favour a looser definition of "changes in
mood, behaviour and physical symptoms in relation to the menstrual
cycle, usually with an increase in intensity premenstrually and
diminution in intensity with the onset of menstruation". Magos &
Studd (1984) also believe that a distinction cannot be made between
symptoms confined to the premenstrual phase and those which are an
exacerbation of chronic problems present throughout the cycle, as
there is no evidence that the two have a different aetiology.
However, "a distinction should be made from premenstrual symptoms that
are not considered abnormal or distressing and are experienced by most
women".
Halbreich et al (1985) also prefer the concept of 'premenstrual
change' and define this as cyclic recurrent change in intensity of
symptoms from the second week of the menstrual cycle compared with the
peak intensity during the luteal phase. However they define a
minimal level of symptomatology which should exist postmenstrually.
Rubinow & Roy Byrne (1984) use the term 'menstrually-related mood
disorder' and are critical of past approaches to the problem, in
particular of the methods used for their evaluation.
1.4 - The prevalence of premenstrual complaints
Against this background of confusion about the basic definition of the
problem, a few workers have attempted to quantify its extent by
surveys of the prevalence of premenstrual problems in various
19
populations of women of reproductive age. One of the earliest was
reported by Pennington (1957). Her sample of 1000 American women was
largely composed of high school and college graduates. 95% had at
some time experienced menstrually-related symptoms, most commonly
dysmenorrhoea, although 72% had experienced mixed psychological and
somatic symptoms with 'nervousness' and irritability in around 40%.
In her paper, Pennington made no distinction between symptoms which
were largely premenstrual and those related to the menstrual phase of
the cycle while Sutherland & Stewart (1965) asking specifically about
premenstrual symptoms, surveyed 150 students and student nurses in
Glasgow. They found that 59% reported premenstrual irritability, 53%
premenstrual depression and 63% a sensation of 'swelling', with a
triad of all three in 39%.
Both the latter studies were based on biased population groups and
make no attempt to distinguish between mild and severe symptoms.
Coppen & Kessel (1963) overcame both these problems in their study of
a random sample of 500 women from 10 English general practices. The
women were asked to rate each symptom retrospectively on a simple
four-point scale. Moderately severe symptoms of irritability, tension
and/or depression were reported by 20% of the women with severe
symptoms in around 9%, although swelling of any degree was reported by
72% of the sample. These symptoms were reported by the women to be
present premenstrually and relieved during menstruation. They were
distinct from menstrual dysmenorrhoea, present to a moderate degree in
one third of the women although an association between the two
complaints was apparent.
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More recently, two large studies have been based in Scandinavia.
Widholm (1985) surveyed 5000 adolescents and their mothers by
questionnaire and reported that 68% of 5000 daughters had experienced
premenstrual tension, with a prevalence of 75% among 1400 mothers. He
found an association between premenstrual tension and dysmenorrhoea in
42% of the daughters and 62% of the mothers with a highly significant
association between these complaints in mother-daughter pairs,
suggesting either a genetic influence or an effect of familial
conditioning. He also surveyed 865 women from three different
professional groups and found that 88% overall reported premenstrual
tension, with no differences between the groups. Around 40% of each
group also complained of dysmenorrhoea. The severity of the symptoms
was not assessed but their mean duration was 4 days.
Andersch et al (1986) surveyed a random sample of 1000 women in the
Swedish city of Goteborg, concentrating on premenstrual complaints and
using a descriptive self-rating scale in an attempt to assess symptom
severity. Again symptom prevalence was high, with 92% reporting at
least one premenstrual change and 72% a combination of mental symptoms
and body swelling. With the exception of anxiety, symptoms were not
age-related. Only 3% classified their symptoms as severe and 11%
expressed a wish to seek medical help.
This extremely high prevalence of premenstrual problems suggests that
the surveys are detecting a normal phenomenon, with severe problems in
no more than 10 percent of women. This raises the question of whether
we are seeing a normally distributed spectrum of problems, or whether
there is in fact a discrete pathological entity with a separate
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causation. However, there are methodological criticisms that are
relevant to the interpretation of the results of these surveys.
Firstly, the premenstrual phase of the cycle was being studied in
isolation from the remainder of the cycle with assumptions that
symptoms were confined to this phase. Moos (1969) found that women
who had high premenstrual scores on his menstrual distress
questionnaire also tended to score highly during other phases of the
cycle. The association between premenstrual tension and menstrual
dysmenorrhoea found in some of these studies raises questions about
the extent to which they may be inter-related although they are
traditionally regarded as being entirely separate. Secondly, the
conclusions of the above surveys were based entirely on the results of
single questionnaires. As discussed later (section 1.9.3), such
results can be misleading. Detailed prospective studies of large
numbers of randomly selected women pose considerable methodological
difficulties but a number of small detailed studies have been reported
and will be discussed below.
1.5 - Normal cyclical variation in mental and physical well-being
There have been a number of prospective studies of menstrual cycle
symptomatology in groups of volunteer subjects. Dennerstein and
Burrows (1979) and Sanders (1981) have reviewed 33 such studies in
detail, 16 of which were examined by both authors. The numbers of
subjects ranged from 2 to 172 (median 20) and the majority (28) were
evaluated over one or two cycles. Only 13 of the studies were based
on daily self-assessment, the remainder using evaluations made at
intervals during the cycle. The methods used varied considerably (see
section 1.9), including the Menstrual Distress Questionnaire, mood
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Table 1.1 - SUMMARY OF PROSPECTIVE STUDIES OF CYCLICAL CHANGE
(From DennersteLn & Burrows, 1979; Sanders, 1981)
Studies reviewed
Median number of subjects
Nature of assessment:












No overall change 4/26
Adverse premenstrual change 22/26
Adverse menstrual change 6/19
Adverse follicular phase change 2/20
Adverse midcycle change 2/26
Positive midcycle change 11/26
b) Physical symptoms:




No overall change 4/5
Improved during luteal phase 1/5
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adjective check lists, verbal anxiety scales, content analysis of
speech, psychoanalysis of dreams and various objective performance
tests. Thus the results may not be strictly comparable. Rather than
repeat in detail the results of these studies which were very clearly
and concisely summarised and tabulated by both the above authors,
their overall conclusions are shown in table 1.1. Excluding the study
with only two subjects, mood was evaluated in 26 of the 32 studies and
only four studies demonstrated no cyclical changes. Adverse changes
were identified premenstrually in 22 of the studies and during
menstruation in six although menstrual evaluation was not invariably
performed. Adverse symptoms at mid cycle were only reported by two
authors but a peak in positive moods or a significant trough in
negative symptoms was reported by 11 groups; positive symptoms
including elation, euphoria, assertiveness and competitiveness. Two
groups reported negative symptom peaks during the follicular phase.
Of the 9 studies which included assessment of physical symptoms,
including pain, headache, breast discomfort and swelling, the majority
found symptoms to peak premenstrually and during menstruation (table
1). Five additional studies were based entirely on objective
performance tests, evaluating either motor or intellectual performance
or a combination of both. Four of the five showed no cyclical
variations and the fifth paradoxically found reaction and calculation
time to be lowest during the luteal phase compared with other cycle
phases. A recent study (Posthuma et al, 1987) identified no phase-
related differences in motor performance in a group of carefully
selected control subjects, while women screened for PMT showed some
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premenstrual functional impairment in only one of the four tests (the
one demanding finest coordination and balance).
1.6 - Sources of bias in menstrual cycle research
The results of these studies confirm the presence of cyclical
variation in physical symptoms, particularly swelling and breast
discomfort. There is also evidence for cyclical changes in mood,
although not all the authors have confirmed this. The reasons for the
discrepancies may in part be methodological, as many different methods
of assessment have been used. In addition, there are differences in
the subjects selected for study. Common recruits are students,
particularly psychology students or student nurses, with bias towards
the younger age groups. The subjects have to be willing to comply
with the demands of the protocol, which are fairly intensive. There
are other sources of bias, for example excluding women on oral
contraceptives or screening out those with psychological problems.
The study reported by Abplanalp et al (1979) positively screened for
'normality' and found no significant cyclical differences apart from a
menstrual peak in anxiety and tension. On the other hand, studies
based on volunteers may tend to attract those with an interest in
menstrual cycle problems, perhaps because they themselves experience
symptoms, as shown by the results of Sanders et al (1983) who
recruited subjects for 'a research project on the menstrual cycle'.
Of 44 volunteers, 21 were found to have significant changes in mood
and physical symptoms. Some data on so-called normal controls was
presented by Dennerstein (personal communication, 1985). Daily mood
profiles from women who volunteered because of absence of premenstrual
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problems showed a marked peak of negative affect during the
postmenstrual phase of the cycle.
Two interesting studies have emphasised other sources of bias in the
assessment of menstrual cycle symptoms. Ruble (1977) studied two
groups of women who were told that the date of menstruation could be
predicted from the result of an EEG and were thereby deliberately
misled about the time when their next period was due. Ratings of
premenstrual-type symptoms were significantly higher in the group who
were told menstruation was due within the next couple of days,
compared with those who were led to believe it was due in 7 to 10
days. The actual timing of menstruation did not significantly differ
between the two groups. In a recent study, Olasov & Jackson (1987)
compared daily symptom ratings over 40 days in a group of psychology
students who had been shown a pre-recorded lecture emphasising the
negative aspects of menstruation and mood change, with a group shown a
lecture stating the case against any relationship between mood and the
menstrual cycle. There were significant differences between the
results; the group who saw the negative aspects lecture having
significantly higher negative symptom scores both premenstrually and
menstrually.
Studies in which the subjects are blind to the true objective of the
investigation may be more likely to yield meaningful results than
those in which the subjects are fully aware. Those of Wilcoxon et al
(1976) and Slade (1984) concealed the purpose of the study and both
confirmed cyclical variations in physical but not in mental symptom,
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any apparent relationship of the latter to menstrual cycle phase being
accounted for in Wilcoxon's study by coincidental stressful events.
Another group in whom awareness of menstrual cycle phase may be absent
are women who have undergone hysterectomy with conservation of the
ovaries. Backstrom et al (1981) monitored seven such women by daily
visual analogue scales for one month prior to and two months following
hysterectomy. All had complained of cyclical symptoms prior to
surgery but five of the seven were unaware of such changes afterwards.
However daily ratings revealed continuing 'premenstrual symptoms',
although significantly reduced in magnitude compared with preoperative
records. Beaumont et al (1975) studied women who had undergone
hysterectomy in the past, also monitoring symptoms and steroid
profiles daily. Here the differences did not reach significance but
there was a trend towards higher scores in the late luteal phase.
These women had been selected at random and their past history
regarding cyclical problems was not stated. However such results do
tend to throw some doubt on the theory that cycle-related symptoms are
purely a result of expectation and conditioning.
The results of the above studies emphasise the complexity of the
relationship between mood and the menstrual cycle. They also raise
the question of the extent to which conditioning, personality and
environmental factors influence such changes, and in particular, the
tendency to complain about them. Some authors have examined these
areas and they will be discussed in the next section.
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1.7 - Premenstrual change, personality and psychiatric disorder
In their large, randomised study of women selected from various
general practices, Coppen & Kessel (1963) investigated not only the
presence of cycle-related symptoms but also personality, as assessed
by the Maudsley Personality Inventory. They found the reporting of
premenstrual psychological symptoms and also headaches and swelling to
be significantly correlated with a high score for neuroticism. The
only symptom unrelated to neuroticism was menstrual dysmenorrhoea.
James & Pollitt (1974) also examined the relationship between
premenstrual symptoms and personality, but in women recruited from a
psychiatric clinic. Their finding of a significant correlation
between premenstrual symptoms and personality extremes of
obscessionality or hysteria may thus be biased by the population under
study. Clare (1979) examined women selected at random from general
practice, using the Moos Menstrual Distress questionnaire (MDQ) to
assess premenstrual complaints and the General Health Questionnaire
(GHQ) for psychiatric morbidity. Seventy five percent of the women
scored positively on the MDQ, and had an even chance of a positive
score on the GHQ. However, 87% of those scoring positively on the GHQ
had a positive MDQ score and reported significantly more premenstrual
symptoms, especially depression, irritability, tension, fatigue and
anxiety than the GHQ negative women. Breast symptoms did not differ
between the two groups. He also studied 170 women attending a
premenstrual tension clinic and found a similar distribution of GHQ
scores as in the normal population sample.
This relationship between psychiatric morbidity and premenstrual
complaints has been demonstrated by other authors. Coppen (1965)
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compared groups of patients attending a psychiatric clinic, with
general practice controls and found a raised prevalence of menstrual
problems in general among those classified as suffering from neurosis,
with high scores for dysmenorrhoea, dyspareunia, and premenstrual
problems. There was however a reduced prevalence among
schizophrenics. Of those with affective disorders, only those of a
depressive type were associated with a raised prevalence of menstrual
problems. Other authors have also found a relationship between
premenstrual problems and affective disorders in general (Wetzel et
al, 1975; Endicott et al, 1981) to the extent that these authors use
the term 'premenstrual affective disorder'. As assessments were
interview-based, these studies may merely be showing a premenstrual or
indeed menstrual, exacerbation of the underlying affective disorder as
no information is available about the extent to which they were
present during the remainder of the cycle. With the exception of
acute schizophrenic crises (Abramowitz et al, 1982), an excess of
acute psychiatric admissions has been shown to occur premenstrually
(Glass et al, 1971; Diamond et al, 1976; Abramowitz et al, 1982) and
menstrually (Janowsky et al, 1979; Abramowitz et al, 1982). However,
a recent report of the timing of suicide attempts (Fourestie et al,
1986), related these to the menstrual phase of the cycle with the
lowest incidence during the luteal phase.
These observations about the relationship between cycle phase and
psychiatric disorders are of interest but assumptions cannot be made
about women who complain of premenstrual symptoms in general. Like
Clare (1979), Rees (1953) had found that many women reporting marked
symptoms of premenstrual tension were of stable personality while many
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severely neurotic women had no such complaints. However, in women
classified as neurotic, a correlation was found between the degree of
premenstrual tension and the severity of the neurosis. Wendestam
(1980) also found a range of personality types in a study of 40 women
diagnosed as suffering from the premenstrual syndrome. He compared
them with a group selected for absence of premenstrual complaints,
with a 'normal population' group and with a group of women with
clinically diagnosed neurosis. The neuroticism scores of the women
classified as sufferers from the premenstrual syndrome were similar in
distribution to the normal population but higher than the group
selected for absence of premenstrual symptoms, who were younger and
less parous than the PMS group.
Not only personality but also social conditioning may alter perception
of menstrual cycle changes, as mentioned in section 1.6. In a sample
of 255 women, Paulson (1961) found those who had high scores for
premenstrual tension, had more disturbed family relationships,
psychosexual problems and negative attitudes to the menarche and
menstruation. However 72% of the group as a whole were unmarried and
thus it may be a biased population sample. Wood et al (1969b) found
women with premenstrual complaints to have a higher incidence of
marital difficulties, dissatisfaction with work and psychosexual
problems compared with non-complainers, although the women on whom
these conclusions were based were a self-selected sample who attended
a health screening clinic (Wood et al, 1969a). Watts et al (1980)
compared 25 women who had been carefully selected for the presence of
premenstrual symptoms with 23 control subjects and found significantly
higher neuroticism scores among the former group, as assessed by the
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Eysenck Personality Inventory. They also showed more negative
attitudes to sex, masturbation and the genital organs. Attitudes to
menstruation, childbearing and child rearing did not differ between
the two groups.
Despite the evidence from these studies, not all authors would agree
that there is an association between personality, psychiatric
morbidity and premenstrual and menstrual problems. Reid & Yen (1981)
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feel there is little evidence to support psychosomatic dysfunction in
women with premenstrual tension. However, they use strict criteria
for the diagnosis of the latter (section 1.3). Gannon (1981) draws
attention to the similarities between items on menstrual distress
questionnaires and standardised personality tests. In other words,
symptoms which are truly menstrual cycle-related may be scoring on the
personality inventories. The converse argument is of course true, as
a neurotic individual is likely to give positive answers for many of
the adverse menstrual symptoms. This emphasises the importance of
prospective daily assessments before reaching conclusions about the
relationship of symptoms to menstrual cycle phase.
The overall impression from this extensive literature is that the
majority of women report adverse symptoms prior to or during
menstruation (e.g. results of surveys by Pennington (1957) and
Andersch (1986)). However, most women do not regard these changes as
abnormal and it is apparent that the reported intensity of such
symptoms or the tendency to complain about them is influenced by a
number of factors, in particular social conditioning and personality.
It is still not clear whether women classified in the literature as
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'premenstrual tension' or 'premenstrual syndrome' sufferers do in fact
suffer from a discrete disorder or whether their symptoms should be
regarded as a pathologically exaggerated response to normal cyclical
changes. The attempts to find an underlying endocrinological cause
are covered in the next sections of this chapter and in chapter 3.
1.8 - Physiological changes during the menstrual cycle and their
relevance to symptomatology
1.8.1 - Glucose tolerance and the menstrual cycle
The frequent reports of food cravings and other symptoms attributed to
hypoglycaemia in association with adverse premenstrual symptoms led to
the hypothesis that the symptom complex is attributable to a
premenstrual impairment of glucose tolerance (Morton, 1950; Morton et
al, 1953). The same author reported increased glucose tolerance in
women tested premenstrually and during menstruation but did not
distinguish between those who were symptomatic and asymptomatic.
Later studies have produced inconsistent results, for example Jarrett
& Graver (1968) found cycle related differences in oral glucose
tolerance while Spellacy et al (1967) reported no such differences
with intravenous tests. These authors did not select women on the
basis of adverse symptoms. In a more recent study comparing
symptomatic women with normal controls, Reid et al (1986) found no
difference in oral glucose tolerance between the two groups or between
the follicular and luteal phases. However the group complaining of
premenstrual symptoms including 'hypoglycaemia' reported hypoglycaemic
symptoms during the course of the OGGT in both cycle phases, although
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their blood sugar levels remained well within the normal range
throughout the course of the tests! The same authors point out that
many of the earlier studies did not adequately control for dietary
alterations which may have been related to the menstrual cycle, for
example binge eating indulged in by many women premenstrually. The
physiological changes, if any, underlying the latter problem remain
unexplained but such eating habits may contribute to sensations of
abdominal fullness and bloating and may in part explain the poor
correlation between symptoms frequently attributed to fluid retention
and objective assessment of the latter (see below).
1.8.2 - Fluid and electrolyte balance
The role of abnormalities of fluid and electrolyte metabolism in the
aetiology of premenstrual symptomatology remains a subject of
controversy. Swelling, peripheral oedema, abdominal bloating and
generalised oedema have all been reported in association with other
clinical features of severe premenstrual tension (Frank, 1931;
Sweeney, 1934; Rees, 1953), leading to the assumption that fluid
retention was the major aetiological factor (Sweeney, 1934; Greenhill
& Freed, 1941; Bickers, 1952). Similar symptoms are also frequently
reported by normal women during the premenstrual phase of the cycle
(see section 1.5). A number of studies based on daily weighing of
volunteer subjects have demonstrated net weight gain premenstrually,
interpreted as indicative of fluid retention (Thorn et al, 1938;
Abramson & Torghele, 1961; Watson & Robinson, 1965). The latter two
authors also reported a small peak at the time of ovulation, when
adverse symptoms are characteristically minimal (section 1.5). A link
between the degree of premenstrual weight gain and the magnitude of
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adverse premenstrual symptoms was reported by Abramson & Torghele
(1961) while others have failed to find a relationship between weight
gain and overall symptomatology (Thorn et al (1938); Appleby, 1960;
Bruce & Russell, 1962; Reeves et al, 1971). Indeed, Golub et al
(1965) were unable to demonstrate any premenstrual weight gain in a
group of college girls, many of whom complained of premenstrual
swelling. One source of confusion in the literature is the use of
terms such as swelling, oedema, bloating, and water retention to
describe what are entirely subjective sensations of discomfort. The
assumption that they are indicative of 'fluid retention' may
frequently be erroneous. As mentioned above, abdominal bloating,
which is a very common premenstrual complaint, may be attributable to
other factors.
Detailed studies of fluid and electrolyte balance have also yielded
conflicting results. Bruce & Russell (1962) reported premenstrual
retention of sodium and water in both control and symptomatic subjects
while Klein & Carey (1957), Michelakis et al (1971) and O'Brien et al
(1980) failed to demonstrate significant cycle related differences.
In the studies of Andersch et al (1978), no overall differences in
total body water were apparent between cycle phases in control or
symptomatic subjects although late luteal phase water/potassium ratio
was significantly elevated in the symptomatic women, suggesting a
shift of fluid from the intravascular to the extravascular
compartments. Observations of changes in capillary permeability
during the menstrual cycle were first made by Petersen & Milles (1926)
and more recently Wong et al (1972) reported significant changes in
capillary filtration coefficient during the luteal phase in
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symptomatic compared with non symptomatic women, indicating a transfer
of fluid from intravascular to extravascular compartment in the former
group. Jones et al (1966) also demonstrated increased permeability of
the capillary walls to proteins during the luteal phase of the cycle
in a group of volunteer women but with no correlation between symptom
severity and degree of capillary permeability.
In summary, these studies suggest that changes in fluid and
electrolyte balance occur during the menstrual cycle with associated
fluid shifts between vascular compartments and perhaps a small net
premenstrual fluid gain. However the relationship between these
changes and premenstrual symptomatology is unclear and does not
provide a convincing explanation for their diverse nature, even in
cases where symptoms possibly attributable to fluid retention
predominate.
1.8.3 - Effectiveness of diuretic therapy
In view of the confusion about fluid and electrolyte changes and
menstrual cycle symptoms, it is not surprising that studies of the use
of diuretics have also been inconclusive. The subject has been
reviewed by Reid & Yen (1981) and O'Brien (1982). Only three out of
six placebo-controlled studies have shown a significant benefit from
active therapy although criteria for inclusion were not uniform. One
of these positive studies selected only women who demonstrated a net
premenstrual weight gain prior to therapy (Werch & Kane, 1976).
Another used the aldosterone antagonist, spironolactone and it was
postulated that the benefit was due to the mild diuretic effect of
aldosterone antagonism (O'Brien et al (1979), a reduction in
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premenstrual weight gain being observed in treated cycles. Both these
studies showed a significant improvement in psychological symptoms in
addition to those attributed to fluid retention.
1.8.4 - Renin-angiotensin-aldosterone system
It is of interest to examine the possible physiological basis for any
changes in the distribution of fluid and electrolytes during the
menstrual cycle. Progesterone itself is known to have a natriuretic
effect (Landau & Lugibihl, 1958) but this is compensated for by a rise
in plasma renin activity and angiotensin II and aldosterone
concentrations (Oparil et al, 1975). These changes are observed both
during normal ovulatory cycles (Sundsfjord & Aakvaag, 1970; Michelakis
et al, 1975) and following an intramuscular bolus of progesterone
(Oelkers et al, 1974) but do not appear to occur in the absence of
ovulation (Michelakis et al, 1975). There is no evidence that
aldosterone levels differ between symptomatic and asymptomatic women
(O'Brien et al, 1980; Munday et al, 1981) and the mechanisms
underlying the increased capillary permeability described above have
not been clarified. While alterations in renin, angiotensin and
aldosterone concentrations may explain some of the normal
physiological changes of the cycle, there is no current evidence to
support or refute an abnormality of the renin-angiotensin system in
the aetiology of more severe degrees of cyclical swelling and the
mental changes experienced by symptomatic women.
1.8.5. - Cyclical oedema
The problem of severe premenstrual swelling is sometimes confused in
practice with a similar but separate clinical entity which also occurs
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in women and is known as cyclical oedema (Thorn, 1957). In its
clinical manifestations, it is also often associated with headache,
increased irritability and other mental changes but is characterised
by the absence of any obvious systemic abnormality and by being
unrelated to menstrual cycle phase. Most authors stipulate a minimal
weight gain which must be recorded in order to make the diagnosis
(Edwards & Bayliss, 1976) although women with complaints of severe
abdominal distension in the absence of overall weight gain have been
described (Thorn, 1968), the latter being reminiscent of many patients
complaining of premenstrual swelling.
The problem has been attributed to a shift of albumin from the
intravascular compartment to extravascular tissues because of
increased capillary permeability, combined with a compensatory
reduction in renal fluid and electrolyte excretion in the upright
position (Edwards & Bayliss, 1976). Reduced urinary dopamine
excretion in women with idiopathic oedema compared with normal
controls has been reported by Kuchel et al (1977) raising the
possibility that both cyclical oedema and premenstrual swelling may be
a consequence of an abnormality in renal dopaminergic function. Renal
dopamine is an important natriuretic agent although its precise role
in homeostasis is uncertain (Lee, 1986) and preliminary studies
indicated no alteration in renal excretion of dopamine during the
normal menstrual cycle in healthy volunteer women (Perkins et al,
1981). Young et al (1983) provide evidence for an underlying
hypothalamic disturbance in cyclical oedema by virtue of differences
in response to TRH and LHRH between patients and control subjects but
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similar studies have not been done in women with severe premenstrual
symptomatology.
A link between stress, psychological disturbance, mental symptoms and
cyclical oedema is recognised (Thorn, 1968; Edwards & Bayliss, 1976;
Pelosi et al, 1986), giving further support to the theory that its
aetiology may be similar to that of some cases of premenstrual tension
associated with swelling and oedema. However, at present the
underlying pathological mechanisms remain obscure.
1.8.6 - Prolactin and the use of bromocriptine
For a time, it was postulated that an abnormality of prolactin
secretion may underlie premenstrual symptomatology. The reasons for
this were twofold. Firstly, reduced levels of progesterone in the
luteal phase in symptomatic women were reported by several authors
(see section 3.2) and prolactin is known to inhibit production of
progesterone by the corpus luteum (McNatty et al, 1974). Secondly, it
was believed that prolactin played a crucial role in salt and water
balance (Horrobin et al, 1971; Buckman et al, 1973). However this was
later discredited by showing that the ovine prolactin which had been
given to healthy volunteers was contaminated by vasopressin (Bond et
al, 1976). Also, elevations of endogenous prolactin stimulated by TRH
failed to alter renal salt and water excretion (Baumann & Loriaux,
1976). Studies of circulating prolactin throughout the menstrual
cycle have also yielded contrasting results, with some studies showing
no change (McNcilly & Chard, 1974) while others identified a peak at
ovulation and higher concentrations during the luteal phase
(Franchimont et al, 1976; Vekemans et al, 1977). However conclusions
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based on small numbers of blood samples may be misleading because of
the episodic nature of prolactin secretion with a marked diurnal
variation (Ehara et al, 1973). Thus it is not surprising that
conflicting results were obtained in women complaining of cyclical
symptoms. Halbreich et al (1976) reported a significant elevation of
serum prolactin concentrations in symptomatic women compared with
normal controls although they could find no correlation with symptom
scores. Later reports (Anderson et al, 1977; Andersch et al, 1979)
failed to demonstrate a difference. Circulating prolactin has been
shown to rise in response to stress (Noel et al, 1972) and this may
account in part for the discrepancy between these studies.
Several placebo-controlled trials of bromocriptine therapy have been
conducted, again with inconsistent results. The one demonstrating
greatest benefit studied women presenting with infertility rather than
with a primary premenstrual tension problem (Benedek-Jaszmann & Hearn-
Sturtevant, 1976) permitting only limited conclusions to be drawn.
Harrison et al (1976) reported a beneficial effect with bromocriptine
while Ghose & Coppen (1977) found no difference. Anderson et al
(1977) reported a significant improvement in breast symptoms but
psychological problems were unchanged. Greater benefit was reported
by Andersch et al (1979), but this was independent of prolactin
levels. The method of symptom recording and measurement in most of
these studies was by use of retrospective interviews and is thus open
to criticism (see section 1.9.3) but overall there is no good evidence
to support a role for prolactin in the aetiology of premenstrual
problems.
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1.8.7 - The menstrual cycle and the breast
Subjective awareness of breast swelling and discomfort during the
premenstrual phase of the menstrual cycle is accompanied by well
documented physical changes. These have been described in detail by
Vorherr (1974) and include increased mammary blood flow, ductular-
acinar sprouting and interlobular oedema. Slight secretory activity
also occurs in the alveolar lining which becomes more marked with the
fall in sex steroid levels at the onset of menstruation but is
followed by regressive changes with loss of oedema and condensation of
the stroma during the early follicular phase. Premenstrual increase
in breast volume has been demonstrated in volunteer subjects (Milligan
et al, 1975) using a water displacement technique. Subjective
awareness of breast changes may thus be regarded as normal although
they vary considerably in magnitude and perception. The problem of
'cyclical pronounced mastalgia' is very common in clinical practice
(Preece et al, 1976) and may occur in association with other cyclical
symptoms or in isolation. Mammograms of these women with marked
symptoms frequently show areas of fibroadenosis (Preece et al, 1976)
although the diagnosis of cyclical mastalgia usually depends on the
reported severity of the discomfort. A study based on luteal phase
blood samples (Sitruk-Ware et al, 1977) showed sufferers from benign
breast diseases to have significantly lower progesterone levels than
normal controls. However single samples only were taken and timed
according to basal body temperature, which may lead to inaccuracies
(see section 3.2). Their findings have been confirmed by others
(Rolland et al, 1979) but the subjects studied included those with
non-cyclic breast pain and both with and without demonstrable
structural changes. The relationship between cyclical breast
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discomfort, hormonal and structural change is still unclear, as is the
association between breast symptoms and other premenstrual problems.
Despite the lack of understanding of its cause, the management of
cyclical breast pain has resulted in more consistent success than that
found with other cyclical symptoms. Bromocriptine has been mentioned
above (section 1.8.6) and significant benefit over placebo has been
reported by Mansel et al (1978) in a 6 month cross-over study of women
with cyclical breast pain. Of other cyclical symptoms, only
irritability showed a significantly better response to active therapy
with bromocriptine. However it did not relieve non-cyclic breast
symptoms. In a similar study, the same group also found a significant
response to danazol in 28 subjects with cyclical mastalgia, although
the incidence of treatment-related weight gain and menstrual
abnormalities was high (Mansel et al, 1982). The mode of action of
danazol is described in a later section (4.4). More recently the
anti-oestrogen tamoxifen has been shown to be effective in women with
both cyclic and non cyclic breast pain (Fentiman et al, 1976). The
success of these therapies presumably reflects the hormonal dependency
of breast tissue although their exact mechanism of action is not
known.
In section 3.5, the effects of oral contraceptives on cyclical
symptoms are reviewed. Milligan et al (1975) showed that breast
volume increases premenstrually in pill cycles as well as natural
cycles although changes are smaller in the former group. Long term
oral contraceptive usage appears to reduce the incidence of benign
breast disease (Boston Collaborative Drug Surveillance Programme,
41
1973; Ory et al, 1976; Vessey et al, 1976) and one study (Royal
College of General Practitioners, 1977) indicated a negative
correlation with the dose of progestogen in the pill. However the
role of oral contraceptives in the management of women with
established breast symptoms is less clear.
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1.9.- Methods of measurement of mood and physical change
Some of the discrepancies in the literature discussed earlier are
likely to be attributable to the variety of methods used to assess
menstrual cycle symptomatology. This is not intended to be a
comprehensive review of all the methods in past and current use but
covers those used in the majority of the studies cited, particularly
those related to therapy. Some of the differences in methodology may
be a reflection of the different backgrounds of individuals and groups
involved in menstrual cycle research. These include general
practitioners (Dalton, Williams), gynaecologists (O'Brien, Backstrom,
Magos & Studd, Wood), endocrinologists (Reid & Yen, Butt),
psychiatrists (Moos, Coppen & Kessel, Sampson, Dennerstein, Bancroft,
Halbreich, Rubinow) and psychologists (Paulson, Paige, Wilcoxon,
Sanders, Endicott, Slade). In addition, the methods used will vary
according to the nature of the study and the population under
investigation, for example more detailed assessments will be necessary
to monitor the results of therapy, compared with simpler methods
suitable for large population surveys.
1.9.1 - Retrospective interviews and questionnaires
Most large surveys rely on data from single interviews or postal
questionnaires, and consequently the methods used must be simple and
comprehensive, in order to encourage maximum compliance. Such methods
were used in the prevalence studies described above, although only
those of Coppen & Kessel (1963) and Andersch et al (1986) attempted to
quantify the severity of the symptoms, rather than asking for a yes/no
response. The former used a simple (nil to severe) scoring system,
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while the latter attempted to standardise the replies by giving
descriptive statements to assist in the grading.
1.9.2 - Special methods of assessment
For more detailed assessment, several methods have been devised which
enable quantification and the application of statistical analysis.
Some groups have used complex methods such as content analysis of
speech (e.g. Paige, 1971) based on recorded interviews. For
assessment of individual parameters of mood there are a number of
specific inventories familiar to psychiatrists (e.g. Hamilton
depression scale, Beck's depression inventory, Speilberger's state
anxiety inventory). Also used frequently for self-assessment are
various Mood Adjective Check Lists (MACL - McNaire & Lorr, 1964;
Mackay et al, 1978). These comprise a list of dimensions, each of
which is described with a few adjectives e.g. not at all, a little,
quite a bit, extremely.
A number of detailed questionnaires, intended specifically for self-
assessment of menstrual cycle-related complaints have also been
developed of which the Menstrual Distress questionnaire (MDQ; Moos,
1968) is the best known. It comprises 47 symptoms, arranged in eight
clusters, each of which is scored on a six-point scale. Steiner et al
(1980) have devised a separate 36 item 'Self Rating Scale for
Premenstrual Syndrome', consisting of a list of descriptive
statements with each one requiring a yes/no answer. Halbreich et al
(1985) have recently compiled a different Premenstrual Assessment
Form, listing 95 items rated on a six-point scale. This differs from
others in scoring for severity of change rather than for symptom
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severity per se. There has been no degree of uniformity in the
application or use of these various methods and with the exception of
a recent study by Casper & Powell (1986) (see below) no published
reports of attempts to critically compare their validity and
efficacy.
1.9.3 - Prospective daily assessment
All the above methods may be used for single assessments or for serial
measurements. However, it has become increasingly evident that single
retrospective assessments of menstrual cycle related symptoms may be
inaccurate and misleading. In one of the earliest detailed studies,
McCance et al (1937) found the discrepancy between retrospective and
daily reports to be 'so frequent as to throw considerable doubt on the
value of any work based on history or questionnaire'. Abplanalp et al
(1979) were unable to demonstrate any significant premenstrual changes
in mood in 33 subjects assessed daily, while a retrospectively
completed MDQ had indicated significant premenstrual problems.
Halbreich et al (1985) found that less than half the women diagnosed
as having premenstrual change on retrospective assessment have this
confirmed prospectively. On the other hand, Taylor (1979) found a
good correlation between a single MDQ and daily assessment. However
he does comment that the subjects who scored highly premenstrually
also scored highly during the remainder of the cycle, and these might
not have met the criteria for premenstrual change used by other
authors.
In view of the overall consensus that retrospective interviews and
questionnaires are inadequate for the assessment of cyclical symptoms,
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most recently published studies have been based on daily recordings,
although again a wide variety of methods have been employed.
1.9.4 - Detailed methods of daily assessment
Many of the above methods have been used for daily self-assessment,
for example the study of symptom profiles in small selected numbers of
volunteers where a combination of methods has sometimes been used, for
example the MDQ and MACL (Silbergeld et al, 1971; Wilcoxon et al,
1976). The MDQ has also been successfully used for monitoring the
results of therapy, for example by Sampson (1979) and Magos et al
(1986), the latter group using a shortened version of 34 symptoms in
six clusters, scoring each item from 0 to 3.
1.9.5 - Simple descriptive scales
The methods used for daily self-monitoring in treatment trials have in
general been simpler than the detailed methods described above,
presumably because of the need to ensure maximum compliance over a
period of several months. Again, there has been no uniformity of
method, each group drawing up a list of symptoms and devising a simple
numerical scoring system using a four to six-point scale (Williams et
al, 1983; Dennerstein et al, 1986, 1987; Watts et al, 1987). In
general, validation of their use in comparison with other methods has
not been described although there has been a recent study (Casper &
Powell, 1986) in which results of assessment by a set of visual
analogue scales (see below) have been compared with two descriptive
methods, one employing a simple numerical scoring system (1 to 3), the
other a yes/no response to a list of statements (Steiner et al, 1980).
The results from the three methods were very highly inter-correlated
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which is encouraging when comparing the results of studies based on so
many different methods of measurement.
1.9.6 - Visual analogue scales
The visual analogue scale (VAS), (Aitken, 1969) is another method
frequently used to quantify mood and physical state, for example in
research into the effectiveness of analgesic drugs (Huskisson, 1974).
Its reliability and reproducibility has been demonstrated in the
latter context (Revill et al, 1976). It is a straight line or set of
lines representing individual parameters, marked at both ends, usually
measuring 10cm, and with both ends defined as extremes of a range for
the particular parameter being measured (e.g. from 'none' or 'not at
all' to 'as bad as I can imagine'). Subjects are asked to define
their own extremes and then to assess the severity of each symptom
serially by marking the line as they feel appropriate. Visual
analogue scales can also be used for bipolar measurements, for example
'most depressed - most happy' (Rubinow et al, 1984).
Sanders (1981) found the method to be acceptable for the measurement
of cyclical changes in a group of 14 women, who preferred it to the
MACL and more complex descriptive methods. Similarly Faravelli et al
(1986), testing it against standard scales for the measurement of
depression found it to be more popular with the patients although 8
out of 100 were unable to use it. The VAS has been used for
measurement of menstrual cycle symptoms by O'Brien et al (1979; 1980),
Sanders et al (1983), Backstrom et al (1981), Abraham et al (1985) and
Rubinow et al (1984). Sanders (1981) has validated a set of visual
analogue scales by comparison with simultaneous recordings made on the
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Lorr-McNaire MACL, finding highly significant correlations between the
two methods. She cited other studies which have similarly validated
their use in the measurement of specific dimensions of mood (e.g.
Zeally & Aitken, 1969).
1.9.7 - Statistical methods
Until fairly recently, statistical comparisons of mood and physical
change across the menstrual cycle have largely employed parametric
methods, in particular analysis of variance (e.g. Wilcoxon et al,
1976, Silbergeld et al). As measurement of mood is based on
allocation of a score to indicate severity and the numerical data is
thus ordinal in nature, this practice is open to criticism (Siegal,
1956). However parametric methods are still used for paired
comparisons in therapy trials where results are based on simple
descriptive scales (e.g. Dennerstein et al, 1985, 1986; Watts et al,
1987).
One of the advantages of the use of the VAS was said to be its
suitability for the application of parametric methods of statistical
analysis (Aitken, 1969). The validity of this has been questioned
(Forrest & Andersen, 1976) as the VAS is essentially an ordinal scale,
its limits being defined by the individual. Maxwell (1978) has
compared parametric and non-parametric statistical tests for both
within-subject and between-subject comparisons using the VAS and
concluded that parametric methods are valid for within-subject
comparisons.
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1.9.8 - Criteria for diagnosis based on quantitative methods of
assessment
Development of these methods of measuring menstrual cycle
symptomatology quantitatively on a continuous basis should have
resulted in more precise diagnostic criteria. However some groups
still specify the need for a 'symptom-free interval' (Williams et al
(1983); Dennerstein et al (1985) which presumably implies scores of
zero for all parameters during the postmenstrual phase. This, as seen
in chapter 2, only applies to a very small proportion of women who
present with premenstrual complaints. Watts et al (1987) refer to an
'appreciable' increase in symptom scores premenstrually without being
any more precise but O'Brien et al (1979) were happy to accept
premenstrual scores consistently higher than those present
postmenstrually. Halbreich et al (1985) regard significant change
between the premenstrual and postmenstrual phases as being at least 2
points on a six-point scale and also specify a minimum acceptable
level of symptomatology during the post-menstrual phase. Using the
VAS, Rubinow et al (1974) used an increase of 30% during the
premenstrual week as indicative of 'menstrually-related mood
syndrome'.
Some groups have devised sophisticated methods of assessing the
significance of individual cyclical changes, with the help of
computerisation, for example the least mean square method of fitting
sine waves described by Sampson & Jenner (1977), using the MDQ. Magos
et al (1986) described a method of trend analysis for assessing level
of change in individuals. For group comparisons, they calculate
maximum and minimum exponentially smoothed averages, representing
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peaks and troughs in symptoms, applying non-parametric methods to
measure statistical differences. Such methods are likely to assign
statistical significance to small differences and may be less useful
than the simpler methods described above as they do not indicate the
baseline level of symptoms in an individual and are difficult to apply
in an ordinary clinical situation.
1.10 - Methods of measurement used in this thesis
1.10.1 - Visual analogue scales
The majority of the measurements used in the studies described in the
later sections of this thesis were made using a standard set of 10cm
visual analogue scales (figure 1.3), completed by the subjects on a
daily basis throughout the period of observation. The dimensions
listed were based directly on those used by Sanders (1981) during the
course of her studies done in this department, under the supervision
of Dr J. Bancroft and in collaboration with Dr T. Backstrom. Her
original list was selected on the basis of earlier studies in the
literature and comprised scales for cheerful and happy, energetic and
active, sociable and friendly, relaxed, changeable, depressed and
unhappy, fatigued and tired, aggressive, irritable, tense and anxious.
The physical symptoms, swelling, headache and breast discomfort, were
rated on a four-point scale. In the present studies, it was decided
to use the 10 cm scales for swelling, breast tenderness and menstrual
bleeding so that methods were uniform. The items of mood were reduced
to five, including those most frequently reported by symptomatic
women, namely tense/anxious, fatigued/tired, irritable,


































































































retained as it was felt that too lengthy a list might reduce
compliance. During the course of the initial study an additional 10cm
scale was added for the measurement of 'pelvic pain' (see section
2.3.5)
In the initial study (chapter 2), the method described above was used
for daily prospective assessment of 100 women who consecutively
presented with premenstrual problems. The analysis was based on three
phases of the cycle, the premenstrual week, the initial 5 days of
menstruation and the postmenstrual week (days 6-12). These correspond
to the following phases studied by Sanders et al (1983), namely, late
luteal (days 23-28), early follicular (days 1-5) and mid-follicular
(days 6-10). The latter study had demonstrated maximum intensity of
negative moods during the late luteal phase with a trough of negative
moods during the late follicular phase, i.e. around the time of
ovulation. It also showed a peak of positive moods around ovulation.
However, in view of previous reports that adverse symptoms may be
related to ovulation (Dalton, 1977; Reid & Yen, 1981) it was decided
to omit this phase from the analysis and take the mid-follicular phase
as the baseline week.
Mean scores for both mental and physical symptoms were calculated for
each subject for each of these three cycle phases to enable
comparisons between the phases to be made. This is described in more
detail in section 2.2.3. Where cycle phase scores were compared
between groups of individuals, results were expressed as the median
and range (or interquartile range) for analysis by non-parametric
statistical methods (see section 1.9.7).
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The method selected to classify and compare the individual subjects
has not been used before in any published study. Magnitude of the
premenstrual symptom change can be measured simply by subtracting the
postmenstrual score from the premenstrual score, the method used by
O'Brien et al (1979). The disadvantage of this is that it does not
take account of basal symptom levels. As discussed in section 1.3,
many authors have emphasised the importance of symptom relief
following menstruation. The degree of symptom relief can be
calculated by expressing the difference between the premenstrual and
postmenstrual scores as a percentage of the premenstrual score as
follows:
*
premenstrual score - postmenstrual score
Post¬
menstrual = x 100%
relief
premenstrual score
Similarly, the degree to which symptoms are relieved during
menstruation can be calculated. The terms postmenstrual or menstrual
mood/physical symptom relief will be used in the text to refer to the
percentage change derived in this way. The method is not only
applicable to scores obtained with visual analogue scales but can also
be used where other methods of measurement have been used, for example
the simple descriptive scale described below. It has the advantage of
simplicity and is self-explanatory, not requiring the introduction of
elaborate and confusing terminology.
This method measures only degree of change and does not indicate the
severity of the premenstrual symptoms in an individual. For example,
53
premenstrual scores of 8.0 and 1.0 would both be relieved by 100% if
the postmenstrual scores were zero. However assessment of severity is
subjectively defined and thus any classification based on comparison
of the cycle phase scores between individuals would not be very
meaningful anyway.
In the second study, (chapter 4) the effects of suppression of
ovulation with two progestogens were compared with placebo. The same
set of visual analogue scales was used in the measurement of response,
again using daily recordings over a period of at least three months.
Suitability for inclusion in the study was based on the degree of
postmenstrual mental relief calculated by analysing the results of two
pre-treatment cycles as above (for details of proposed diagnostic
categories see chapter 2). To determine the effects of therapy, mean
cycle phase scores were compared as described in detail in section
4.2.5. Parametric methods, in this case analysis of variance, were
used to assess statistical significance, as repeated measurements were
being made by the same individuals (see section 1.9.7). Where any
between group comparisons were made, non-parametric tests were used.
1.10.2 - A simple descriptive scale
In the third study, a different method of self-assessment was used,
based on a simple descriptive scale (see section 1.9.5). It was first
tested in a small pilot study (described in section 2.6) where it was
compared with the visual analogue scales in a sample of subjects. The
reason for selecting an alternative method was the length of time over
which recordings would be made. Therapy with the LHRH agonist would




































































make the total duration of the study at least 9 months. As some of
the subjects would be women who had not primarily presented with
premenstrual complaints, it was felt that compliance would be reduced
if the method of recording was too detailed. Failure of subjects to
complete the VAS charts was a problem encountered in the progestogen
study (chapter 4), where the duration of recording did not exceed 6
months. For a similar reason, the items listed on the simple chart
were reduced to 6, namely, bleeding, pelvic pain, irritability,
depression, breast discomfort and swelling (figure 1.4). Spaces were
left for other problems to be rated daily if appropriate. The
subjects were asked to score each symptom daily on a four-point scale,
indicating the severity from 0 to 3 (severe). Non-parametric tests
were used for the statistical analysis.
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1.11 - Conclusions
1) The endocrine changes of the menstrual cycle are complex, involving
the ovary, anterior pituitary, hypothalamus and the central nervous
system.
2) Cycle related changes in mood and physical symptoms are reported by
such a high proportion of the female population that their presence
cannot always be regarded as pathological although they appear to be a
cause of significant morbidity in a minority of women.
3) The relationship between the menstrual cycle and physical symptoms
appears to be more clear cut than mental change where factors such as
social conditioning, personality and psychiatric morbidity all appear
to play a variable but important role.
4) The physiological basis of the adverse physical symptoms is not
clear. Alterations in fluid and electrolyte balance and breast
morphology with menstrual cycle phase are recognised but differences
accounting for symptomatology and their relationship to psychological
symptoms have not been identified.
5) There is considerable lack of uniformity between investigators with
regard to basic definitions of menstrual cycle-related problems and
the methods used in their investigation. The most useful methods are
those based on prospective daily self-rating, of which several have
been validated.
In chapter 3, the relationship between hormones and mood will be
further considered. Chapters 2, 4, 6 and 7 of this thesis will be
concerned with women who present for help with premenstrual problems
and the role of hormonal manipulation in their management. The




THE CHARACTERISTICS OF 100 WOMEN PRESENTING WITH PREMENSTRUAL
PROBLEMS
2.1 - Introduction
In chapter 1 of this thesis, some of the difficulties and
discrepancies surrounding our current understanding of menstrual cycle
related problems have been outlined. Even the basic nomenclature and
definition is a source of controversy. This chapter is concerned with
the group of women who suffer from disturbances of mood which they
relate to the menstrual cycle, specifically the premenstrual phase,
and which are sufficiently severe for them to seek medical help,
thereby posing a management problem for both general practitioners and
hospital specialists.
Prior to 1980, when this study commenced, there were no published
reports of profiles of mood and physical symptoms throughout the
menstrual cycle in women presenting with premenstrual tension. There
was a large literature of published clinical trials involving numerous
approaches to therapy, mostly with negative results. In addition, a
number of studies had examined hormone profiles but usually without
defining symptom patterns and severity in the cycles under study (see
section 3.2). It was evident that in order to clarify the situation
with regard to diagnosis, cause and treatment, a reappraisal of the
condition was urgently needed. Accurate delineation of the problem
within a group of symptomatic women would provide a basis for drawing
up diagnostic criteria, reveal possible subsets of patients for study
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of aetiology and should lead to rationalisation of therapy, both in
the selection of subjects for clinical trials and for management of
individual patients.
The object of this study was therefore to assess prospectively a
series of women who consecutively presented to a specialist clinic
because of problems attributable to 'premenstrual tension', in order
to clarify the relationship of their symptoms to the premenstrual
phase of the cycle and to menstruation itself. In addition, other
factors that might be related to their problem could be studied with
the aim of devising a simple system of classification as a basis for
further research.
2.2 - SUBJECTS AND METHODS
2.2.1 - Subjects
All the women included in this report were referred to the
Reproductive Endocrine clinic of the Edinburgh Royal Infirmary with
cyclical mood changes thought by themselves and/or by the referring
practitioner to be attributable to premenstrual tension. The criteria
for inclusion included a complaint of one or more of the symptom triad
of irritability, tension and depression with or without the other
physical and mental symptoms commonly associated with the condition.
Also for inclusion in the study, the women had to give a history of
relief of their symptoms during or following menstruation. All the
women were sufficiently distressed by their symptoms to seek
specialist help and the majority had received various therapies in the
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past although none were on any specific therapy, hormonal or
otherwise, during the period of observation. Women were not excluded
on the basis of a past history of psychiatric illness or treatment
because the object of the study was to gain information about the
entire population of women referred with cyclical problems of this
nature.
2.2.2 - Assessment of symptoms
At the initial visit a full medical, social, psychiatric and
gynaecological history was taken and the women screened for the
presence of significant general or pelvic disease. The psychiatric
history was recorded as positive if they had received treatment for
any past or current problems or had at any time attended a psychiatric
clinic for treatment or been hospitalised for a psychiatric problem.
Attendance or treatment for problems specifically related to the
menstrual cycle or puerperium were not considered indicative of a
positive psychiatric history. Those who were eligible on the basis of
their presenting symptoms were asked to complete a standard set of
visual analogue scales (figure 1.3) each evening for at least 35 and
usually 60 days (see sections 1.9.6 and 1.10.1 for a description of
the method). The parameters being assessed were tension/anxiety,
lethargy/tiredness, cheerfulness, irritability, depression, breast
discomfort, swelling and menstrual bleeding. During the course of the
study the charts were modified to include pelvic pain in the symptom
list. The women were asked to define their own limits for each
parameter between 0 (not at all) and 10 (extreme) and mark the 10cm
line accordingly.
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2.2.3 - Data analysis
For the analysis, three separate phases of the menstrual cycle were
studied (see section 1.10.1). The premenstrual phase included the 7
days prior to but not including day 1 of menstruation (days -7 to -1
inclusive). The menstrual phase included the first 5 days from the
onset of menstruation (days 1 to 5), regardless of the duration of
bleeding. The post-menstrual phase was taken from day 6 to day 12 of
the cycle, inclusive. Overall mean scores for both mental and
physical symptoms were calculated for each subject for each of these
three cycle phases to enable comparisons between the phases to be
made. The scores for irritability, tension, depression and lethargy
were combined for each phase and a mean 'adverse mood' score
calculated. Mean physical symptom scores were calculated by combining
breast discomfort and swelling in a similar way. If data from two
complete menstrual cycles was available, calculation of the mean score
was based on both cycles.
The level of change of the symptoms between the premenstrual and the
postmenstrual phases of the cycle was then calculated for the physical
and the mental symptoms in turn for each subject. The mean
postmenstrual symptom score was first subtracted from the mean
premenstrual score. This symptom difference was then expressed as a
percentage of the premenstrual score to give the degree of
'postmenstrual mood/physical symptom relief' for each individual
subject, as shown in section 1.10.1. The degree of menstrual
mood/physical symptom relief was then similarly calculated. The
analysis was performed with the assistance of 'Minitab data analysis
software' using an IBM-PC compatible microcomputer system.
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Descriptive analysis of the data was then performed as described in
the results section. Statistical comparisons were made using non-
parametric methods of analysis. The Mann-Whitney two-sample test was
used to compare two groups, the Kruskal-Wallis one-way analysis of
variance for comparison of more than two groups, Chi-squared test to
compare categories and Spearmann's rank correlation coefficient as a
measure of correlation.
As an additional assessment of day to day changes in individual
symptoms throughout one complete menstrual cycle, mean daily symptom
scores were also calculated. For this, it was necessary to
standardise all the cycles to 28 days. Day 1 was taken as the onset
of bleeding (excluding spotting) and day 28 was the day immediately
prior to its onset. The days were counted backwards to day 12 and
then forwards for 11 days so that any ajustments for length were made
in the mid-late follicular phase, regarded as the 'baseline' phase
both symptomatically and hormonally (section 1.10.1). The results
were computed and plotted out for the entire sample of 100 women and
also for the sub-groups identified during the above analysis (see
results section). Statistically significant cyclical changes were
detected using analysis of variance for repeated measures.
Any cycles which were markedly atypical in terms of length or bleeding
pattern were excluded from the analysis as were those complicated by
coincidental major life events such as bereavement or significant
physical illness likely to upset the normal cyclical mood pattern.
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2.2.4. - Endocrine measurements
A random subsection of the subjects underwent simple assessment of
ovarian function by estimation of total oestrogen and pregnanediol
excretion in early morning samples of urine, collected weekly and
stored in the subjects' own domestic freezers in between visits to the
hospital. The results were to act as a baseline for a parallel study
of the effect of ovulation suppression with certain progestogens (see
chapter 4) and those women who expressed an interest in this study
were asked to collect urine samples. In addition it was hoped to
detect some spontaneous anovular cycles in order to study differences
in symptom profiles between these and normal cycles in the same
individuals. Those women in particular with a history of occasional
atypical cycles or variable symptom patterns were asked to collect
weekly urine samples.
2.2.5 - Assay methods
Total urinary oestrogens were measured by fluorimetry after semi¬
automatic extraction, using the method described by Brown et al
(1968). Pregnanediol was measured by gas-liquid chromatography




2.3.1 - Characteristics of the subjects
The mean age of the women was 35.2 years (range 24-49). Their marital
status, parity, current method of contraception and socio-economic
status are summarised in tables 2.1.1 - 2.1.4. Women using hormonal
contraception had not been specifically excluded from the study but
only four were in this category, two of them using a progestogen-only
pill. In none of them had the pill been prescribed as a remedy for
their cyclical symptoms. For those women in part or full-time
employment, the occupation stated is their own, in the case of
housewives the occupation of the spouse is given. The mean duration
of their symptoms at presentation was 5.4 years (range 6 months to 22
years). The distribution of symptom duration is shown in table 2.1.6.
The source of the original referral to the clinic is shown in table
2.1.5.
2.3.2 - Compliance
Of the 100 women initially eligible for the study, none expressed any
misgivings about completing the visual analogue scales as instructed.
However 16 failed to satisfactorily complete or return the charts. In
order to collect data from 100 patients, the next 16 completed sets of
charts received from eligible patients were also analysed. The
characteristics of the non-compliars, together with their reasons for
not completing the study are shown in table 2.2. Although there
appears to be a higher proportion of single and nulliparous women
among the non-compliars, the only statistical difference between this
group and those who completed the charts was in relation to
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TABLE 2.1 - CHARACTERISTICS OF THE IOO SUBJECTS




2.1.2 MARITAL STATUS: married 76
single 6
sep/div 18








TABLE 2.1 - CHARACTERISTICS OF THE 100 SUBJECTS (cont)
2.1.4 OCCUPATION











2.1.5 SOURCE OF REFERRAL
General practitioner 62
Gynaecologist 31
Family planning clinic 5
Psychiatrist 2
2.1.6. DURATION OF SYMPTOMS
Less than 2 years 9
2-5 years 38
5-10 years 32
More than 10 years 17
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TABLE 2.2 - CHARACTERISTICS OF THE 16 NON-COMPLIARS




2.2.2. MARITAL STATUS: married 10
single 3
sep/div 3




2.2.4. REASONS FOR NON-COMPLIANCE
Charts mislaid 2
Too time consuming 3




occupation. Significantly fewer of the non-compliars were housewives
(Chi-squared = 4.12, 1 degree of freedom; p<0.05).
When the charts were incorrectly filled out (table 2.2.4), this was
generally due to failure to mark the line appropriately, giving a
descriptive term instead. Of those who felt their problems had
resolved during the course of the assessment months, all had remained
well when contacted 6 months later. There were several subjects who
realised during the course of completion of the daily records that
their problems were not truly related to the menstrual cycle. However
only one of them actually stopped completing the charts. The others
are included in the main analysis as previously they had attributed
their problems to premenstrual tension.
2.3.3.- Menstrual and postmenstrual relief of mood and physical
symptoms
A classification of the extent to which the premenstrual mental and
physical symptoms were relieved during the postmenstrual and menstrual
phases of the cycle respectively is shown in table 2.3. Fourteen of
the women actually showed a postmenstrual exacerbation of their mental
symptoms and near complete relief (75% or more) was apparent in only
one third. However two thirds of the women showed relief of physical
symptoms, when present, of 75% or more. During menstruation itself,
both mental and physical symptoms actually worsened in a third or more
of the subjects. Mental symptoms were relieved by 50% or more in only
20 women. Menstrual data was obtained from only 98 of the women, due
to failure of two to complete the charts during menstruation.
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TABLE 2.3
Postmenstrual relief of mental and physical symptoms
Degree of relief Mental Physical




symptoms exacerbated 14 10
no cyclical symptoms 7
Menstrual relief of mental and physical symptoms
Degree of relief Mental Physical
50% or more 20 34
0-49% 35 24
exacerbated* 0-49% 25 14
exacerbated* 50% or more 18 19
*No relief as symptoms worse during menstruation
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Further analysis was performed to study mental and physical symptom
profiles before, during and after menstruation, subdividing the women
into five groups according to the degree of postmenstrual relief of
the mental symptoms as classified in table 2.3. Analysis of the
mental symptoms is shown in figure 2.1, where results are expressed as
the median and interquartile range for each cycle phase within the
groups. While the severity of symptoms during the premenstrual phase
of the cycle did not differ significantly between the groups (H=3.357,
p=0.50; Kruskall Wallis one-way analysis of variance), a marked
difference in median symptom severity was seen during menstruation
itself (H=15.21, p<0.01). The median mental symptom score was
actually greater during menstruation than premenstrually in the two
groups with least postmenstrual relief. The median menstrual score
was lowest in the group with greatest postmenstrual relief of mood.
The physical symptom profiles were similarly analysed according to the
degree to which the mental symptoms were relieved postmenstrually
(figure 2.2). Median severity of the physical symptoms during the
premenstrual phase did not significantly differ between the groups
(H=2.819) and here differences during the menstrual phase just fell
short of significance (H=8.754, p<0.10>0.05). An overall improvement
of physical symptoms was seen during menstruation in all the groups
with the exception of the one in which mental symptoms were
exacerbated postmenstrually. Here a marked menstrual peak was seen.
However even in this group, median physical symptom score was reduced












































































































This method of analysis of the data expresses only magnitude of change
of the symptoms and does not detect individual women with low levels
of symptomatology. There were seven women with no complaints of
physical discomfort, distributed throughout all five groups. Because
of the subjective nature of the ratings, comparison between individual
absolute scores may be invalid, but 11 women consistently had a mean
score below 2.5 in all three cycle phases for both mental and physical
symptoms. They were distributed between all five of the subgroups.
Three of them consistently had mean scores below 1.0, one from the
group with greater than 75% relief postmenstrually. Review of their
clinical notes did not reveal any other predominant symptoms which
were not included among those on the VAS forms. Examination of the
latter showed that adverse symptoms had lasted for between one and
three days only but presumably had caused distress and led to their
presentation.
2.3.4 - Symptom profiles throughout the menstrual cycle
The mean daily symptom scores throughout one complete menstrual cycle
for the whole group of 100 women are shown in figure 2.3. Because of
similarities between the profiles for the individual psychological
symptoms, only those of irritability and depression are displayed.
The results of analysis of variance indicate significant cyclical
chances in symptoms (figure 2.3). Symptoms all reached a sharp
peak, maximal one day prior to and on the day of onset of menstrual
bleeding. A steep increase in the intensity of the physical symptoms
occurea from day 20 of the cycle, parallelled by a similar slightly








































































Symptom profiles were also plotted for the five subgroups identified
by calculation of the postmenstrual mood relief as described above.
These are shown in figures 2.4.1 - 2.4.3, where the groups are
numbered in ascending order of degree of postmenstrual relief as
indicated in the legends. Results confirm that there was little
relationship between mood and the menstrual cycle in the two groups
with least postmenstrual mood relief, although physical symptoms were
clearly related to cycle phase. In particular, daily scores for
depression show no significant variance in either subgroup. Those
women with intermediate degrees of relief (25-75% - figure 2.4.2)
showed significant cyclical changes in mood but with raised and
fluctuating scores in the middle phase of the cycle. This contrasts
with the profiles seen in the group with greatest relief (figure
2.4.3). The pattern of the premenstrual symptom rise was similar in
the three latter groups, although the sharp increase in symptom
intensity occurred earlier in the women from group 5.
2.3.5 - Factors associated with degree of postmenstrual relief
In order to examine factors that might have influenced the patterns of
mood change identified in section 2.3.3, the subjects were similarly
categorised according to the degree of postmenstrual relief of the
mental symptoms. The association with past psychiatric history,
marital status and parity is shown in table 2.4. Women with
postmenstrual mental symptom relief of 75% or more included
significantly fewer with a past history of psychiatric treatment or
marital breakdown than those with postmenstrual mood relief below 75%.
There were also significantly fewer with three or more children.
Occupation did not differ between the groups (not illustrated).
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Figures 2.4.1 - 2.4.3
Symptom profiles throughout one complete menstrual cycle, showing mean
daily scores for individual symptoms. The women are grouped according
to the degree of postmenstrual relief of the psychological symptoms.
Key and F-values derived by analysis of variance
Unless stated P<0.01
Group 1 Group 2 Group 3 Group 4 Group 5
Relief None 1-24% 25-50% 50-74% 75-100%
Irritability 1.45 * 1.56 + 7.70 4.95 20.73
Depression *oo 0.95 * 2.44 4.41 14.25
Breast pain 4.04 3.78 7.78 4.90 19.70
Swelling 3.80 2.70 4.63 2.65 14.71
Degrees of
freedom





Daily symptom profiles throughout one complete menstrual cycle.









Daily symptom profiles throughout one complete menstrual cycle.
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The association between menstrual and postmenstrual mood relief (see
figure 2.1) is also shown in table 2.4. The majority of the women
with no postmenstrual relief of mood recorded their mental symptoms at
maximum levels during menstruation itself. Worsening of adverse mood
during menstruation was also present in around half the subjects with
minimal or intermediate degrees of postmenstrual mood relief. The
difference between these groups and the women with postmenstrual
relief of 75% or more is highly significant. However a marked
exacerbation of the mental symptoms during menstruation (50% or more)
was more frequent in the groups with minimal or no postmenstrual
relief (less than 25%).
2.3.6 - Pelvic pain and menstrual relief of symptoms
The influence of a history of psychiatric treatment, marital breakdown
or larger family size on mood relief during menstruation was also
examined. However all three factors were equally prevalent among
those with exacerbation of symptoms compared with those whose symptoms
were relieved. The persistence of the adverse mood state during
menstruation in such a high proportion of the women prompted an
investigation into the extent to which this was related to any
associated menstrual pain. The daily charts were thus modified during
the course of the study to include an additional 10cm line for
assessment of 'pelvic pain'. Data was available from 52 cycles. A
poor correlation was obtained between menstrual mood scores and
menstrual pain scores (r=0.274). However when the cycles were
subdivided according to whether adverse mental symptoms were relieved
(n=25) or exacerbated (n=27) during menstruation (figure 2.5), a
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Figure 2.5
Pelvic pain score (median and 3rd quartile) premenstrually and during
menstruation subdivided according to whether mental symptoms are





















significantly higher median menstrual pain score was evident in the
group whose mental symptoms were exacerbated during menstruation
(w=824; P=0.048 by Mann-Whitney test). Median premenstrual pelvic
pain scores were similar in the two groups.
2.3.7 - Individual comparison between cycles
Complete data from all three phases of two consecutive menstrual
cycles was obtained from 54 of the women. Highly significant
(P<0.001) correlations were obtained between the two cycles when
comparing the premenstrual (r=0.650), menstrual (r=0.617) and
postmenstrual (r=0.762) mood scores and the menstrual (r=0.410) and
postmenstrual (r=0.597) relief. The overall data from the two cycles
did not show a worsening or improvement of symptoms during the period
of observation.
2.3.8 - Menstrual cycle data and results of endocrine monitoring
Of the menstrual cycles studied, the mean length was 28.7 days (range
23-57 days). In ninety four percent of the subjects, the length fell
within the limits of 25 to 35 days (table 2.5). Weekly monitoring of
urinary ovarian steroid metabolites enabled adequate assessment of
ovulation to be performed over at least one cycle in 58 women. Three
anovular cycles were detected in three individuals and were all
atypical in terms of length and bleeding pattern. Normality of the
luteal phases was assessed on the basis of the following criteria:
Two consecutive urinary pregnanediol:creatinine results of at least









2.5.2 - NATURE* Ovulatory 51 (88%)
Anovular 3 (5%)
Inadequate luteal phase 4 (7%)
* Data from 58 subjects
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OR one result above 2.0 mg/g preceded or followed by one of at least
1.0 mg/g and separated by a 7 day interval.
In addition, in all the cycles judged to be normal, the urinary
pregnanediol:creatinine concentration had reached 1.0 mg/g by day 17
of the cycle.
These were the standard criteria used by the clinical laboratory in
which the assays were performed. As shown in table 2.5 only four
cycles were classified as having an inadequate luteal phase. In all
four, bleeding paterns were normal and they had been included in the
detailed symptom analysis, unlike the anovular cycles which had been
excluded because of their abnormal nature. These abnormal cycles were
distributed evenly throughout all the symptomatic groups.
Urinary steroid excretion profiles were calculated for the group as a
whole and for the three main sub-groups identified during the course
of analysis of the psychological symptoms (section 2.3.3). The cycles
were standardised to 28 days as described in section 2.2.3. Mean
urinary total oestrogen:creatinine concentration and
pregnanediol:creatinine concentration were calculated for each 3-4 day
interval throughout one complete menstrual cycle. The results are
given in table 2.6. There were no statistically significant
differences between the results for the three groups, assessed by
multiple Mann-Whitney tests. The steroid excretion profiles for the
group as a whole are shown in figure 2.6. The relationship between
symptomatic changes and pregnanediol excretion for the group as a
whole is illustrated in figure 2.7. Although the rise in symptom
intensity does follow the luteal phase rise in progesterone, the two
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TABLE 2.6
RESULTS OF MONITORING OF URINARY STEROID EXCRETION (MEAN + SD)
DAYS WHOLE GROUP RELIEF <25% RELIEF 25-75% RELIEF >75%
A - TOTAL URINARY OESTROGEN:CREATININE
I-3 8.3 + 5.6 6.3 + 2.8 8.4 + 3.5 10.1 + 8.3
4-6 8.7 + 4.8 9.2 + 4.5 9.7 + 6.6 7.7 + 3.8
7-10 9.4 + 5.2 9.8 + 7.1 7.9 + 4.5 10.8 + 4.9
II-13 14.6 + 6.6 13.2 + 4.9 14.0 + 9.0 17.7 + 4.6
14-16 21.1 + 12.1 20.0 + 7.2 20.5 + 15.1 22.7 + 10.8
17-19 16.8 + 7.6 18.4 + 6.4 18.2 + 8.3 15.1 + 7.6
20-21 17.1 + 8.8 15.9 + 8.9 17.2 + 9.4 18.5 + 8.2
23-25 16.0+8.0 17.9+4.4 15.3+9.9 15.9+7.7
26-28 13.5 + 8.6 11.9 + 4.2 14.4 + 11.9 13.7 + 6.2
B - URINARY PREGNANDIOL: CREATININE
I-3 0.59 + 0.34 0.40 + 0.23 0.65 + 0.27 0.71 + 0.44
4-6 0.43 + 0.24 0.54 + 0.24 0.42 + 0.24 0.35 + 0.23
7-10 0.35 + 0.23 0.31 + 0.28 0.32 + 0.17 0.40 + 0.22
II-13 0.37 + 0.23 0.29 + 0.16 0.31 + 0.21 0.28 + 0.12
14-16 0.61 + 0.44 0.53 + 0.27 0.58 + 0.36 0.92 + 0.56
17-19 1.79 + 1.86 1.32 + 1.29 1.32 + 0.85 2.38 + 2.46
20-22 3.34 + 3.02 3.06 + 2.20 3.00 + 2.44 4.42 + 4.78
23-25 2.91 + 1.13 3.24 + 1.38 2.74 + 0.95 2.91 + 1.20


































Urinary pregnanediol:creatinine excretion throughout one complete
menstrual cycle, compared with symptom profiles for irritability and
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are not parallel. The peak of adverse symptoms appears to




The results of this study confirm the unreliability of assessment of
premenstrual complaints based on history taking alone (see section
1.9.3). Of these women who all related their problems to the
premenstrual phase of the cycle, prospective assessment showed the
symptoms to peak around the onset of menstrual bleeding in the group
as a whole. However only one third of the sample recorded complete or
near complete relief of their psychological symptoms following
menstruation. Physical symptoms were more consistently related to
menstrual cycle phase.
The population studied here may be regarded as representative of women
who seek medical help for their problems. They are biased in that
they have been referred to a hospital clinic and this will reflect the
different attitudes of individual general practitioners. There may be
an additional source of bias in that referrals are also made to a
psychiatrist working in the same department and there may be
differences in the characteristics of these two groups. For example,
the high proportion of women in this analysis whose symptoms
centred around menstruation may reflect that they had been referred to
a gynaecologist although no particular emphasis on gynaecological
history was made in the initial interview and gynaecological pain was
not initially one of the listed symptoms. In addition, the clinic
they attended was one specifically associated with reproductive
endocrine disorders rather than general gynaecology.
The analysis has identified a subgroup of women presenting with
premenstrual complaints whose symptoms were more clearly related to
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the premenstrual phase of the cycle compared with the remainder of the
sample (those with postmenstrual relief of 75% and over). They
differed significantly from the women with lesser degrees of
postmenstrual mood relief in terms of their psychiatric history,
marital status and family size. These women may represent sufferers
from classical 'premenstrual tension' (Frank, 1931 - see section 1.3).
This would be the group on which to concentrate research into possible
underlying causes, and to focus initially in treatment trials. Some
studies (e.g. Dennerstein et al, 1985; 1986) claim to have screened
out this group for therapy but the majority of studies have been less
specific in their selection criteria, which possibly accounts for some
of the discrepant results between the various trials.
One third of the women showed little relationship between adverse mood
and menstrual cycle phase, although physical symptom profiles
maintained a cyclical pattern. High levels of adverse psychological
symptoms were present throughout the cycle. The term 'menstrual
distress' was used by Dalton (1977) to describe women with
premenstrual symptoms which were not followed by a 'symptom free' week
postmenstrually. It was also used by Dennerstein et al (1984) to
classify women with premenstrual exacerbation of underlying
diagnosable psychiatric problems. On the basis of the above results,
it is suggested that the term is appropriate for those women with
postmenstrual mood relief of less than 25%. This symptom profile
indicates that the distress is an accentuation of an underlying
problem which is present throughout the cycle whether or not there is
a diagnosable psychiatric condition present. It is important to
recognise these women in general gynaecological practice as they may
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be inappropriately subjected to hysterectomy for non-specific
menstrual complaints. One study of psychiatric morbidity in a
gynaecological clinic (Byrne, 1984), used the General Health
Questionnaire to assess the presence or absence of psychiatric
disorders. A high prevalence of such problems, together with a
history of marital breakdown was found, particularly among women who
presented with complaints of pelvic pain. There was also an
association with stressful life events as measured by the Present
State Examination, with significantly lower scores in a control
group.
A third of the subjects showed intermediate degrees of postmenstrual
relief (between 25 and 75 percent according to the classification used
here). This is numerically a wide range and there is likely to be
overlap with the other two groups. Their psychological and physical
symptom profiles were similar to those of the women with greater
postmenstrual relief but with higher baseline levels of the
psychological symptoms. They differed from those women with more
complete degrees of postmenstrual relief by including significantly
more with a history of past psychiatric problems, marital breakdown or
larger family size. When compared with those with minimal or no
postmenstrual relief, a similar number had a history of these latter
factors. It is therefore not clear whether the women in this group
actually differ from those whose problem has been labelled 'menstrual
distress' except in relation to degree of relief of their symptoms
during and following menstruation.
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Comparison of the endocrine profiles of the women in these different
groups did not identify any hormonal basis for the difference. The
majority of the menstrual cycles which were monitored hormonally were
normal in terms of the characteristics of their luteal phases and
there was not an abnormal prevalence of anovular cycles. The evidence
for and against a specific disorder of ovarian function is discussed
in detail in the next chapter. From the results of the present study,
it is not possible to reach any more detailed conclusions about the
nature of the monitored cycles in the absence of data from control
subjects and without accurate timing of ovulation with serial LH assay
(see chapter 3). The profiles illustrated in figures 2.6 and 2.7
would not give support to a simple relationship between symptoms and
either oestrogen or progesterone although an underlying hormonal basis
seems likely. Equally, the psychological symptom pattern could be
related to anticipation of impending menstruation, signalled by the
physical symptoms. In later chapters of this thesis, suppression of
ovulation and menstruation in women with cyclical symptoms is
investigated. In practical terms, women with minimal or no
postmenstrual relief are unlikely to benefit from any form of
endocrine manipulation. For those in the intermediate category,
anticipated benefit should be proportional to the magnitude of the
relief although this hypothesis has never been tested.
It is possible that for many women who complain of adverse
premenstrual mental changes, exaggerated physical symptoms are acting
as a cycle marker so that they are making false assumptions about the
relationship of other symptoms to cycle phase, for example the women
illustrated in figure 2.4.1a. Similarly, in a subgroup of the women,
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menstrual discomfort may be causing an exacerbation of mental symptoms
during menstruation. It is also possible that some of these women
have decreased tolerance to normal degrees of physical discomfort
present premenstrually and during menstruation. Wood et al (1979a,
1979b) found a significant association between emotional difficulties
and psychosexual problems and complaints of both premenstrual tension
and menstrual pain. The only way of clarifying the relationship
between the two groups of symptoms would be to abolish the physical
components of the cycle and assess mental change in isolation. This
approach is discussed in greater detail in a later section of this
thesis.
Assessment of personality was not undertaken in this investigation
because of potential difficulties in interpretation (see section 1.7).
However it would have been interesting to correlate personality with
degree of postmenstrual relief. As discussed earlier (section 1.7),
an association between premenstrual complaints and neuroticism has
been reported, also a relationship with psychiatric disorder. The
results of the present study distinguish between premenstrual
complainers whose symptoms are relieved postmenstrually and who are
free of psychiatric problems and those with lesser degrees of
postmenstrual relief. These latter women frequently have a background
of psychiatric problems. Because psychiatric assessment was based
only on reported past history, it might have underestimated the
prevalence of psychiatric disorder in this group, in particular
disorders of personality.
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Both marital status and number of children were significantly
associated with the degree of postmenstrual mood relief. A past
history of marital breakdown may be an indicator of current life
stresses, of minor psychological upset or alternatively of
difficulties with personal relationships. Similarly, family size may
be associated with environmental stress. It would have been relevant
to assess formally the presence of stressful life events as there was
an impression, while interviewing some of the women, that such factors
were important. The role of stress in the aetiology of menstrual
cycle related symptoms is of potential relevance. It is possible that
there is an underlying physiological reason why women may be more
vulnerable to stressful events premenstrually. Past studies have
demonstrated that a wide range of medical conditions such as asthma
and epilepsy may be worsened premenstrually (Magos & Studd, 1985) and
the exacerbation of certain psychiatric disorders has already been
discussed (section 1.7). Accidents, petty crime (Dalton, 1960a&b;
1961) and also major crime (Brahms, 1981) have been attributed to the
'premenstrual syndrome'. However, it is more likely that a tendency
to poor performance and to perform violent and criminal actions is
being exacerbated in a predisposed individual. The exact nature of
any physiological factor is as yet unknown. One recent study of blood
pressure patterns in women showed a premenstrual rise in blood
pressure only when the measurements were made in the laboratory
situation. When repeated in familiar surroundings, no premenstrual
rise was seen (Greenberg et al, 1985). This suggests that the minor
stress of the experimental situation was provoking this premenstrual
blood pressure rise which was not seen during other phases of the
cycle or when the stress was removed. Variation in the response of
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the autonomic nervous system to stress according to menstrual cycle
phase may be an important factor in the aetiology of cycle related
symptoms. This theme is discussed in greater detail in chapter 7 of
this thesis.
The visual analogue scales used here appear to be a suitable method of
prospective assessment, adequately completed by 84% of the original
sample. Their major disadvantage is that they are time consuming to
analyse and thus are not suitable for routine screening purposes in a
busy out-patient clinic or surgery. An alternative chart for routine
use has been devised and its use is described in a later section
(2.6). An assumption is being made that data obtained by monitoring
one or two menstrual cycles is representative of the majority of such
cycles experienced by an individual over several months. However good
correlations were obtained between consecutive cycles in cases where
sufficient data was available. Validity of the method might also be
affected by a tendency for individuals to exaggerate the severity of
their symptoms during assessment. One study has demonstrated that
symptom scores using the VAS tend to be shifted towards the severe end
of the scale compared with other methods (Faravelli et al, 1976).
However, the method of analysis used here, based on severity of change
in relation to baseline recording should allow for that tendency.
There are two recently published studies in which premenstrual
complainers were assessed prospectively using visual analogue scales.
One was based on a psychiatric clinic (Rubinow et al, 1984), the other
on women referred to a gynaecological department (Abraham et al,
1985). A third group has reported a similar investigation (Halbreich
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et al, 1985) using a different method of continuous assessment. All
have come to very similar conclusions about the various patterns of
symptomatology and the overall low proportion of women who actually
exhibit a clear cut 'premenstrual tension syndrome'. One of the
groups attempted to study a control population (Abraham et al, 1975)
and found a similar prevalence of premenstrual symptoms among the
volunteers. The patient group had higher symptom ratings during
menstruation, again confirming the high prevalence of menstrually
related complaints among the population of 'premenstrual
complainers'. However, these results, like those presented in this
chapter, do question the degree to which the reporting of cyclical
symptoms depends on individual perception and attitudes rather than to
the actual severity of the symptoms.
2.5 - Conclusions
Women who present for help with emotional problems which they
attribute to the menstrual cycle should be asked to keep a prospective
daily record of their symptoms, in order to determine their
relationship to menstrual cycle phase. Their assessment must include
a full social and psychiatric history and ideally an evaluation of
personality and the presence of stressful life factors. The term
'premenstrual syndrome' does not appear to add anything positive to
our understanding of the problems of these women. It merely refers to
a group of symptoms and does not distinguish between normal
physiological variation and a pathological condition. Nor does it
allow for the fact that symptomatic women exhibit different symptom
patterns. The alternative term 'menstrually related mood disorder'
(Rubinow et al, 1984), although rather cumbersome is more appropriate
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and clinically applicable. Its use is supported by the results of the
present investigation.
It is suggested that classification of menstrually related mood
disorder should be based on quantification of the degree of
postmenstrual 'relief' of symptoms. This will be more informative
than methods which do not take the baseline symptom levels into
consideration. It is proposed that the term 'premenstrual tension' be
restricted to women whose adverse mental symptoms are considerably
relieved during the postmenstrual week. An arbitrary quantitative
limit of relief by 75% or more postmenstrually could be used, although
this may need to be altered in the light of further information from
larger numbers of women. Where postmenstrual relief is negative or
minimal (less than 25%), the term 'menstrual distress' is appropriate
as symptoms usually persist throughout the cycle with slight
exacerbation at menstruation. Between these limits there is a group
of women who exhibit perimenstrual exacerbation of symptoms present to
a varying degree throughout the cycle. These may be related to
underlying problems which need to be defined for each individual, for
example home stresses or a mild depressive illness. In practice there
is bound to be overlap between these groups but it is necessary to set
some limits when deciding about the suitability of therapy or criteria
for inclusion in a treatment trial. Evaluation of responses to
treatment should be performed with reference to pre-treatment degrees
of postmenstrual mood relief. Not only will this assist with
interpretation of results but also lead to further information about
the relationship between symptom patterns and various causative
factors.
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2.6 - Evaluation of a simple descriptive scale in patients with
premenstrual complaints
2.6.1 - Introduction
The visual analogue scales used for evaluation of women with
premenstrual complaints in the study described in this chapter have
previously been validated and are already in use in this context (see
section 1.9.6). However, they are time consuming to analyse and not
well suited for use in a busy gynaecological clinic or in a general
practitioner's surgery where rapid on-the-spot analysis is necessary
as an aid to diagnosis and further management. The object of the
small study described below was to evaluate a simple descriptive chart
in a population of women similar to those of the main study.
2.6.2 - Subjects and methods
All the women evaluated in this way were consecutively referred to the
Reproductive Endocrine Clinic of the Edinburgh Royal Infirmary with
premenstrual complaints. The criteria for inclusion were similar to
those of the initial study (see section 2.2.1), except that women on
oral contraceptives were specifically excluded. All the women were
asked to complete the charts for 56 days starting on the day following
their visit to the clinic. Six items were listed (figure 1.4; section
1.10.2) although space was left for inclusion of other symptoms if
these predominated. Each symptom was scored daily on a 4-point scale
as indicated.
For the analysis, the premenstrual, menstrual and postmenstrual phases
were defined as previously described (sections 1.10.1; 2.2.3). Mental
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and physical symptom scores for each cycle phase were calculated for
each subject taking the mean of the scores for the two individual
cycles. The physical score was the mean of the scores for breast
discomfort and swelling and the mental symptom score the mean of
scores for depression and irritability unless any other mental
symptoms were listed. The percentage difference between the
premenstrual and postmenstrual symptom scores and between the
premenstrual and menstrual scores were calculated as described in
section 1.10.1, giving the degree of postmenstrual and menstrual
relief of both physical and mental symptoms.
An additional group of 15 subjects were asked to complete visual
analogue scales for the initial assessment cycle and then the simple
descriptive charts for the second month to enable a direct comparison
of the two methods to be made. The postmenstrual mood relief obtained
by the two methods was compared by calculation of Spearmann's rank
correlation coefficient.
2.6.3 - Results
40 subjects were initially evaluated with the simple descriptive
charts, of whom 37 returned charts which were satisfactorily
completed. This non-compliance rate of 7.5% is lower than the rate of
16% with the VAS charts (section 2.3.2). In two cases, numerical
scores were not used, merely ticks to indicate the presence of
symptoms and the third subject 'mislaid' the chart.
In figure 2.7, the 37 women with completed charts are classified on
the basis of the degree of postmenstrual and menstrual relief of the
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Table 2.7
37 women who completed simpie descriptive scales each day compared
with 100 who completed daily visual analogue scales (VAS)
MENTAL SYMPTOMS
number (%) VAS score (%)
Postmenstrual relief
75% or more 17 (45%) 32%
25% - 74% 10 (27%) 35%
Less than 25% 10 (27%) 31%
Menstrual relief
Present 19 (51%) 56%



























mental and physical symptoms. The corresponding figures obtained
using visual analogue scales in the larger study (see table 2.3) are
given for comparison. Although a higher proportion of the subjects
completing the simple scales appeared to have greater than 75% relief
of their mental symptoms postmenstrually, the proportions in the three
groups do not differ statistically (chi-squared=2.10; 2 degrees of
freedom). However, complete (100%) post-menstrual relief of mental
symptoms was recorded by 10 (27%) of those completing the simple
charts, compared with only 7 (7%) of the VAS group. At the other end
of the scale, postmenstrual exacerbation of mental symptoms was
recorded by 17% on the simple charts and 14% on the VAS charts. The
breakdown of physical symptom relief was remarkably similar in the two
groups.
Fourteen of the fifteen subjects asked to complete both types of
assessment scale on consecutive cycles did so as instructed. Comments
received about the two methods generally favoured the visual analogue
scales in terms of greater sensitivity in expression of day to day
fluctuations in mood and the women appreciated the space available on
the VAS forms for additional remarks. One or two commented that they
felt less motivated to complete the simpler charts each day. However
others expressed relief that the duration of VAS recordings was
limited to only one cycle. The degree of postmenstrual relief of the
mental symptoms calculated by the two methods in the two consecutive
cycles was found to be significantly correlated (r=0.629; p<0.02). In
this group of subjects, only one of the fourteen recorded 100% relief
of mental symptoms postmenstrually on the simple charts and the median
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postmenstrual mood relief was no higher (50% with the simple charts
compared with 61% with the VAS).
2.6.4 Discussion
The simple descriptive charts were very easy to analyse both visually
and quantitatively and were appropriately completed by the majority of
the women. When compared with visual analogue scales in the same
group of women they appear to yield similar results. A highly
significant intercorrelation between visual analogue scales and simple
descriptive scales tested during the same cycle has recently been
reported by Casper & Powell (1986). This is not altogether surprising
when the recordings are being done simultaneously. Testing in
consecutive cycles, as in the present study, may result in a greater
discrepancy between methods. However highly significant correlations
between symptom scores in consecutive cycles were previously found
(section 2.3.6) and also reported by others (Chuong, 1985).
The simple charts appear to produce a shift in favour of recording
complete postmenstrual symptom relief compared with the visual
analogue scales. This may be because the simpler scoring system is
liable to result in lack of recording of minor levels of
symptomatology. In addition, the subjects may be more aware of cycle
phase because of the way in which the chart is set out. Despite this,
the two methods detected a similar number of women whose symptoms were
clearly not premenstrual. Thus the use of a simple descriptive chart
in the context of a general clinic or a general practitioner's surgery
seems justified. Their sensitivity appeared to be greater in the
group who had first completed the VAS charts for one month, perhaps
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reflecting that these women had become accustomed to the practice of
daily recording. In the clinical study described in chapter 6 of this
thesis, where assessment of symptom response to prolonged therapy with
an agonist of LHRH is based on these simple charts, the majority of
the subjects had completed the standard VAS charts for two months at
some time prior to recruitment.
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CHAPTER 3
THE ENDOCRINE BASIS OF CYCLICAL CHANGE AND THE EFFECT OF HORMONE
MANIPULATION - LITERATURE REVIEW
3.1 - Introduction
The relationship between premenstrual tension and the luteal phase of
the cycle has led to speculation that there is an underlying disorder
of ovarian function. Frank (1931) attributed the symptoms in severe
cases to an excess of the 'female sex hormone'. He observed
favourable results after extreme measures such as venesection,
'elimination' by diuretic agents or laxatives, and, if all else
failed, ovarian irradiation! Israel (1938) more specifically
considered the cause to be that of progesterone deficiency and found
progesterone therapy to be beneficial in five out of seven cases with
pituitary ablation therapeutic in another six. Morton (1950)
demonstrated a luteal phase deficiency of progesterone in a high
proportion of sufferers, based on endometrial biopsy studies and
urinary pregnanediol excretion. However all subjects were sampled
relatively late in the cycle. He also found that the symptoms could
be induced by administration of large doses of oestrogen. On the
other hand Gillman (1942) described profound mental symptoms in one
subject following intramuscular administration of progesterone and
symptoms including irritability, swelling and depression were
recognised side effects of therapy with synthetic progestogens (Garcia
et al, 1958), suggesting progesterone to be the provoking factor.
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More recently several different approaches have been used in an
attempt to clarify the relationship between ovarian steroids and the
mental and physical symptoms which are associated with the
premenstrual phase of the menstrual cycle. These approaches can be
summarised as a list of questions:
1. Is there a distinct disorder of ovarian function in women
classified as sufferers from premenstrual tension?
2. If so, does this respond to hormonal manipulation with currently
available exogenous ovarian steroids?
3. Does the addition of cyclical progestogen provoke adverse physical
and mental symptoms in postmenopausal women receiving hormone
replacement therapy with oestrogen?
4. Do the combinations of oestrogen and progestogen present in the
oral contraceptive pill produce adverse mood and physical changes and
if so, is this related to the oestrogenic component, the progestogenic
component or the relative proportions of the two?
5. Conversely, does the presence of the more constant plasma ovarian
steroid levels associated with oral contraceptive therapy suppress or
reduce cyclical symptoms?
6. Do other methods of suppression of ovulation abolish or reduce
cyclical symptoms?
In this chapter the literature relevant to these questions will be
reviewed in depth, although not necessarily in the order listed above.
In addition, other current theories of the cause of premenstrual
tension will be briefly discussed where relevant.
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3.2 - Circulating ovarian steroids in normal and symptomatic women
There have been a number of studies based on assay of circulating
ovarian steroids in small numbers of symptomatic subjects compared
with women selected as controls. Most of these studies are open to
serious criticism. In particular mood and symptom profiles during the
cycle under study have usually not been presented for either the
symptomatic or the control group. Some of the studies have been based
on women presenting for medical help with their problem and others
have recruited volunteers reporting cyclical changes so the
populations under study may not be uniform.
Several groups have reported reduced luteal phase plasma progesterone
concentrations. Backstrom & Carstensen (1974) found significantly
higher oestrogen:progesterone ratios in ten sufferers from
premenstrual anxiety and irritability on days 6 to 3 before
menstruation, compared with eight healthy non-complainers. Two other
women who suffered only from premenstrual headaches had results within
the control range. Sampling was only carried out for six days
premenstrually but the study was later repeated (Backstrom et al,
1976) when daily sampling was carried out for ten premenstrual days in
15 patients complaining predominantly of premenstrual anxiety and in
17 control subjects. Progesterone concentrations were again
significantly lower during the mid-luteal phase in the symptomatic
group. Oestradiol concentrations were lower early in the luteal phase
but significantly higher in the late luteal phase, the latter preceded
by significantly elevated FSH concentrations, although the mechanism
of the latter rise is unclear.
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The results of Munday et al (1981) were similar to those of Backstrom
(1974, 1976). Twenty women diagnosed as suffering from premenstrual
tension on the basis of daily symptom recording, were compared with 10
control volunteers by venous blood sampling every 2-3 days. They
reported significantly lower progesterone concentrations in the mid-
luteal phase with significantly higher oestradiol concentrations in
the late luteal phase in patients compared with the control subjects.
Smith (1975) studying subjects with premenstrual depression found
plasma progesterone concentrations to be significantly lower over the
seven premenstrual days compared with control subjects although the
concentrations were not related to the symptom severity in any one
cycle.
Others have failed to confirm the above findings. Taylor (1979a)
could find no significant differences between plasma progesterone or
oestradiol or their ratios in 39 young women sampled daily during the
premenstrual week and on alternate days for the remainder of the
cycle. Presence or absence of cyclical symptoms was determined by
daily symptom ratings but as a group these were not women who had
presented with premenstrual problems and thus were not truly
representative of a pathological group. Interestingly, he found age
was positively correlated with plasma progesterone concentration.
Andersch et al (1979) also failed to demonstrate any differences in
ovarian steroids between 20 women defined as premenstrual tension
sufferers and an equal number of healthy volunteers studied over two
cycles but subjects were only sampled once during the luteal phase.
In contrast, O'Brien et al, (1980) compared 18 symptomatic women with
10 asymptomatic controls and found the symptomatic group to have
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significantly higher concentrations of progesterone during the post-
ovulatory phase although samples were taken only four times during the
cycle and the mean age of the two groups is not stated. In addition,
the 'symptomatic' group were selected from a group of volunteers on
the basis of a premenstrual symptom rise on daily visual analogue
scale recordings and had not originally presented for medical help
with their problems.
In a further study, Backstrom et al (1983) were unable to demonstrate
any significant differences in plasma oestrogen and progesterone
concentrations, sampled at least three times weekly, between
symptomatic and asymptomatic women. The subjects were two groups of
18 women drawn both from a clinic population and from a volunteer
group. All completed symptom diaries each day throughout the study
cycle and were classified on the basis of the results into high mood
change and low mood change groups. Thus the methods used may be
regarded as superior to those of his earlier studies (Backstrom 1974,
1976).
These above studies may also be criticised on the grounds that no
accurate estimation of timing of ovulation was made, making the
assumption that it preceded menstruation by exactly 14 days which is
not invariably the case (Smith et al, 1984). The subjects of O'Brien
et al (1980) kept basal body temperature charts which would not now be
regarded as being of sufficient accuracy for timing (Templeton et al,
1982). In a study based on daily overnight 12 hour urine collections,
Dennerstein et al (1984) were able to detect the pre-ovulatory
oestrogen peak in order to standardise results during the luteal
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phase. They found a high incidence (20%) of abnormal cycles among 19
patients, compared with a 4% incidence among 104 normal controls.
Abnormalities included anovular cycles and short and deficient luteal
phases. Another observation, that of a delayed rise in pregnanediol
in patients compared with controls is invalidated by the imbalance of
numbers in the two groups. However, they also reported significantly
lower luteal phase peak pregnanediol concentrations among the patients
compared with selected age-matched controls. The results may be
criticised on the grounds that all the control data was based on 24
hour urine collections rather than the 12 hour collections of the
patient group although the authors claim that no bias was introduced
into the results by the use of the two different methods. These
authors, unlike others, were careful to distinguish between patients
with clearly defined premenstrual problems, compared with a 'menstrual
distress' group (see section 2.4) where no such endocrine
abnormalities were apparent.
Watts et al (1985) timed ovulation accurately by assay of plasma LH in
35 women defined as premenstrual tension sufferers on the basis of
daily symptom recording compared with 11 control subjects. Apparent
differences in luteal phase progesterone and oestradiol profiles
between the two groups were largely accounted for by the occurrence of
earlier ovulation in 18 of the 35 patients, compared with only 2 of
the 11 controls. Follicular ultrasound in a sample of both groups
showed the former to ovulate at smaller follicle diameters and lower
concentrations of plasma oestradiol than the control group. Some of
the patients showed a delayed progesterone fall in the late luteal
phase, accounting for delay in onset of menstruation. Interestingly,
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plasma Cortisol concentrations were uniformly and significantly
elevated in the patients compared with the controls, perhaps an
indicator of increased stress. The potential importance of
environmental stress in the aetiology of menstrual cycle related
symptoms is discussed in section 2.4 and chapter 7. The significance
of their findings have yet to be clarified, but these results tend to
throw doubt on the validity of the earlier studies which failed to
accurately time ovulation.
Considering the confusion in the literature about the basic criteria
for diagnosis of premenstrual problems (section 1.3) and the
heterogeneous group of women who present for help (chapter 2), it is
not surprising that the above studies have yielded such discrepant
results. As the majority of the above studies are open to criticism
om methodological grounds, it is difficult to draw any definite
conclusions, other than that as yet no gross abnormality in ovarian
steroidogenesis has been demonstrated. Future research should be
directed at studying the mechanisms controlling the cycle rather than
drawing conclusions from minor differences in circulating ovarian
steroids or their urinary metabolites.
3.3 - Other possible mechanisms
Several other theories have been put forward to explain the phenomenon
of premenstrual change, either as alternatives to an imbalance of
oestrogen/progesterone or in association with such a disorder. The
lack of evidence supporting an abnormality of prolactin secretion has
been discussed in section 1.8.6. Another popular theory was based on
the observation that some cases of depression induced by the combined
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oral contraceptive pill (see section 3.5) are due to a relative
deficiency of vitamin B6 (pyridoxine). This subject is
comprehensively reviewed by Rose (1978). There is some evidence that
oestrogens increase the dietary requirement for vitamin B6 by
induction of the enzyme tryptophan oxygenase with resulting increased
turnover of the pathway of tryptophan metabolism. In addition,
oestrogen esters may compete with vitamin B6 for an apoenzyme involved
in the conversion of tryptophan to 5-HT (serotonin) in the central
nervous system. Impaired synthesis of the latter has been postulated
as a cause of depression (Ashcroft et al, 1966). Abnormal tryptophan
metabolism, corrected by pyridoxine supplementation in a proportion of
women with oral contraceptive pill associated depression was
demonstrated by Adams et al (1974) in a placebo-controlled study.
However there is no evidence that dietary pyridoxine requirements
alter during the course of the normal menstrual cycle (Rose, 1978) and
the benefit from its use in women with premenstrual tension was not
confirmed in a placebo-controlled study (Stokes & Mendels, 1972).
Indeed there is a risk that the consumption of high doses of
pyridoxine by some premenstrual tension sufferers may result in toxic
side effects (Dalton, 1985).
3.3.1 - Prostaglandins and the use of prostaglandin synthetase
inhibitors
Prostaglandins are known to act as local hormone mediators of the
actions of ovarian steroids in the uterus and to undergo changes in
concentration during the ovulatory menstrual cycle (see section
1.2.3). This has led to theories that abnormalities of prostaglandin
metabolism may be causative in premenstrual tension. Many of the
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adverse symptoms associated with the latter may be provoked by the
systemic administration of various prostaglandins, particularly E2 and
F2a and prostaglandins are also present in gut, kidney, breast and the
central nervous system (see reviews by Craig, 1980 and Budoff, 1986).
However there is no direct evidence to support such a disorder and
studies of plasma concentrations are unhelpful as prostaglandins are
cleared rapidly from plasma. Similarly, claims that dietary
supplementation with high doses of certain vegetable oils (e.g.
evening primrose oil) has a beneficial effect by increasing the
synthesis of prostaglandins of the Ei group relative to the E2 group
(Abraham, 1983; Brush, 1982) remain unsubstantiated.
There have been several studies of the effects of prostaglandin
synthetase inhibitors in women with premenstrual complaints.
Significant benefit with mefenamic acid relative to placebo was
reported by Wood & Jakubowicz (1980) and Jakubowicz et al (1984) in
women whose symptoms were present both premenstrually and also during
menstruation, with no benefit in the minority of subjects whose
symptoms were confined to the premenstrual phase. An association
between premenstrual and menstrual complaints was found in a
proportion of the subjects described in chapter 2 (sections 2.3.4 &
2.3.5). These results may thus support a possible role of
prostaglandins in this sub-group of symptomatic women but not those
with symptoms confined to the premenstrual phase of the cycle.
Prostaglandin synthetase inhibitors are of proven value in the relief
of dysmenorrhoea (see review by Owen, 1984). In the latter condition
abnormally high concentrations of prostaglandins in menstrual fluid
have been demonstrated (Pickles et al, 1965; Chan et al, 1979; Dawood,
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1983). There is also evidence for the involvement of PGe2 in the
aetiology of migraine (Budoff, 1986). It is thus possible that relief
of psychological symptoms by prostaglandin synthetase inhibitors is
secondary to relief of physical discomfort and headache. In a trial
comparing naproxen sodium with placebo, Budoff (1986) found a
significant benefit from active therapy for only 4 out of 46 symptoms
assessed, one of these being headache. The others were tension, lack
of self-control and 'jittery feelings'. None of these studies
reported a reduction in breast discomfort, in contrast to that of
Rolland et al (1979). The latter group did not however study the
effects of prostaglandin synthetase inhibition (with aspirin or
indomethacin) on other physical symptoms or on mood.
On the basis of the evidence presented above, no firm conclusions can
be reached about the role of prostaglandins in the aetiology of
premenstrual symptoms. A lack of consistent response to prostaglandin
synthetase inhibitors does not exclude such a role as the doses used
may have been insufficient and higher doses would be liable to produce
unacceptable side effects.
3.4 - Cycle manipulation with exogenous ovarian steroids
Another approach to the study of the relationship between hormones and
mood has been by observation of the effects of administration of
exogenous ovarian steroids. The early reports of adverse effects
following administration of large doses (section 3.1) have been
followed up more recently by studies of the effects of various regimes
of hormone replacement therapy in postmenopausal women. Hammarback et
al (1985) studied 22 women who were receiving percutaneous oestrogen
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replacement, 11 of whom were given oral progestogen supplements during
the last 10 days of therapy, while the other half received the
oestrogen alone. Analysis of daily visual analogue ratings showed
small but significant changes in mood and physical symptoms in the
latter part of the cycle in those receiving the progestogen. This
study did not include a placebo control but the latter was included in
a similar study by Magos et al (1986) involving 58 hysterectomised
postmenopausal women receiving hormone replacement with oestradiol and
testosterone implants. Compared with placebo, 5 mg of norethisterone
given for 7 days out of 28 was associated with a significant increase
in negative affect and physical symptoms. A dose of 2.5 mg also
resulted in higher scores which did not reach significance but some
cyclical changes were seen also with the placebo tablets, illustrating
the vital importance of such a control group.
While these results appear to support the theory that premenstrual
symptoms are provoked by progesterone, they are based on the
administration of synthetic progestogens of the 19-nortestosterone
group which may be more liable to produce such effects in low dosage
than 'natural' progesterone (Dalton, 1977). Even if they provide an
explanation for cyclical changes they still do not explain whether
similar mechanisms underlie normal physiological variation in mood and
physical symptoms, compared with those which might be regarded as
pathological. Neither of these studies involved women who were
selected as having previously suffered from cyclical symptoms. A
potentially useful model for further study in premenopausal women
would be suppression of endogenous ovarian activity by an agonist of
LHRH with the addition of varying replacement doses of both 'natural'
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and synthetic oestrogens and progestogens. The action and application
of LHRH agonists is discussed in greater detail in chapters 5 and 6.
3.5 - Studies based on contraceptive steroids
Greatest experience of the use of oestrogens and progestogens in
clinical practice has been in the field of contraception, particularly
oral contraception. Adverse effects have been documented but so has
improvement in well-being (Bakker & Dightman, 1966; Kane et al, 1967).
It was not clear from early studies whether these changes were
attributable to the progestogen or oestrogenic component and whether
other factors were involved. There have been a few detailed studies
of the effects of the oral contraceptive pill on mental and physical
well-being and also of its effects on pre-existing cyclical symptoms.
The latter is of interest in view of the absence of ovulation and the
more constant hormonal environment associated with therapy. The
number of detailed studies performed have been few but are of
relevance to several areas of this thesis and some of these will be
discussed in detail. They are summarised in table 3.1.
3.5.1 - Descriptive studies
Several descriptive studies have been reported, all with the object of
determining whether oral contraceptive steroids cause adverse physical
and mental changes. The majority also specifically considered effects
on pre-existing cyclical symptoms although only two of the studies
followed these prospectively, the others relying on retrospective
interviews. In these studies, the subjects were either assessed
before and during therapy or compared with a control group of women


















































































































































































































































































































































Bakker & Dightman (1966) found no increase in tension or depression in
100 women receiving a single agent (Enovid) over 4 years. The women
reported an overall improvement in premenstrual tension during
therapy. Isolated episodes of depression occurred but were attributed
to adverse environmental factors or affected individuals with a pre-
pill history of depression. Kutner and Brown (1972b) in a cross
sectional study also found current depression to be significantly
related to a past history of depression, regardless of contraceptive
status. They found that there were significantly fewer reports of
premenstrual moodiness and irritability among current pill users
compared with past users or women who had never used oral
contraception (Kutner and Brown, 1972a). Depression was highest in
women taking pills with a lower progestogen content.
However, in a randomised study designed to look at side effects of
four different oral contraceptive preparations, Nilsson & Solvell
(1967) were unable to demonstrate any differences related to the
formulations selected, using monthly interview assessments. Forty
percent of their sample of 159 women complained of premenstrual
tension prior to starting the oral contraceptive and a statistically
significant decrease was reported during the initial 4 months of the
study, with a further decline to five percent at 12 months.
Unfortunately there was no placebo control.
In another early study in which a group of women commencing the pill
were compared with a group starting barrier contraception, Herzberg
and Coppen (1970) also reported a significant improvement in
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premenstrual mood in the pill group. Assessment was by regular
retrospective interviews. However premenstrual and menstrual swelling
and headache were unchanged. Physical side effects were commoner in
the pill group and although the incidence of psychological side
effects was small, depression was reported by more of the pill takers.
In keeping with the studies mentioned above, the latter were
significantly more likely to have a pre-pill history of depression,
compared with the pill takers as a whole. Their pretreatment Maudsley
Personality Inventory also showed higher scores for neuroticism and
extraversion. No relationship between pill formulation and reported
side effects was apparent.
Beneficial effects of oral contraceptives on cyclical symptoms were
supported in a more intensive study in which Paige (1971)
prospectively studied mood and cyclical changes in 102 married
subjects, 52 who took combined oral contraception, 12 on sequential
oral contraception and 38 who used non-hormonal methods. Detailed
assessment by content of speech analysis was carried out four times
during each cycle. This showed cyclical differences in negative
affect in the non-pill and sequential pill group which were not
present in those on the combined pill.
In another detailed prospective study, Wilcoxon et al (1976)
recruited volunteers who were not aware of the true purpose of the
study. Detailed daily assessments were carried out on 11 female
students not taking oral contraceptives, 11 using the combined pill
and 11 male subjects who were arbitrarily assigned 'pseudocycles'.
Overall behavioral changes, both positive and negative were lowest in
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males and lower in the women receiving the pill than the no-pill
group. Negative mood and anxiety showed a peak during menstruation in
the no-pill group and premenstrually in the pill group. Physical
symptoms peaked both premenstrually and menstrually in both female
groups, but scores were highest during menstruation in the no-pill
group. However an analysis of co-variance suggested that the negative
mood changes were more closely associated with stressful events which
occurred premenstrually in both groups, rather than with cycle phase
although no such cluster of stressful events was seen in the males.
The results support a 'damping down' effect of normal behavioural
changes in women on oral contraception with reduction of symptoms
during menstruation but not premenstrually. In common with the last
study, these subjects had self-selected their contraceptive methods
and thus conclusions based on comparisons between the two may not be
truly valid.
All the above studies were based on contraceptive formulations
containing higher doses of oestrogen than those in current use. One
uncontrolled study was based on a single cycle of daily ratings in 12
subjects receiving a combined pill containing 30 meg of oestrogen. No
significant change in anxiety was seen during the course of the cycle
although there was a steady increase in the depression score (Forrest,
1979). The author attributed this to a metabolic effect of the pill
(see section 3.3). A more recent cross-sectional study (Andersch &
Hahn, 1981) can be presumed to have included women on low-dose
formulations although this is not actually stated. The authors
selected women from five specific age groups, comparing 217 current
pill users with 595 women not on the pill. The women were given a
121
questionnaire which asked specifically about six premenstrual symptoms
and their severity. A significantly reduced prevalence of
irritability, sadness, anxiety and breast discomfort but not swelling
was reported by 25 year old pill users. Similar but non-significant
trends were also seen in pill users aged 32, 39 and 46, although these
groups were smaller. However, the reverse was true for pill users
aged 18, where the prevalence of all the individual symptoms, both
physical and psychological, was greater compared with non pill users.
Age may have influenced the results of another, earlier, cross-
sectional study of a student population reported by Sheldrake &
Cormack (1976). Using a single retrospective questionnaire check-list
which asked about both menstrual and premenstrual symptoms, a reduced
prevalence of physical symptoms was reported by 756 pill takers,
compared with 2543 students not on the pill. However the former group
reported an increased prevalence of adverse psychological symptoms
during the premenstrual but not the menstrual phase of the cycle.
This latter observation is in keeping with those of Wilcoxon et al
(1976) in the study discused above which was also based on
undergraduate students. The data of Sheldrake & Cormack was not
subjected to statistical analysis but does raise the question of an
age-related effect which may need to be taken into consideration when
interpreting the results of pill studies. Such an effect may however
be related to fundamental differences between the individuals who
choose to use the pill and non-users.
With the possible exception of women in the younger age groups, the
studies discussed above did not reveal any overall adverse
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psychological effects from oral contraceptives, except in women with a
past history of such problems. Indeed the majority reported an
improvement in cyclical symptoms. Ideally such studies should be
randomised and a placebo group included. Clearly this raises problems
when the object of the therapy is to prevent conception.
Preconditioning and expectation are likely to play an important role
in an individual's response to therapy. An interesting study which
could never now be repeated was reported by Aznar-Ramos (1969) from
Mexico. One hundred and forty seven young married women were given
placebo tablets and told they were an oral contraceptive. A
remarkably high incidence of 'steroid-like' side effects were
reported. Bakker & Dightman (1966) categorised the adverse effects of
oral contraception into 3 groups; those actually attributable to the
steroids themselves, those where the pill might be regarded as a
'scapegoat' eg weight gain and those which are suggestion-induced, for
example by hearing about adverse effects from other sources. It is
thus apparent that only limited conclusions may be drawn from these
uncontrolled studies.
3.5.2 - Placebo-controlled studies
One early study, in contrast to the others discussed here, was based
on women receiving depot medroxyprogesterone acetate for contraception
(Seymour & Powell, 1970). One common side effect of this preparation
is irregular bleeding and amenorrhoea (Fraser & Weisberg, 1981) for
which cyclical oestrogen was given to half the 752 subjects, with
placebo to the other half in a double blind manner. Side effects
during the period of supplementation were documented and found to be
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identical in the two groups, with the exception of amenorrhoea which
was higher in the placebo group.
Four placebo-controlled studies of the effects of the oral
contraceptive pill have been reported, all using rather different
designs and methodology. The largest was described by Goldzieher et
#
al, 1971a & b) who studied 398 subjects over 1523 cycles, comparing
the side effects of different contraceptive formulations with each
other and with placebo. Assessments were made by monthly interviews
with no attempt to study cyclical patterns. After preliminary
pretreatment assessment, the subjects were randomly assigned to
several groups. All received a single therapy for four cycles after
which those on placebo crossed over to either low oestrogen (50 meg)
or no oestrogen (progestogen-only) formulations. The high oestrogen
groups crossed over to no oestrogen and vice versa. Results showed
all physical and mental symptoms normally associated with the
menstrual cycle or with contraceptive steroid therapy to be reduced
during treatment, with the exception of nausea. A significant fall in
reports of depression were seen in all groups during therapy with no
significant differences between groups although there was a trend
towards higher reporting in the groups taking high oestrogen
preparations. However after the cross-over there was no significant
deterioration in the group switching to high oestrogen. Nervousness
showed significantly less reduction during the first treatment cycle
among women taking high oestrogen preparations compared with the
placebo group. This however did not persist beyond cycle 1 and no
increase in nervousness was apparent when the oestrogen free group
switched to high oestrogen.
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An overall low incidence of adverse reactions to contraceptive
steroids was also reported by Cullberg (1972), although in this study
reactions were least in the placebo group. Four groups of 80 women
were randomised between therapy with placebo or with one of three
combined oral contraceptives containing 50 meg of ethinyloestradiol
and 1.0, 0.5 and 0.06 mg of norgestrel respectively. Assessments were
made by interview and questionnaires before and after two months of
therapy. The group taking the oestrogen-dominated preparation were
rated significantly higher for irritability and depression than the
other three groups but prior assessment of personality had shown the
adverse reactors of this group to be emotionally more labile and more
neurotic. An association between adverse reactions to oral
contraceptives and neuroticism had also been reported by Herzberg &
Coppen, 1970 (see section 3.5.1 above). Women with a previous history
of premenstrual irritability were more likely to experience relief on
the high progestogen preparation and exacerbation with the high
oestrogen formulation. However among women without a previous history
of emotional upset, there were more adverse reactions to the high
progestogen preparation.
Two detailed placebo-controlled studies assessed symptoms on a daily
basis and, in contrast to most of the other studies reported above,
found cyclical patterns to persist during oral contraceptive therapy.
Morris & Udry (1972) randomised 51 women to therapy with a combined
preparation, a sequential preparation or placebo over one cycle. They
did not study specific symptoms but each subject recorded her overall
feeling of 'well-being' each day. There were no overall significant
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differences between the groups but those on placebo felt least well
during menstruation and both pill groups felt worst premenstrually.
Silbergeld et al (1971) performed a cross-over study in 8 women,
comparing two cycles on active therapy with two cycles on placebo.
The pill reduced physical discomfort and irritability but increased
nausea, breast discomfort, swelling and drowsiness. Significant cycle
phase effects were seen irrespective of therapy for pelvic discomfort,
breast tenderness, irritability, tension and aggression but not
depression. All these symptoms peaked either premenstrually or during
menstruation. However the oral contraceptive did appear to reduce the
magnitude of these changes.
3.5.3 - Conclusions from contraceptive studies
Overall, these studies do not demonstrate an excess of adverse
reactions to oral contraceptive steroids, regardless of formulation.
However the majority included relatively high doses of ethinyl-
oestradiol (50 meg), higher than that in current use and the
conclusions cannot necessarily be applied to lower dose preparations.
The results support a 'damping down' but not obliteration of cyclical
symptoms in women who experienced such problems prior to therapy.
It is relevant that all three studies which showed persistence of
cyclical symptoms were based on daily recordings. The presence of
such changes does not necessarily imply that they were distressing to
the individual or would have been reported in an interview. However,
the presence of a premenstrual symptom peak is difficult to explain on
the basis of hormonal changes. Endogenous ovarian steroids remain
suppressed throughout therapy with little fluctuation even in the
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pill-free week and the exogenous steroids are fairly constant except
on withdrawal (Elstein et al, 1976; Brenner et al, 1977). Persistence
of premenstrual symptoms under these circumstances does suggest that
other factors such as conditioning (see section 1.7) are involved.
There is some evidence that oestrogen-dominated preparations evoke
more adverse reactions than other preparations, particularly in
individual predisposed to such problems. Several of the studies found
a relationship between past psychological problems and 'pill-induced'
mood changes. This implies either that these women are more sensitive
to the effects of exogenous steroids or that the pill was being
'blamed' for the symptoms. Only one of the studies (Cullberg, 1972)
reported greater adverse effects from a progestogen dominated pill, in
this case women previously free of psychological problems or cyclical
symptoms.
3.6 - Progesterone and progestogens in the management of premenstrual
tension
While the results of these oral contraceptive studies are of interest
in relation to the effects of exogenous ovarian steroids on mood, the
subjects were not selected for study because of pre-existing cyclical
problems and to date there have been no reported controlled trials of
the therapeutic use of the pill in premenstrual tension. There have
been a number of treatment trials (see below) investigating the use of
progesterone and progestogens in the management of premenstrual
tension. The results are a source of further information about the




The use of supplementary progesterone during the second half of the
cycle was first advocated by Dalton (1977), based on the assumption,
then and still unproven (see section 3.2), that the syndrome was
attributable to a progesterone deficiency. She claimed considerable
success from therapy (Dalton, 1977) but performed no controlled
trials. Some of her patients required very large doses for relief (up
to 1200mg/day) which results in plasma concentrations greatly in
excess of those seen physiologically. Urinary pregnanediol
concentrations five to ten-fold higher than those present in the mid-
luteal phase of the normal cycle were observed in two patients managed
personally who had increased their daily dose of intravaginal
progesterone to 1200mg/day. Doses of between 200 and 500 mg have been
reported to induce rapid hypnosis when administered as an intravenous
bolus (Merryman et al, 1954). It is thus very probable that these
large rectal/vaginal doses are having a direct pharmacological
sedative action.
Two placebo controlled studies failed to support Dalton's results.
Smith (1975) showed no benefit from 50 mg of progesterone given
intramuscularly on alternate days from day 19 of the cycle in patients
with premenstrual depression. In a double blind cross-over study,
Sampson (1979) compared progesterone 200mg twice daily with placebo,
given for 12 days premenstrually over one cycle. Symptoms were self
assessed daily with the Moos Menstrual Distress questionnaire. Thirty
five out of 39 subjects completed the study but no significant benefit
was seen. Twenty four of the subjects were then treated with
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progesterone 400 mg bd compared with placebo. Here there was a
worsening of symptoms with the active therapy, perhaps unexpected in
view of the above observations made by Dalton.
A third cross-over controlled study investigating the use of
progesterone did show a positive benefit over placebo (Dennerstein et
al, 1985). This differed from the earlier trials in the use of an
orally active form of progesterone (micronised progesterone which is
not currently available for routine use). This was given at a dose of
300 mg daily, starting approximately 3 days after ovulation. Two
active and two placebo cycles were studied in 24 subjects, only one of
whom subsequently withdrew. Assessments were made by monthly
interviews, affective tests and daily symptom records. Overall
changes were in favour of the progesterone, but of a large number of
parameters assessed by interviews and psychometric tests, only fluid
retention, control, stress and anxiety were significantly improved
with active therapy during the first treatment month. Only 'fluid
retention', assessed subjectively, showed significant improvement over
both treatment cycles. The daily symptom records (10 symptoms) showed
a significantly better response to active therapy for depression and
swelling during the first month. Hot flushes as well as swelling were
significantly improved over both cycles. The greater response to the
active therapy during the first rather than the second treatment month
does question whether the effect would have been sustained for much
longer. The positive effect of progesterone demonstrated by this
study appears to be restricted largely to physical symptoms and does
not convincingly support the theories that premenstrual symptoms are a
consequence of progesterone deficiency. However the effects on 'fluid
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retention' would be worthy of confirmation in a further study which
incorporated more detailed assessment of fluid and electrolyte balance
and daily weighing (see section 1.8.2).
3.6.2 - Progestogens
The need to administer progesterone by intramuscular injection or by
the rectal or vaginal route led to investigation of the use of oral
synthetic progestogens as an alternative. This was again based on the
assumption that the underlying problem was one of progesterone
deficiency. An early placebo-controlled study was reported by Swyer
(1955), who compared the effects of ethisterone, mephenesin (a muscle
relaxant) and placebo taken from days 15-25 of the cycle. No
significant differences emerged although mephenesin brought relief
more often than ethisterone. Jordheim (1972) compared
medroxyprogesterone acetate (MPA) 7.5 mg for 10 days premenstrually
with MPA combined with a thiazide diuretic in a double blind cross¬
over study of 35 patients. Unfortunately there was no placebo group
although he did compare the combined therapy with placebo in a group
of student nurse volunteers. No significant differences emerged,
although the premenstrual symptoms did not appear to be exacerbated by
the progestogen.
More recently there has been considerable enthusiasm for the use of
dydrogesterone (Duphaston - Duphar). It was selected because of its
closer structural resemblance to progesterone than other synthetic
progestogens, although it has less progestogenic potency (Swyer &
Little (1962). The chosen regimen has been 10 mg twice daily from
days 12-26, i.e. commencing in the late follicular phase or around the
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time of the mid-cycle surge. The reason for the choice of this
regimen has not been stated. The widescale current use of the therapy
was based on a single-blind study by Kerr et al (1980), who recruited
103 patients for treatment over 6 cycles, but encountered a drop out
rate of 35%. All patients were initially assessed over one cycle and
described as 'symptom free' 2 days after the onset of menstruation.
After an initial placebo cycle, active therapy was given for 3 cycles,
followed by 2 further placebo cycles. The results are reported in
terms of the gynaecologist's assessment by interviews conducted prior
to each change over and at the beginning and end of the study. The
results of daily diary charts completed by the subjects were not
described. A 43% response to the initial placebo cycle was reported
with an overall improvement in depression, irritability, and abdominal
swelling but no reduction in breast discomfort. 21% of the subjects
improved only on the active therapy.
Clearly the single-blind design of the last study is open to criticism
and a large multi-centre study was set up in four European countries,
based on general practitioner populations of women. This was not a
cross-over study but involved treatment over 3 cycles with either
Duphaston or placebo, after an initial control month. Simple diary
cards were used to record the presence and severity of 6 psychological
and 7 physical symptoms on a daily basis, and the subjects were
interviewed and their symptoms rated each month. A preliminary report
of the Dutch part of the study involving 150 women, of whom 123
completed the treatment, showed significant differences between the
two groups (Haspels et al, 1981). Overall symptoms scores at the end
of therapy demonstrated that 73% of the subjects had improved on
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active therapy and 53% on placebo. This difference was statistically
significant. However, the only individual symptoms to show a
significant improvement were depression and breast discomfort. The
full study was reported by Williams et al (1983). Data from only 300
of the 421 subjects recruited was analysed, the remainder being
excluded prior to analysis for various reasons. Drop out during
therapy was low in both groups, at 14.3% from active and 12.1% from
placebo therapy. Results were again expressed in terms of the results
of the monthly interviews and data from the daily record cards was not
presented, perhaps because insufficient numbers had been completed or
handed back. There were no significant differences between the two
groups for any individual symptoms although trends favoured the
Duphaston for depression, aggression, backache and swelling. They
favoured placebo for nausea. However 'global' assessment of efficacy
made by both the subjects and the physicians at each visit
significantly favoured active therapy at the end of three but not two
months.
In view of doubts regarding the methodology of these studies and the
rather equivocal results, further double blind placebo-controlled
studies have also been conducted by Sampson and colleagues and
Dennerstein and colleagues, crossing over two months of active therapy
with two months of placebo. Using identical methods of assessment to
those used in their double blind study of oral progesterone,
Dennerstein et al (1986) failed to find any significant differences
between active therapy and placebo, although the maximum benefit from
both was present during the initial two treatment cycles. A
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preliminary report by Sampson et al (1983) also failed to demonstrate
a significant benefit from active therapy.
Overall these results do not convincingly support any positive effect
from Duphaston although it is still possible that the benefit reported
by Williams et al (1983) from more prolonged therapy reflected a
gradual decline of the placebo effect over the 3 months of the study.
One interesting result to emerge from the study of Kerr et al (1980)
was that luteal phase progesterone concentrations were significantly
reduced during active therapy. This suggests that any benefit from
the Duphaston is exerted through interference with ovulation rather
than by 'boosting' progesterone levels. Past studies of the effect of
cyclical dydrogesterone therapy on ovulation have yielded conflicting
results; some reporting lack of inhibition (Bishop et al, 1962) at a
dose of 10 mg bd from days 5 to 26. However, ovulation suppression
with the same dose regime has also been reported but in a much smaller
number of subjects (Jaffe et al, 1969). A recent study by Lenton
(1984) of six subjects who commenced therapy in the mid-follicular
phase has demonstrated absence of a mid-cycle gonadotrophin surge but
with subsequent luteinisation. It is thus probable that commencement
of therapy prior to this surge modifies later events in the cycle with
consequent effects on cyclical symptoms. This suggests that an
alternative approach to treatment may be by suppressing ovulation.
3.7 - Studies involving inhibition of ovulation
Studies investigating the effect of inhibition of ovulation with
cyclical progestogens and with LHRH analogues are the basis of
chapters 4, 5 and 6 of this thesis. Recently there have been several
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published reports of alternative approaches to ovulation suppression.
One involved administration of an implant of oestradiol (100 mg) to
suppress ovarian activity, accompanied by regular oral progestogens to
induce withdrawal bleeds. This was compared with an identical placebo
regime (Magos et al, 1986). The study did not incorporate a cross¬
over and the placebo response was initially extremely high at 93%,
possibly because of the 'surgical' nature of the treatment. However
as the placebo effect declined with time, the active therapy became
significantly more effective. Although the success of this therapy is
attributable to suppression of ovulation, a direct steroid effect
cannot be excluded. Serum oestradiol concentrations were considerably
elevated 3 months after administration of a 100 mg depot of oestradiol
(Thorn et al, 1981) and gradually rising concentrations have been
documented over 36 months in postmenopausal women receiving 50 mg
depots for hormone replacement therapy (Barlow et al, 1986). Thus it
is possible that supranormal oestrogen levels are being achieved,
equivalent to those around mid-cycle, which has been associated with
an increased sense of well-being and a peak of positive mood (Sanders
et al, 1983). Anecdotal evidence is available from one patient
managed personally who was treated in this way while resident in
London and who continued therapy for almost 3 years. On stopping
therapy, her serum oestradiol remained over 1000 pmol/1 for over 18
months from the time of the last implant with resulting irregular
bleeding and endometrial hyperplasia. This raises concern about the
long term safety of such therapy in young women particularly with
regard to the risk of endometrial carcinoma.
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Another way of suppressing ovulation is with the antigonadotrophin
danazol. Gilmore et al (1985) conducted an elaborate double-blind
cross-over study of danazol 400 mg daily compared with placebo, each
over three cycles. Only 20 of the 39 subjects recruited completed
both phases of the study but among those who did, significant
improvements in physical and mental symptoms were seen. In a second
report (Watts et al, 1987), 27 out of 40 women completed a study
comparing three different doses of danazol with placebo over three
cycles but not incorporating a cross-over. Twelve of the thirteen
drop-outs were from active therapy and related to side effects.
Nevertheless, in those completing the study, significant symptomatic
improvement was documented by daily records. A 200 mg daily dosage
was better tolerated but was not invariably associated with
suppression of menstruation. Whether or not ovulation was suppressed
was not reported. However the 400 mg dose was associated with
amenorrhoea in the majority of the subjects and the benefit of therapy
may be related to loss of awareness of impending menstruation. A
better model for ovulation suppression would involve maintenance of
menstrual cyclicity, such as occurs with the combined oral
contraceptive pill or with cyclical norethisterone (see chapter 4).
One theoretical concern about the long term use of danazol is its
metabolic effects. Danazol has androgenic, anabolic and
antioestrogenic properties (Luciano et al, 1981). Presumably because
of these androgenic effects (Heller et al, 1983), it has been shown to
produce significant alterations in lipoproteins, with consistent and
significant falls in high density lipoprotein-cholesterol (HDL-C) to
around 40% of pre-treatment levels (Malkonen et al, 1980; Allen &
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Fraser, 1981; Fahraeus et al, 1984). The dose used in these studies
was 400-800 mg/day but similar changes have been reported with daily
doses as low as 200 mg/day (Luciano et al, 1983). Significant rises
in low density lipoprotein-cholesterol were found in some of these
studies (Malkonin et al, 1980; Allen & Fraser, 1981; Fahraeus et al,
1984). Both an elevation of LDL-C and, in particular, a fall in
circulating HDL-C are regarded as strong risk factors for the
development of coronary heart disease (Gordon et al, 1977; Kannel et
al, 1979). The above studies all demonstrated a rapid reversal of the
abnormal lipoprotein profiles to normal 1-2 months after cessation of
therapy. This is reassuring in relation to the management of
endometriosis where therapy rarely exceeds 6-9 months in duration but
is of considerable concern if danazol is to be used widely in the
management of premenstrual tension where therapy may be continued for
a number of years.
3.8 - Conclusions
Despite this extensive literature, it is difficult to draw firm
conclusions about the relationship between endogenous and exogenous
ovarian steroids and mood and physical change. In answer to the
questions posed at the beginning of this chapter (section 3.1), a
number of comments can be made.
1. There is no good evidence to support a disorder of ovarian
steroidogenesis in women with premenstrual problems although
conclusions are limited by differences in the populations selected for
study and methodological deficiencies.
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2. The approach to therapy most widely used to date, namely based on
'boosting' luteal phase progesterone concentrations, has on the whole
been unsuccessful and is probably ill-founded, although further
studies of oral progesterone are indicated.
3. Progestogens given cyclically to women receiving oestrogen alone
for hormone replacement therapy can produce mild symptoms similar to
those present premenstrually in normal women, but so also can
placebo.
4. There is little evidence that any combined oral contraceptive
formulations provoke adverse mental symptoms in normal women although
they may exacerbate pre-existing problems in susceptible individuals.
5. Hormonal manipulation of the cycle by contraceptive steroids does
appear to reduce cyclical symptoms, although this conclusion is based
on populations of 'normal' women rather than those presenting with
adverse symptoms.
6. Although therapies which involve ovulation suppression appear to
reduce the intensity of cyclical symptoms, there may be other
mechanisms involved in their action.
The next sections of this thesis explore alternative methods of
ovulation suppression in the management of premenstrual problems.
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CHAPTER 4
SUPPRESSION OF OVULATION WITH CYCLICAL ORAL PROGESTOGENS - THE
EFFICACY OF MEDROXYPROGESTERONE ACETATE AND NORETHISTERONE COMPARED
WITH PLACEBO
4.1 - Introduction
As already discussed (section 3.2), there is no convincing evidence
for any gross endocrine abnormality in the aetiology of premenstrual
tension. The relationship between the symptoms and the luteal phase
of the cycle does however suggest that suppression of ovulation would
be a logical approach to management. There is a surprising lack of
studies which use this approach in the literature. The effect of the
oral contraceptive pill on mood and cyclical change has been evaluated
in the past and results have on the whole supported a damping down of
cyclical problems with its use (section 3.5). However the subjects of
such studies had been receiving therapy for contraceptive purposes,
not for management of cyclical problems and thus represent a different
population of women. The age and reproductive status of our
population of premenstrual tension sufferers (see section 2.3.1)
makes the use of the combined pill inappropriate as a therapy as
surgical sterilisation was the most frequent method of contraception
and half the women were aged 35 years or more. Progestogens used
alone will inhibit ovulation in adequate doses (Garcia et al, 1958;
Taymor, 1964) when commenced in the follicular phase or used
continuously but have never been previously evaluated in this way for
the management of cyclical symptoms. The object of the following
study was to investigate the effect of suppression of ovulation with
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two commonly used progestogens on the symptoms of premenstrual
tension. A small uncontrolled pilot study had already been conducted
on 9 women attending the clinic, with promising results (Backstrom,
1979 - unpublished observations). It used the dose regime and
schedule which was adopted in the present study.
The two progestogens selected were norethisterone (Primolut-N -
Schering Pharmaceuticals) and medroxyprogesterone acetate (Provera -
Upjohn Ltd). Their structures are shown in figure 4.1.
Norethisterone (NET) is a derivative of 19-nortestosterone (Pincus,
1956), and is used extensively in oral contraceptives as well as in
the management of other gynaecological conditions (Bishop & de
Almeida, 1960; Rock et al, 1960) although its use in gynaecological
practice has not been subjected to controlled clinical trial. At a
dose of at least 10 mg daily from days 5-26 of the cycle it was shown
to suppress ovulation (Garcia et al, 1958; Brown et al, 1962) with
associated relief of dysmenorrhoea (Bishop, 1962).
Medroxyprogesterone acetate (MPA), a derivative of 17a-hydroxy-
progesterone, was first described by Wied & Davis (1959) and was
available in a parenteral as well as an oral form from an early stage.
Its lack of androgenicity led to its early use in the management of
threatened and recurrent abortion (Goldzieher, 1964). The prolonged
ovulation inhibiting effect of the depot form was initially regarded
as an unfortunate side effect of therapy (Rubin, 1964), before its
potential as an injectable contraceptive was further investigated
(Coutinho, 1966). The oral form was investigated as a contraceptive
in combination with oestrogen (Eichner, 1963) although it never became
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Figure 4.1



























established as a component of the combined pill because of a single
report of an association with benign breast tumours in beagle bitches
(Finkel & Berliner, 1973). Later literature on this subject has been
reassuring (Fraser & Weisberg, 1981). As a single agent, suppression
of ovulation with oral therapy was reported at a dose of 10 mg/day
from day 5 of the cycle (Eichner, 1963). Its use in the management of
premenstrual tension was anecdotally mentioned in the same report
although not subsequently investigated any further.
4.2 - SUBJECTS AND METHODS
4.2.1 - Subjects
All the women recruited into the study had been fully evaluated over
at least one and usually two control cycles to establish the
relationship of their symptoms to menstruation (see section 2.2.2).
However the results of this preliminary evaluation were not always
available at the time of recruitment. In light of the results
presented in chapter 2, only data from those whose premenstrual mental
symptoms were relieved by at least 25 percent during the postmenstrual
phase was considered suitable for analysis. None of the subjects
received any other form of medication during the course of the study
and were all free of significant medical conditions. A normal
menstrual interval not exceeding 26-32 days was also necessary for
inclusion. All the subjects felt that their symptoms were
sufficiently disabling to wish active therapy and all gave informed
consent to participate in the study, for which prior ethical committee
approval had been obtained. They were not routinely informed that one
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of the bottles contained placebo, nor that two were identical. They
were told that the object of the study was to study the effect of
hormonal treatment and that the dose of therapy would alter during the
course of the study. Only one subject asked if a placebo was being
used and she later withdrew because of acute symptoms of anxiety
during the second treatment cycle.
4.2.2 - Therapy and design
Originally, a randomised double-blind study comparing both
progestogens with placebo was planned but it was not possible to
obtain identical preparations of both active agents within a
reasonable interval of time. It was therefore decided to run two
separate studies, one following the other, allowing a period of
approximately 2 years for recruitment to each. The
medroxyprogesterone acetate study started in 1981; the norethisterone
study at the end of 1983. Both were of identical design,
incorporating 3 study cycles randomised between 2 active treatment
cycles and one placebo cycle. The studies were entirely double-blind
with the placebo cycle falling before, in between or after the two
active cycles (see figure 4.2). The dose of both progestogens was 5
mg three times daily, taken for 21 days each cycle. Treatment was
initiated on day 5 of menstruation for study cycle 1. Thereafter
subjects were instructed to break the therapy for 7 days before
recommencing and to continue for the full 21 days regardless of
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4.2.3 - Assessment of symptoms
Mood and physical symptoms were recorded daily throughout the study
using visual analogue scales as previously described (section 1.10.1)
and the subjects were asked to continue recordings for at least 14
days after completion of the third bottle. This instruction was not
initially given leading to loss of data from cycle 3 in three
subjects, one where menstruation was delayed in a placebo cycle and in
two who commenced recordings prior to the onset of the study and
subsequently ran out of forms before completion of cycle 3. There was
space on the charts for comments and for recording of side effects.
The subjects were given a contact phone number in case of problems or
queries relating to therapy. All were seen routinely at the end of
the three months or sooner if requested.
4.2.4 - Endocrine monitoring
The majority of the subjects were asked to collect samples of early
morning urine on a weekly basis for assay of total oestrogens and
pregnanediol (see section 2.2.5) in order to determine whether
ovulation was being suppressed during active therapy and to ensure
that the control cycles were ovulatory. These were stored in the
subjects' own domestic freezers and delivered to the laboratory every
four weeks.
4.2.5 - Data analysis
The data obtained from therapy with the two progestogens and their
matched placebos was analysed separately and will be presented in
different sections. The completed visual analogue scales (VAS) were
initially analysed cycle by cycle without breaking the code. For each
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cycle, three phases were defined, and a mean score calculated for each
symptom in each subject for each cycle phase. These phases were the
seven premenstrual days, days 1-5 of menstruation inclusive and seven
1postmenstrual' days, usually days 6-12 inclusive. Where withdrawal
bleeding did not occur, the first 5 days off therapy were analysed as
the menstrual phase, unless there had been a previous bleed when the
latter was taken as menstruation. The high incidence of breakthrough
bleeding made division of the cycle into phases difficult in some
cases. Sometimes it was necessary to make a distinction between
'spotting' and onset of more normal flow, the latter then being
regarded as menstruation. This was later verified (see section
4.3.3). All the subjects clearly documented the nature of the
bleeding which greatly facilitated the analysis.
Mean individual symptom scores for each cycle phase and for each
subject were then computed and analysed with the help of 'Minitab Data
Analysis Software' on an IBM PC-compatible microcomputer system. The
overall differences between the three treatment cycles (active 1,
active 2 and placebo) for individual mental and physical symptoms were
then analysed by cycle phase for the group as a whole. Statistical
significance was tested using analysis of variance. Parametric
statistical methods were only used for within-subject comparisons as
discussed earlier (section 1.9.7). Where any inter-subject
comparisons were made, non-parametric tests were used and are
individually described in the text.
For the endocrine data, results of urinary pregnanediol:creatinine and
total oestrogen:creatinine excretion were plotted out for each subject
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through each individual cycle, standardising the cycles as described
in section 4.3.7. For pregnanediol, mean concentrations were
calculated at regular intervals of 3-5 days to enable comparisons to
be made between the different treatment cycles. In the case of total
oestrogen excretion, such detailed information was not required and
overall mean concentrations for each individual treatment cycle were




Details of the 56 subjects who entered the studies are shown in table
4.1. The proportion with complete and analysable data was 59% of
those given medroxyprogesterone acetate (MPA) and 66% of those given
norethisterone (NET). However the proportions who withdrew because of
adverse effects were almost identical at 19% and 17% respectively.
Eight of the ten with side effects complained of worsening of their
premenstrual symptoms or their occurrence earlier than anticipated in
the cycle. In one, an acute depressive illness was precipitated
during what turned out to be a placebo cycle. The side effects in the
other two subjects were leg pains (MPA) and abdominal pain and
flatulence (NET). The latter was not relieved on stopping therapy and
the former had been present prior to its onset. Of those in the MPA
group who failed to provide a complete set of data, two had completed
the charts for the placebo cycle and one active treatment cycle,
but their results were not included in the analysis. It was not
necessary to exclude any subjects from analysis on the grounds that
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TABLE 4.1. - RECRUITMENT TO PROGESTOGEN THERAPY STUDIES
4.1.1 - Medroxyprogesterone acetate
Entered 32
Completed & data analysed 19 (59%)
Data incomplete 4
Failed to return charts 2
Lost to follow up 1
Withdrew from side effects 6 (19%)
4.1.2 - Norethisterone
Entered 24
Completed and data analysed 16 (67%)
Data incomplete 2
Failed to return charts 1
Therapy not commenced 1
Withdrew from side effects 4 (17%)
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the degree of postmenstrual relief was less than 25% in the control
cycles. However, some of those who withdrew from the study fell into
this category (see below).
4.3.2 - Subjects who completed the studies
The characteristics of the subjects in the two groups who completed
the study and the severity of their presenting symptoms are summarised
in table 4.2. The only significant difference between the two
treatment groups was the severity of the mental symptoms during
menstruation, the median score being higher in the group receiving MPA
(W=181.5; P=0.0052 (Mann Whitney test). However there was a greater
proportion of single women in the MPA group compared with the NET
group where more of the subjects were divorced or separated.
Details of the 18 women who withdrew or failed to provide a completed
set of visual analogue scale charts are given in table 4.3, which
combines those who withdrew from both studies. Their general
characteristics were similar to those who completed the studies apart
from a significantly greater number with a past history of psychiatric
therapy. The severity of their premenstrual symptoms was no different
but the median mood score during the menstrual phase of the cycle was
significantly higher. Although the median postmenstrual mood score
did not significantly differ from the group who completed the study,
review of the individual cases showed that 7 out of the 18 women who
withdrew would have been excluded from the subsequent analysis on the
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Pretreatment mood scores (mean + SD)
Premenstrual 4.4 + 2.0 3.5 + 1.2
Mens trual 3.3 + 1.9 1.7 + 1.5
Postmenstrual 1.7 + 1.4 1.0 + 1.1
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TABLE 4.3











Age at recruitment 34 (25-45)
Parity 2 (0-3)
Psychiatric history 11 *
mean SD
Premenstrual mood score 4.3 1.7
Menstrual mood score 4.6 2.7 *
Postmenstrual mood score 2.4 2.1
* significantly different from subjects who completed (p<0.05)
150
4.3.3 - Effect of therapy on mood and physical symptoms
4.3.3a - Medroxyprogesterone acetate
The effect of both cycles of active therapy and of the placebo is
compared in figures 4.3.1 - 4.3.3. The P values indicate where the
results of analysis of variance showed an overall significant
difference between the three treatment cycles. The data is given in
greater detail in tables 4.4.1 to 4.4.3. The only significant
differences between active treatment and placebo was in the reduction
of premenstrual breast discomfort (figure 4.3.1; table 4.4.1). The
crude data is given in table 4.4.4. Further analysis, using Dunnett's
T-test, to determine the source of the variance showed significant
differences (P<0.01) between each individual active treatment cycle
and the placebo. The results from each cycle phase showed no
exacerbation of physical or psychological symptoms during active
therapy. There appear to be non-significant trends in favour of
reduction of premenstrual symptom intensity during active therapy,
compared with placebo.
As shown later (section 4.3.6), active therapy with MPA caused
considerable disruption of the normal bleeding pattern with frequent
onset of bleeding early in the cycle. To ensure that the results were
not being biased by basing the analysis around the onset of atypical
menstruation, the data was reanalysed by calculating the mean score
for each symptom for the last 14 days of the cycle (the latter 9 days
of therapy and the initial 5 days off therapy). Analysis of variance
showed significant benefit from active therapy only for the symptom of
breast discomfort (table 4.4.5), with no significant improvement of
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Figures A.3.1 - 4.3.3
Effect of medroxyprogesterone acetate (MPA) and placebo therapy on






Statistical analysis is by repeated measures analysis of variance
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PREMENSTRUAL SYMPTOM SCORES (MEAN & SD)
Medroxyprogesterone acetate v placebo
Symptom Active 1 Active 2 Placebo F * P
Cheerfulness 5.04 5.48 4.18 1.10 NS
(2.50) (2.45) (2.98)
Lethargy 2.40 2.44 3.28 0.87 NS
(2.01) (2.35) (2.54)
Tens ion 2.36 2.17 3.38 1.24 NS
(2.32) (2.56) (2.77)
Irritability 2.47 2.15 3.20 0.98 NS
(1.97) 2.39 (2.69)
Depression 1.72 1.92 2.96 1.43 NS
(1.94) (2.72) (2.58)
Breast pain 0.46 0.82 2.83 8.32 <0.01
(0.92) 1.58) 2.80)
Swelling 0.76 1.23 1.89 2.16 NS
(1.04) (1.95) (1.88)
* Degrees of freedom 2 & 54



















MENSTRUAL SYMPTOM SCORES (MEAN & SD)
Medroxyprogesterone acetate v placebo
Symptom Active 1 Active 2 Placebo F * P
Cheerfulness 4.98 5.51 4.94 0.36 NS
(2.21) (1.96) (2.32)
Lethargy 2.28 2.96 3.09 0.62 NS
(1.83) (2.49) (2.64)
Tension 1.84 1.93 2.91 1.13 NS
(2.03) (2.07) 2.87)
Irritability 2.17 1.86 2.92 1.15 NS
(1.78) (1.92) (2.67)
Depress ion 1.47 1.25 2.64 1.74 NS
(1.64) (1.71) (2.85)
Breast pain 0.67 0.39 1.33 2.22 NS
(1.48) (1.24) (1.42)
Swelling 1.10 1.31 1.46 0.16 NS
(1.70) (2.24) (1.66)
* Degrees of freedom 2 & 54
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POSTMENSTRUAL SYMPTOM SCORES (MEAN & SD)
Medroxyprogesterone acetate v placebo
Symptom Active 1 Active 2 Placebo F *
Cheerfulness 5.89 5. 50 5. 58 0..14
(2.12) (2 .33) (3 .06)
Lethargy 1.91 2. 10 1. 96 0.,04
(2.09) (2 .11) (1 .77)
Tens ion 1.41 1. 21 1. 49 0.,14
(1.77) (1 .76) (1 .57)
Irritability 1.46 1.29 1.18 0.17
(1.51) (1.70) (1.20)
Depress ion 1.29 1.29 0.84 0.43
(1.76) (2.08) (1.23)
Breast pain 0.70 0.61 0.51 0.14
(1.23) (1.19) 0.87)
Swel1ing 0.69 0.50 0.56 0.18
(0.88) (1.07) (1.03)
* Degrees of freedom 2 & 54
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TABLE 4.4.4
PREMENSTRUAL BREAST DISCOMFORT - INDIVIDUAL DATA
Medroxyprogesterone acetate v placebo
SUBJECT Active I Active 2 Placebo Order
JB 0.14 2.29 2.14 AAP
PB 0.14 1.86 5.43 PAA
CB 0.00 0.00 9.71 AAP
RC 0.00 0.00 5.00 APA
IC 4.00 6.29 3.86 APA
WC 0.00 0.00 2.29 AAP
MD 0.43 0.14 0.00 PAA
BG 0.00 0.00 0.00 PAA
AG 0.29 0.00 0.86 APA
HH 0.43 2.43 1.71 AAP
MI 0.00 0.00 6.00 PAA
HK 1.14 1.00 3.43 AAP
JL 0.57 0.00 7.71 PAA
FM 0.14 1.57 1.71 AAP
PP 0.00 0.00 1.57 APA
MT 0.14 1.57 1.71 AAP
ST 0.43 0.00 0.00 APA
MU 0.00 0.00 0.86 PAA











SYMPTOM SCORES DURING SECOND HALF OF CYCLE (MEAN & SD)
Medroxyprogest erone acetate v placebo
Symptom Active 1 Active 2 Placebo F * P
Cheerfulness 5.21 5.42 4.39 1.08 NS
(2.26) (2.00) (2.42)
Lethargy 2.22 2.82 2.84 0.56 NS
(1.77) (2.14) (2.05)
Tens ion 1.85 2.03 2.79 1.11 NS
(1.78) (2.02) (2.32)
Irritability 2.12 1.73 2.91 2.00 NS
(1.70) (1.45) (2.28)
Depression 1.52 1.37 2.66 2.98 NS
(1.76) (1.65) (1.95)
Breast pain 0.65 0.64 1.80 3.21 <0.05
(1.19) (1.28) (2.22)
Swelling 1.07 1.14 1.36 0.19 NS
* Degrees of freedom 2 & 54
the psychological symptoms. These results are consistent with those
obtained by the other method of analysis described above.
4.3.3b - Norethisterone
The results of treatment in all three cycle phases and for each
individual symptom are summarised in figures 4.4.1 - 4.4.3 and given
in more detail in tables 4.5.1 - 4.5.3. No significant differences
between the treatment cycles were seen during any of the three cycle
phases. Here trends were towards higher symptom scores during the
initial active cycle, with the exception of premenstrual breast
discomfort where scores were highest with placebo (figure 4.4.1; table
4.5.1).
4.3.4 - Influence of pretreatment mental symptom profiles
4.3.4a - Medroxyprogesterone acetate
The potential importance of defining women with premenstrual
complaints in relation to the degree to which their symptoms are
relieved postmenstrually has been discussed in chapter 2. The lack of
response to active treatment might be related to inclusion of a
proporton of subjects whose symptoms were not clearly related to the
premenstrual phase of the cycle. The 19 subjects who completed the
MPA study were therefore subdivided into two groups according to the
degree of postmenstrual relief of their mental symptoms in the control
cycles. There were 9 women with pre-treatment postmenstrual mood
relief below 75% ('low' relief) and 10 with mood relief greater than
75% ('high' relief). Comparison of the effects of active treatment
and placebo on the mean premenstrual psychological symptom scores for
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Figures 4.4.1 - 4.4.3
Effect of norethisterone (NET) and placebo therapy on individual





Statistical analysis is by repeated measures analysis of variance
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PREMENSTRUAL SYMPTOM SCORES (MEAN & SD)
Norethisterone v placebo
Symptom Active 1 Act ive 2 Placebo F * P
Cheerfulness 4.15 5. 01 4. 70 0.51 NS
(1.80) (1 .60) (2 .56)
Lethargy 2.10 1. 75 2. 16 0.16 NS
(2.00) (1 .86) (2 .08)
Tension 2.76 1. 84 1. 95 0.79 NS
(2.66) (2 .11) (2 .33)
Irritability 3.35 2. 20 2. 53 0.88 NS
(2.71) (2 .06) (2 .36)
Depress ion 2.17 1. 04 1. 54 0.96 NS
(2.21) (1 .95) (2 .30)
Breast pain 1.05 0. 63 2. 09 2.47 NS
(1.92) (0 .99) (2 .44)
Swelling 2.70 1. 52 2. 23 1.11 NS
(2.34) (2 .02) (2 .25)
* Degrees of freedom 2 & 44

















MENSTRUAL SYMPTOM SCORES (MEAN & SD)
Norethisterone v placebo
Symptom Act ive 1 Active 2 Placebo F * P
Cheerfulness 4. 51 5.53 4. 79 0.60 NS
(2 .63) (2.01) (2 .53)
Lethargy 1. 65 1.00 1. 91 0.88 NS
(1 .90) (1.43) (1 .87)
Tens ion 2. 12 1.55 1. 26 0.60 NS
(2 .27) (2.01) (2 .03)
Irritability 2. 28 1.83 1. 71 0.44 NS
(1 .96) (1.79) (1 .70)
Depress ion 1. 38 1.16 1. 34 0.07 NS
(2 .08) (1.96) (1 .75)
Breast pain 0. 56 0.59 0. 55 0.01 NS
(1 .09) (0.96) (0 .86)
Swelling 2. 43 1.68 1. 90 0.47 NS
(2 .35) (1.90) (2 .40)
* Degrees of freedom 2 & 44
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POSTMENSTRUAL SYMPTOM SCORES (MEAN & SD)
Norethisterone v placebo


















































* Degrees of freedom 2 & 44
the individual subjects (table 4.6) showed a greater placebo effect in
the group with low postmenstrual mood relief prior to therapy.
However the differences between active treatment and placebo in the
group with high pretreatment relief still failed to reach
significance. Among the individual subjects, 7 out of the 10 with
high pretreatment mood relief recorded least benefit from placebo
treatment, compared with the two active cycles. This compared with 2
out of the 9 with low pretreatment relief (table 4.6). Again, this
just fell short of statistical significance (P=0.051 by Fisher's exact
test).
4.3.4b - Norethisterone
Analysis of mean psychological symptom scores (not illustrated) failed
to demonstrate any influence of pretreatment mood profiles in the
response to NET or placebo.
4.3.5 - The placebo effect
In the presentation of the above results, there is no indication of
the order in which active and placebo treatments were administered.
The numbers of subjects receiving the placebo first, second or third
are shown in table 4.7.1. Further analysis was carried out in an
attempt to determine whether the order in which the placebo was given
in relation to the active treatment affected the results. The
premenstrual symptom scores for tension, depression and irritability
during each of the three treatment cycles were ranked in descending
order of severity for the individual subjects, adding the ranks for
the three symptoms to give an overall rank total for each cycle in
each subject. A rank of 1 indicated maximum severity so that a low
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TABLE 4.6
EFFECT OF PRE-TREATMENT POSTMENSTRUAL RELIEF OF MENTAL SYMPTOMS
Medroxyprogesterone acetate v placebo
Mean premenstrual mood scores for individual subjects
SUBJECT Active 1 Active 2 Placebo
















































+ indicates subjects who responded least well to placebo
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rank total score for the placebo cycle indicated little effect from
the placebo. The rank total scores for the placebo cycles were then
analysed by the order of therapy, namely according to whether the
placebo had been given first, second or last. Any significant
differences were determined by use of the Kruskal-Wallis non-
parametric test. The results for each progestogen are shown in table
4.7.2 and do not identify a significant order effect although it is
apparent from 4.7.1 that the MPA was biased towards more placebo
cycles placed third in order, with fewest placebo cycles placed third
in the NET group. In view of this the results were pooled and
reanalysed but again no significant differences emerged (table
4.7.2.)
4.3.6 - Cycle control during active and placebo therapy
4.3.6a - Medroxyprogesterone acetate
During active treatment cycles, there was considerable disruption of
normal menstrual cyclicity, as illustrated in table 4.8.1. Only one
quarter of the cycles were entirely normal and prolonged bleeding of
normal or lighter than normal flow was recorded in 17 (42.5%) of the
cycles. The placebo treatment cycles were entirely normal in 16 cases
but menstruation was delayed beyond 7 days of stopping therapy in two
cycles (to 11 and 12 days respectively). In two, menstruation
occurred early in the cycle (8 and 10 days before stopping the
tablets) and in both cases was preceded by ovulation. All four
abnormal cycles occurred where placebo therapy was third. In a fifth,
where placebo therapy was the middle cycle, there was complete
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TABLE 4.7 - PLACEBO CYCLES - EFFECT OF ORDER
4.7.1 - Placebo cycle order - number in each category
Placebo order MPA NET BOTH
Cycle 1 6 6 12
Cycle 2 5 6 11
Cycle 3 8 4 12
4.7.2 - Analysis of placebo rank totals by treatment order
median rank total
Placebo order MPA NET BOTH
Cycle 1 4.25 6.25 4.75
Cycle 2 6.00 6.00 6.00
Cycle 3 5.75 5.50 5.75
H* 2.11 0.37 1.70
P NS NS NS
*Kruskal Wallis test
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amenorrhoea but ovulation was not assessed. None of the monitored
cycles were anovular (see below).
4.3.6b - Norethisterone
By comparison with MPA, satisfactory cycle control was achieved with
NET, 25 (78%) of cycles being entirely normal with prolonged bleeding
in only 4 (12.5%) (table 4.8.2). The placebo cycles were normal in 14
of the 16 subjects. Menstruation was delayed beyond one week of
stopping the tablets (9 days) in one subject who received the placebo
tablets after both active cycles. In one case, where placebo came in
the middle, the cycle appears to have been anovular because of absence
of menstruation but this was not confirmed by endocrine monitoring.
4.3.7 - Results of endocrine monitoring
4.3.7a - Medroxyprogesterone acetate
Measurement of weekly urinary pregnanediol:creatinine in 28 of the
cycles indicated ovulatory levels in only one sample from a single
cycle where it coincided with the treatment-free week. Complete sets
of results of weekly monitoring throughout each treatment cycle were
available from 13 of the subjects. Mean pregnanediol:creatinine
concentrations calculated for 5 day intervals from days 1-10 and 3 day
intervals thereafter are given in table 4.9.1. For this, it was
necessary to standardise each cycle to 28 days, taking the start and
finish of tablet taking as days 5 & 26 respectively for active
treatment cycles. Placebo cycles were standardised around day 1 of
menstruation. Data from control cycles in the same individuals is
given for comparison. Results from the active treatment cycles
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TABLE 4.8 - CYCLE CONTROL DURING ACTIVE PROGESTOGEN THERAPY
4.8.1 - Medroxyprogesterone acetate
Normal cycle (24 days or longer) 10
Normal cycle with BTB (7 days or less) 4
No withdrawal bleed, BTB less than 10 days 8
Amenorrhoea 1
Prolonged bleeding (10 days or more) 17
(median 14, range 10-19 days) —
TOTAL 40
4.8.2 - Norethisterone
Normal cycle (24 days or longer) 25
Normal cycle with BTB (7 days or less) 3
Amenorrhoea 0
Prolonged bleeding (10 days or more) 4
(median 16, range 12-20)
TOTAL 32
(BTB - break through bleeding)
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confirmed inhibition of ovulation. No significant differences in
luteal phase characteristics between the placebo and control cycles
were apparent.
The results of urinary total oestrogen:creatinine are given in table
4.10. The results are expressed as mean concentrations for each
individual cycle. Significant suppression of urinary oestrogen
excretion occurred during active treatment, compared with placebo.
However results during placebo treatment were significantly higher
than during pretreatment control cycles. This may be a rebound effect
in those cycles which followed or fell between active therapy.
4.3.7b - Norethisterone
During active treament, one ovulatory urinary pregnanediol result was
detected although this cycle was associated with a short luteal phase.
Complete weekly urinary steroid excretion data was available from 13
women and the results are shown in tables 4.9.2 and 4.10, with data
from control cycles for comparison. The pregnanediol results indicate
ovulation inhibition during active therapy and there was also
significant suppression of urinary total oestrogen:creatinine
excretion. Results from the placebo cycles show no significant
differences from control cycles. There appeared to be greater
suppression of oestrogen excretion^^ NET, compared with results
obtained from the women treated with MPA (table 4.10), although




RESULTS OF URINARY PREGNANEDIOL:CREATININE EXCRETION (MEAN + SD)
Days Active 1 Active 2 Placebo Control
4.9.1 - MEDROXYPROGESTERONE ACETATE
I-5 0.36 + 0.12 0.29 + 0.24 0.23 + 0.09 0.37 + 0.22
6-10 0.45 + 0.25 0.29 + 0.11 0.38 + 0.09 0.44 + 0.22
II-13 0.37 + 0.17 0.37 + 0.27 0.30 + 0.09 0.49 + 0.47
14-16 0.44 + 0.22 0.24 + 0.14 1.13 + 0.96 0.66 + 0.25
17-19 0.30 + 0.29 0.32 + 0.18 1.56 + 0.25 1.39 + 0.29
20-22 0.39 + 0.07 0.35 + 0.14 2.64 + 0.98 2.80 + 1.80
23-25 0.33 + 0.20 0.53 + 0.39 2.24 + 1.31 2.18 + 0.77
26-28 0.43+0.74 0.36+0.15 1.01+0.32 1.96+1.09
4.9.2 - NORETHISTERONE
1.5 0.50 + 0.26 0.38 + 0.25 0.29 + 0.24 0.48 + 0.26
6-10 0.40 + 0.21 0.27 + 0.15 0.30 + 0.19 0.45 + 0.22
11-13 0.39 + 0.21 0.34 + 0.24 0.39 + 0.32 0.35 + 0.30
14-16 0.29 + 0.15 0.35 + 0.19 0.52 + 0.46 0.81 + 0.45
17-19 0.39 + 0.27 0.35 + 0.22 1.32 + 0.57 1.81 + 1.15
20-22 1.03 + 1.93 0.12 + 0.11 2.34 + 1.38 3.25 + 1.51
23-25 0.35 + 0.27 0.21 + 0.16 4.24 + 2.26 4.06 + 1.76
26-28 0.30 + 0.21 0.22 + 0.12 1.24 + 1.08 1.90 + 0.88
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TABLE 4.10
RESULTS OF URINARY TOTAL OESTROGEN:CREATININE EXCRETION
Expressed as mean _+ SD for each complete treatment cycle
Active 1 Active 2 Placebo Control
MPA 10.1 + 5.9 10.1 + 5.1 16.3 + 8.8 14.0 + 10
P * 0.005 0.0002
NET 8.0 + 4.0 6.5 + 3.4 11.6 + 7.4 12.7 + 8.
P * 0.013 0.0002
* Mann-Whitney test comparing active cycles with placebo
Comparison between treatment cycles with MPA and NET:
Active 1 Not significant
Active 2 P = 0.0003
Placebo P = 0.0045
(Control Not significant)
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4.3.8 - Outcome of therapy
At the end of the three study cycles, the women were given the option
of continuing on active therapy if they felt that they had benefited
during at least two of the treatment months. Nine of the 16 (56%) who
had completed NET opted to continue and 6 (37.5%) found a sustained
benefit over a period of at least 6 months. Fifteen of the 21
completing MPA (71%) opted to continue and 9 (43%) are known to have
completed 6 months on therapy, with 7 continuing to date. Only three
of the group stopped specifically because of the bleeding problems and
in those who continued the problem has lessened considerably. Three
of the women have achieved a more satisfactory benefit from an
alternative therapy, in two cases danazol and in the third an LHRH
agonist. All three were women whose symptoms on initial assessment
were considerably relieved postmenstrually. The remaining subjects
have coped without active therapy.
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4.4 - DISCUSSION
These results fail to demonstrate any significant relief of the
adverse psychological symptoms during active therapy with
medroxyprogesterone acetate or norethisterone in women complaining of
premenstrual problems. However MPA did significantly relieve the
symptom of breast discomfort, compared with placebo treatment. Both
progestogens suppressed ovulation and thus the results do not support
the hypothesis that inhibition of ovulation will eradicate
premenstrual symptoms. In contrast to the results of some of the
studies discussed earlier (section 3.4), there was no indication that
either progestogen actually provoked PMT-like symptoms. With the
exception of the few subjects who withdrew from therapy, mood scores
were no worse during active therapy than during placebo treatment.
These results therefore throw doubt upon the relationship between
adverse mood and both exogenous and endogenous ovarian steroids.
The only significant benefit of therapy with either progestogen was
the reduction of breast discomfort during active therapy with MPA.
There was also a trend towards improvement of breast discomfort with
NET. Breast discomfort is one symptom which has been consistently
related to the premenstrual phase of the cycle in normal subjects as
well as in women who present for help with premenstrual problems (see
chapters 1 & 2). Although the mechanisms underlying the symptom are
unclear, well documented morphological changes are seen in the breast
as a consequence of cyclical hormonal action (see section 1.8.7).
Thus the benefit from progestogen therapy is likely to be a result of
endocrine suppression. Neither progestogen significantly relieved
the sensation of 'swelling', although the basis for the latter symptom
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is poorly understood (see chapter 1). There were trends towards
improvement rather than worsening of this symptom.
A direct comparison between the effects of the two different
progestogens is not possible because the two groups were not
randomised. Both appeared to effectively inhibit ovulation although
suppression of follicular activity, as measured by urinary oestrogen
excretion, was greater with NET. There was a trend towards
improvement of the psychological symptoms with MPA but not with NET.
This improvement in mood may have been secondary to relief of breast
pain but it is also tempting to postulate that the improvement was
related to the cycle disruption which occurred in such a high
proportion of the MPA treated cycles. Early onset of menstruation or
of break-through bleeding may remove anticipation of later
menstruation. A similar observation was made by Sampson (1981) who
reported relief of cyclical symptoms when progesterone was given in
sufficient dosage to disrupt the cycle. This question might be
clarified by comparing the dose of MPA used in the piesent study with
a higher dose which gave better cycle control.
In chapter 2, the importance of quantifying the degree to which the
mental symptoms are relieved postmenstrually has been stressed. Low
levels of postmenstrual relief are indicative of underlying problems
which are present throughout the cycle and thus unlikely to be helped
by hormonal manipulation. Those women in the MPA group with
low postmenstrual mood relief during the pre-treatment cycle showed a
greater response to the placebo than did the women with high
postmenstrual mental relief prior to therapy. Had the study been
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confined to the latter group, with increased numbers, the differences
between active and placebo therapy might have achieved significance.
However no similar trends were seen with NET.
Of the subjects recruited to both studies, only two thirds or less
completed them satisfactorily and yielded analysable data. Many
published studies have not stated compliance rates but there are
others in which drop outs are high (Williams et al, 1983; Sampson,
1983; Kerr et al, 1980; Gilmore et al, 1985; Watts et al, 1987).
All these studies took place over at least three cycles and two of
them over six (Williams et al, 1983; Gilmore et al, 1985), involving
daily recordings which are demanding for the subjects. Indeed
published results of the studies by Kerr (1980) and Williams et al
(1983) did not give a breakdown of the daily symptom ratings, basing
their published results only on interviews and it is possible that
this was because of the incompleteness of their data. The subjects in
the present study were not seen monthly. More frequent visits to
hospital might have encouraged better record-keeping and yielded more
complete data from those who finished the study.
In terms of its design, this study is open to a number of criticisms.
It would have been better to have included at least two, preferably
three, placebo and active cycles with cross-over midway. This would
allow for a changing placebo response as the latter is known to be
greatest in the initial treatment cycle (Sampson, 1979) and decline
thereafter (Magos et al, 1986; Watts et al, 1987). It would also
control for any carry-over effects of hormonal suppression at the
cross-over and may have yielded more conclusive results. However such
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a regimen may have resulted in even poorer compliance and incomplete
data collection as the method of recording was already relatively
demanding for the subjects; particularly in view of the high drop out
rate from the other studies discussed above. In the present study,
there was little evidence for carry-over effects of hormonal
suppression as endocrine monitoring showed that the placebo cycles did
not differ significantly from control cycles. Two active cycles were
ovulatory which may have reduced the response. On the other hand, the
delay in ovulation and menstruation seen in some placebo cycles when
these followed two active treatment cycles may have caused bias
because the premenstrual week then fell outwith the phase of tablet-
taking.
The problems encountered with irregular bleeding and poor cycle
control illustrate the difficulties of conducting a double-blind study
of this nature and may explain the lack of any other similar studies
in the literature. Where active treatment is likely to cause easily
identifiable physical changes or endocrine based carry-over effects,
an alternative design would be to eliminate the cross-over and
randomise active and placebo treatment between two groups of
symptomatic women. Much larger numbers of subjects would be needed
with the latter design to enable statistical comparisons to be made
and it would be difficult to control for all possible variables in the
randomisation process. However it would permit the assessment of the
effects of both placebo and active therapy over a more prolonged
interval of time. The effect of passage of time is likely to be
important in this condition and ideally the design of any treatment
trial should include a tablet-free interval. This has not been built
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into any of the other published treatment studies and there is little
information in the literature about long-term follow-up of women with
premenstrual complaints.
The differences encountered in cycle control with the two progestogens
were not altogether unexpected. Early studies demonstrated the very
excellent cycle control with NET (Garcia et al, 1958) which was
attributed in part to its oestrogenicity (Paulsen et al, 1962). On
the other hand, cyclical oral MPA which has no intrinsic oestrogenic
activity, is associated with breakthrough bleeding, even in
combination with oestrogen (Eichner, 1963). Despite the apparently
similar doses of the two required to suppress ovulation, marked
differences in their ability to delay menstruation have been
demonstrated (Swyer & Little, 1962). The differences seen in the
above studies may simply be related to the lesser degree of follicular
suppression seen with the MPA. However, higher incidences of bleeding
abnormalities have been reported with the contraceptive depot
medroxyprogesterone acetate compared with its norethisterone related
counterpart, norethisterone oenanthate (WHO task force, 1983),
although endocrine suppression and endometrial changes are very
similar (Mishell et al, 1968; Chaudhuri et al, 1985). The differences
in the effect of the two progestogens on the endometrium may reflect
differences elsewhere, in particular the breast and central nervous
system. While this may offer an explanation for some of the
observations of the present study, these can only be speculative
because the two groups were not randomly selected.
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The numbers of subjects completing the study were small and this may
have contributed to the negative results. Because of the trends
favouring treatment with MPA compared with placebo, further studies
would appear to be justified, in particular using a higher dose
regimen and with better subject selection. It is relevant to consider
safety apects of progestogen therapy, particularly in view of the
recent epidemiological evidence that the dose of the progestogenic
component of the oral contraceptive pill is associated with
atherosclerotic cardiovascular disease (Meade et al, 1980).
Progestogens of the 19-nortestosterone group have been shown to lower
high-density lipoprotein cholesterol (HDL-C), (Gustafson & Svanborg,
1972; Malkonen et al, 1980; Howard et al, 1982) although the effect is
less marked than that of danazol (see section 3.7). A comparative
study of different oral progestogens failed to show any such effect
with medroxyprogesterone acetate (Silverstolpe et al, 1979) which is
non-androgenic. However long term therapy with depot MPA has been
shown to produce a fall in HDL-C (Kremer et al, 1980), perhaps as a
result of lowered circulating oestrogens (Mishell et al, 1972).
Fortunately this problem does not appear to be associated with oral
administration (Bradley et al, 1978), presumably because the degree of
oestrogen suppression is less complete. In view of their widespread
and long-term use in fertility control, both depot MPA and the depot
form of NET, norethisterone oenanthate, have been subjected to
extensive scrutiny to establish their safety with respect to factors
such as blood coagulation, liver function, glucose tolerance, blood
pressure and carcinogenesis. The results have been reassuring (Fraser
& Weisberg, 1981; Howard et al, 1982).
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4.5 - Conclusions
In the doses and regimes selected for study, both medroxyprogesterone
acetate and norethisterone suppressed ovulation although follicular
activity was more effectively suppressed with the norethisterone and
with considerably better cycle control. MPA significantly improved
the physical symptom of breast discomfort in comparison with placebo
but neither therapy significantly improved the psychological symptoms.
Small but similar numbers from both groups were unable to tolerate
therapy due to adverse psychological effects. In the case of MPA, but
not NET, there were trends towards greater relief of the psychological
symptoms with active therapy. With MPA the placebo response appeared
to be greater in those women whose showed low levels of postmenstrual
relief of their symptoms during control cycles, although these
observations just fell short of statistical significance.
Suppression of ovulation with norethisterone with preservation of
normal menstrual cyclicity is in theory a good model for testing the
effect of ovulation suppression. Its lack of benefit does put into
question the relationship between menstrual cycle symptomatology and
the endocrine events of the cycle. There may be other explanations
for the lack of effect of NET but the results obtained with MPA
are suggestive of a benefit related to disruption of menstrual
cyclicity rather than to inhibition of ovulation. The studies
described above are subject to a number of criticisms but despite
these, failed to demonstrate a significant benefit from ovulation
suppression in women with premenstrual tension.
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CHAPTER 5
PITUITARY-OVARIAN SUPPRESSION WITH ZQLADEX DEPOT (GOSERELIN) - AN
AGONIST ANALOGUE OF LHRH
5.1 - Introduction
Suppression of ovarian function is normally achieved by administration
of exogenous ovarian steroids, usually a combination of an oestrogen
and a progestogen in a dose regimen designed to maintain control and
regular shedding of the endometrium. High dose progestogens or
danazol are alternatives in certain situations where maintenance of a
regular menstrual pattern is not essential. As discussed earlier
(chapters 3 and 4), such steroids may provoke adverse mental or
physical side effects and are in certain situations contraindicated on
medical grounds. This section of the thesis is concerned with a new
class of therapeutic agents which inhibit ovarian cyclicity by
pituitary suppression. These are the synthetic agonist analogues of
luteinising hormone-releasing hormone (LHRH). Because they are free
of any oestrogenic or progestogenic actions and suppress production of
endogenous ovarian steroids, their administration should also inhibit
physical and mental symptoms which are secondary to these steroids.
In this chapter, the endocrine and clinical effects of a newly
available depot preparation of an LHRH agonist are described. The
subjects of the study are 20 premenopausal women, of whom a subgroup
presented with uterine fibroids and the remainder with premenstrual
problems. The response of the uterive fibroids to therapy will also
be presented in this chapter. The effects of ovarian suppression on
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cyclical mental and physical symptoms are described in detail in the
next chapter (chapter 6).
5.1.1 - LHRH and its agonists
Ovarian function is controlled by specific glycopeptide hormones
secreted by the anterior lobe of the pituitary, follicle stimulating
hormone (FSH) and luteinising hormone (LH) (see section 1.2.1). In
turn, synthesis and secretion of these pituitary gonadotropins is
modulated by a hypothalamic decapeptide, luteinising hormone-releasing
hormone (also called gonadotrophic hormone-releasing hormone).
The structure of LHRH was first described by Schally and co-workers in
1971. Ability to synthesise it opened up many new possibilities for
therapeutic uses, particularly for ovulation induction. However the
very short half life of the natural peptide led to development of
synthetic agonist analogues, obtained by substitution of various amino
acids to obtain derivatives which were more potent and longer acting.
A single dose of one of these superactive agonists stimulates release
of LH and to a lesser extent FSH from the anterior pituitary, but
repeated administration results in pituitary desensitisation and
inhibition of gonadotrophin release (Sandow, 1983).
LHRH and its analogues cannot be administered orally but are absorbed
when given intranasally or subcutaneously. A number of analogues are
available for use in humans and are the subject of current or





































5.1.2 - Endocrine and clinical effects of LHRH agonists during
prolonged administration
Prior to the commencement of this study of the new depot preparation
(Zoladex), there were only a few published reports of the effects of
administration of LHRH agonists to premenopausal women although the
literature on the subject is now rapidly growing. Initial interest
was in their potential use for the control of fertility. Two groups
have published data on the effects of chronic intranasal
administration of the agonist buserelin, using single daily doses of
400 or 600 meg (Schmidt-Gollwitzer et al, 1981; Bergquist et al,
1982). Inhibition of ovulation was observed in over 90% of cycles
studied but variable effects on oestradiol were seen, with
concentrations in some subjects intermittently approaching the
preovulatory range, although there was a trend towards greater
suppression with more prolonged therapy. Approximately one third of
subjects developed amenorrhoea but irregular bleeding episodes were a
problem in some cases and one of the groups found evidence of
endometrial hyperplasia in 8 out of 31 biopsies (Schmidt-Gollwitzer &
Hardt, 1981), indicating an unopposed oestrogen effect. Ovulatory
ovarian activity recurred rapidly on discontinuation of the agonist.
Intranasal administration of another agonist, nafarelin, has been
investigated more recently for its contraceptive efficacy at daily
doses of 125 and 250 meg. Inhibition of ovulation in 261 out of 262
treatment months was reported by Gudmundsson et al (1986) with
suppression of oestradiol to early follicular phase concentrations
after 4 weeks. The majority (77%) of the subjects became amenorrhoeic
after the initial 3 months of therapy, particularly those on the
189
higher dose and hot flushes were the main reason for withdrawal from
therapy (9/47 subjects). In contrast, Brenner et al (1985) reported
12 ovulations in 114 treatment cycles, two of these at the higher
dosage, with poor suppression of oestradiol and a high incidence of
irregular bleeding. The reason for the discrepancy between these two
reports is unclear unless there were problems with compliance in the
latter study.
Similar variability of response to intranasal buserelin was seen in 5
women with endometriosis treated with a dose of 200 meg three times
daily for 6 months (Shaw et al, 1983) although 3 of the 5 remained
suppressed and no ovulations were seen. Increasing the dose of
therapy results in greater ovarian suppression (Hardt & Schmidt-
Gollwitzer, 1983) although even at daily doses of 800-1200 meg, 4 out
of 9 subjects showed marked intermittent fluctuations in serum
oestradiol. Another problem with intranasal administration is the
duration of the initial stimulatory phase, the acute response of LH to
individual doses being maintained, although attenuated, for over 2
weeks (Lemay et al, 1985; Hardt & Schmidt-Gollwitzer, 1983), with more
rapid loss of acute FSH response. The stimulatory phase of oestradiol
secretion lasted between 1 and 5 weeks in the same group of subjects.
Similar findings were reported with nafarelin when women with
endometriosis were treated with a daily dose of 1000 meg although more
reproducible ovarian suppression was obtained once the initial
stimulation had resolved (Schriock et al, 1985).
This prolonged initial stimulatory effect is avoided by subcutaneous
administration of the agonist. Lemay et al (1984) gave 200mcg of
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buserelin twice daily by the subcutaneous route for the first week of
therapy in 10 women with endometriosis and found that marked
gonadotrophin stimulation was seen only with the first injection and
abolished thereafter. FSH was suppressed to baseline levels within 48
hours although a more progressive decline in LH was seen. The same
group (Maheux et al, 1985) treated women with uterine fibroids with
subcutaneous bolus therapy over six months and found that oestradiol
stabilised at early follicular phase levels after three weeks with
failure of suppression in only one out of 10 subjects. Serum LH
declined only slowly over 3 months.
In an attempt to achieve more constant plasma levels of agonist,
Healey et al (1986) treated 5 women with uterine fibroids with a
subcutaneous infusion of buserelin. They started therapy in the mid-
luteal phase of the cycle, in contrast to the other groups quoted
above, where therapy was initiated in the early follicular phase. The
rationale for this was based on observations of Fraser & Sandow (1985)
who found that oestrogen stimulation did not occur when subcutaneous
infusions of the agonist were commenced in the late luteal phase in
stump tailed macaque monkeys. This lack of initial oestrogen
stimulation was confirmed in the clinical study.
5.1,3 - Administration by subcutaneous depot
The greater and more predictable suppression achieved with
subcutaneous administration of the agonist is outweighed by the lack
of acceptability of frequent subcutaneous bolus injections or an
infusion pump. Constant and sustained plasma levels of agonist are
best obtained with a subcutaneous depot and recent efforts on behalf
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of the pharmaceutical companies have been directed towards development
of the latter (Hutchison & Furr, 1987). Zoladex depot (goserelin) is
manufactured by ICI Pharmaceuticals, Macclesfield, UK. The analogue
(D-ser(tBu)6,Aza-Gly10-LHRH) is dispersed in a biodegradable lactide-
glycolide copolymer rod which is prepacked in a special syringe
applicator. The 3.6mg depot releases the agonist continuously at an
average rate of 120 meg/day over approximately 30 days. Preliminary
studies in males with advanced prostatic carcinoma showed this dose to
be effective in inducing reversible suppression of gonadotrophins and
testosterone (Williams et al, 1984; Ahmed et al, 1985). In addition,
limited experience of treatment of women with disseminated breast
cancer demonstrated pituitary-ovarian suppression (Millstead, 1984 -
personal communication) although no previous studies had been
performed on women with benign conditions.
The object of the present study was to investigate the endocrine and
clinical effects of goserelin (Zoladex depot) 3.6mg in premenopausal
women treated for up to 6 months. A secondary objective was to
establish the time taken following cessation of therapy for return of
ovulatory menstruation and also to determine the optimum time in the
cycle for initial commencement of treatment. Two groups of women were
selected for study, a group complaining of premenstrual mental and
physical symptoms and a group with symptomatic uterine fibroids. Some
of the subjects had both problems. Initial approval was given for
recruitment of 12 subjects, all of whom would commence therapy in the
luteal phase of the cycle and another 6 who would start in the early
follicular phase. Any who defaulted at an early stage could be
replaced by another recruit who fitted the criteria for inclusion. In
192
this chapter the endocrine results will be presented in detail,
together with a summary of the effect on uterine fibroids. The
effects on cyclical symptoms will be presented and discussed in the
next chapter.
5.2 - SUBJECTS AND METHODS
5.2.1 - Subjects
A total of 20 women were recruited to the study, of whom 17 completed
6 months therapy. All were premenopausal, with regular menstrual
cycles (range 26-32 days). A condition for recruitment was that they
had been surgically sterilised (the company had not received approval
at that stage for clinical studies in potentially fertile women) and
thus all were parous. They ranged in age from 31 to 48 years (mean
40.8 years) with a mean parity of 2 (range 1-5). Mean weight was 62.3
kg (range 52.0-82.0 kg) prior to therapy and 60.7 kg (range 52.2-81.5
kg) at its completion. Seven of the women had initially presented
with premenstrual problems and the other 13 had uterine fibroids
diagnosed clinically and confirmed by ultrasound. All were medically
fit and receiving no additional form of hormonal therapy or any other
medication which might interfere with interpretation of the results.
The nature and objectives of the study were explained in detail to
each of the subjects who gave written consent to participate. Full
details of the protocols had been submitted in advance to the local
ethical committee for approval.
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5.2.2.- Therapy
The depot injections were administered at 28 day intervals, starting
between days 20-25 of the cycle (14 subjects) or days 1-6 (6
subjects). Therapy was continued for a maximum of 6 months. Zoladex
depot was injected into the subcutaneous tissues of the anterior
abdominal wall, using the pre-packed sterile syringe applicator.
Initially, infiltration of the skin with 2% lignocaine was performed
routinely but after modification of the design of the needle by the
manufacturers this was no longer found to be necessary.
5.2.3 - Endocrine monitoring
Each subject was asked to collect early morning samples of urine
(20 mis) twice weekly for (i) at least one complete cycle prior to
commencement of therapy, (ii) for its duration and (iii) after its
cessation until the return of menstruation. Some subjects were asked
to continue collections until the third post treatment menstruation.
Between visits, the samples were stored by the subjects in their own
domestic freezers. The samples were assayed for oestrone glucuronide,
pregnanediol and creatinine. Results were expressed as the
steroid:creatinine ratios. Venous blood was withdrawn immediately
prior to administration of each depot and 1 and 3 months post-therapy
for estimation of LH, FSH, oestradiol and progesterone. In addition,
more detailed endocrinology was performed on a sub-group of 7 women
commencing therapy in the luteal phase, who had additional samples
withdrawn on days 1,2,3,7,14,21 of the first treatment cycle and day
14 of cycle 2 (taking day of administration of depot as day 0
regardless of actual menstrual cycle day). These 7 subjects also had
monthly venous blood samples assayed for testosterone, androstenedione
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and sex hormone binding globulin (SHBG). The laboratory methods are
described in section 5.2.7.
5.2.4 - Other laboratory measurements
Venous blood was also taken monthly for measurement of full blood
count, platelets, urea, bilirubin, alkaline phosphatase, alanine
aminotransferase, calcium, phosphorus, total proteins and albumin.
Six subjects had a short Synacthen test performed prior to therapy and
during the last treatment cycle.
5.2.5 - Clinical assessment
The subjects were interviewed monthly and asked specifically about
changes in presenting symptoms and any side effects attributable to
therapy. In particular, they were questioned specifically about the
occurrence of hot flushes, night sweats, vaginal dryness and sexual
problems. Symptoms were rated by the interviewer on a four-point
scale. All subjects kept a menstrual calendar and those with cyclical
symptoms completed a daily symptom diary chart (see section 6.2.3).
5.2.6 - Assessment of uterine volume
At diagnosis, an initial ultrasound scan was performed to confirm the
presence of fibroids and to exclude any coincidental ovarian
pathology. Volume measurements were performed immediately prior to
the initial depot, monthly during therapy and three months after its
completion. Total uterine volume was measured by ultrasound using a
real-time linear array machine (Picker LS 700). The maximum length
(excluding the cervix) and the widest transverse diameters in 2 planes



















4/3TTr3 which approximates to the product of the three diameters
multiplied by 0.523. This method of assessment had been previously
validated by comparing ultrasound measurements prior to hysterectomy
with direct measurement of the unfixed operative specimen. A highly
significant correlation between the two methods was obtained (r=0.96;
figure 5.1).
5.2.7 - Laboratory methods
Plasma was stored at -20 degrees before radioimmunoassay (RIA) of LH,
FSH, oestradiol, progesterone, testosterone, androstenedione and SHBG.
Plasma LH and FSH were measured by double antibody RIA (Hunter &
Bennie, 1979) and the results expressed in terms of standards obtained
from the National Institute of Biological Standards and Control, Holly
Hill, London (LH 64/80, 77 U/ampoule, FSH 69/104, 10 U/ampoule). The
intra-assay coefficients of variation were 10% and 9% respectively for
LH and FSH, while the interassay coefficients of variation were 16%
and 15% respectively. Limits of sensitivity were 0.2 U/l and 0.1 U/l
for LH and FSH respectively. Oestradiol and progesterone were
measured by RIA (Scaramuzzi et al, 1975; Backstrom et al, 1982).
Sensitivities were 10 pg/ml for oestradiol and 200 pg/ml for
progesterone. Intra- and inter-assay coefficients of variation were
9% and 13% respectively for oestradiol and 8% and 15% for
progesterone.
Androstenedione and testosterone were measured in duplicate by
specific RIA (McNatty et al, 1976; Baird et al, 1974, 1981).
Following extraction with hexane:ether (4:1), androstenedione and
testosterone were separated by alumina chromatography before assay.
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The interassay coefficients of variation for androstenedione and
testosterone were 12% and 11.5% respectively and the limits of
sensitivity 50 and 10 pg/ml. The SHBG assay was a modification of the
method of Rosner (1982) described by Anderson et al (1976) using both
unlabelled and [3H]-dihydrotestosterone (DHT). The method measures
total binding capacity of plasma in the form of the mass of 5a-
dihydrotestosterone required to saturate the available binding sites.
The SHBG-DHT complex is precipitated with ammonium sulphate and the
radioactivity in the supernatant used to assess the SHBG binding
capacity.
The aliquots of early morning urine were assayed for oestrone-3-
glucuronide by direct RIA after 100-fold dilution using specific
antisera supplied by P. Samarajeewa, Courtauld Institute, Middlesex
Hospital (Baker et al, 1979). Sensitivity was 6 ng/ml and intra- and
inter-assay coefficients of variation 7.9% and 15.8% respectively.
Pregnanediol was determined by gas-liquid chromatography (Chamberlain
& Contractor, 1968). Creatinine was measured by autoanalyser using
the Jaffe reaction and the results expressed as the steroid:creatinine
ratios.
5.3 - RESULTS
5.3.1 - Patient compliance
Of the 20 women who commenced therapy, only 3 failed to complete the
full 6 months. Two of these had presented with cyclical symptoms and
dropped out after 3 and 5 months respectively. Further details are
given in section 6.3.1. Only one subject with fibroids withdrew prior
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to completion. She presented one week after the administration of
depot 2 with continuous heavy bleeding accompanied by cramp-like
pelvic pain. This was followed by prolapse of a degenerating
submucous fibroid which was removed under general anaesthesia. She
elected to undergo hysterectomy which was performed 2 weeks later. At
operation the uterus contained a large infarcted intramural fibroid.
5.3.2 - Endocrine response
5.3.2a - Plasma ovarian steroids and gonadotrophins
The gonadotrophin, oestradiol and progesterone assay results from the
7 subjects who underwent more frequent sampling during the initial
treatment cycle are shown in figure 5.2 and the results of monthly
sampling from the 17 subjects who completed 6 months therapy in table
5.2. One way analysis of variance for repeated measures was used to
test for overall significant differences. Results show an initial
marked rise in the concentration of LH to reach a peak within 24 hours
of the initial depot, accompanied by lesser stimulation of FSH (figure
5.2a). Rapid return to basal levels occurred over the next 48 hours.
Thereafter concentrations of FSH remained within the pretreatment
range. In contrast, plasma LH showed a significant and sustained
suppression for the duration of therapy (F=4.22; p<0.01 by analysis of
variance). Plasma oestradiol (figure 5.2b) fell to early follicular
phase levels (normal range of 55+20 pg/ml - mean+SD ) within 14 days




Plasma LH, FSH, oestradiol and progesterone (mean + SEM) during
therapy with Zoladex depot 3.6mg, starting in the mid-luteal phase of
the first treatment cycle. Results are from 7 subjects sampled on
days 0,1,2,3,7,14,21 of the initial treatment cycle, days 0,14 of















Changes in plasma oestradiol and gonadotrophins (mean + SEM)







Pre 248.7 + 48.2 6.6 + 0.9 4.4 + 0.7
1 51.3 + 5.6 2.2 + 0.4 3.1 + 0.3
2 47.6 + 3.0 2.1 + 0.3 4.1 + 0.4
3 50.7 + 3.3 2.4 + 0.3 5.0 + 0.5
4 53.3 + 3.3 2.2 + 0.5 4.7 + 0.4
5 56.3 + 3.9 2.3 + 0.4 5.8 + 0.6














































Changes in plasma androgens and sex hormone binding globulin (SHBG)
(mean+SEM) during therapy with Zoladex depot (n=7)
CYCLE Androstenedione Testosterone SHBG
(pg/ml) (pg/ml) (nmol/1)
Pre 978 + 129 205 + 26 68.0 + 10.8
1 627 + 66 147 + 19 60.0 + 9.7
2 634 + 90 120 + 17 59.0 + 8.5
3 879 + 162 119 + 17 60.8 + 8.5
4 673 + 90 104 + 5.9 69.3 + 11.0
5 878 + 212 120 + 10 63.8 + 11.3
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5.3.2b - Androgens and SHBG
Mean plasma testosterone concentrations were also significantly
reduced during therapy (F=3.33; P<0.05 - figure 5.3; table 5.3).
However an initial fall in plasma androstenedione was not sustained
beyond the third treatment cycle and did not reach statistical
significance (P=1.17). Plasma SHBG showed a small but non-significant
reduction (F=0.62 - table 5.3).
5.3.2c - Urinary ovarian steroid metabolites
Mean values of urinary ovarian steroid metabolites were calculated for
each 3-4 day interval before, during and after completion of therapy
in those 12 subjects who commenced Zoladex treatment in the mid-luteal
phase of the cycle (figure 5.4.1). The post-treatment results are
standardised around day 1 of the initial menstruation. Ovulation,
assessed by twice weekly urinary pregnanediol, was inhibited in all
the subjects throughout treatment. The mean urinary oestrone
glucuronide:creatinine ratio remained within or just below the early
follicular phase range of the pretreatment cycle. Differences in
ovarian steroid profiles during the initial treatment cycle were seen
between those women who commenced therapy in the mid luteal phase of
the cycle (median day 23), as illustrated in figure 5.4.1 and those 6
subjects who commenced in the early follicular phase (median day 4),
shown in figure 5.4.2. When the initial depot was given in the luteal
phase, suppression of urinary oestrogen was apparent after 14 days in
all the subjects. A more variable response was seen in the group
where therapy was initiated in the follicular phase, 3 of the subjects
showing marked oestrogen stimulation lasting between 14 and 21 days
(eg figure 5.5.1a) while stimulation was mild and transient in the
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Figure 5.4.1
Urinary steroid metabolites (mean +_ SD) for each half week period
before, during and after 6 months therapy with Zoladex depot in 12
subjects who commenced treatment in the mid-luteal phase of the
cycle. Post treatment results are standardised around day 1 of first
menstruation.












































other 3 subjects (eg figure 5.5.1b). For the remainder of therapy,
mean urinary ovarian steroid metabolites in those starting therapy in
the follicular phase did not differ from those who started in the
luteal phase (figure 5.4.1) and are thus not plotted out in full. One
subject who inadvertently commenced therapy around mid-cycle showed
marked oestrogen stimulation although this was not associated with any
adverse clinical effects. Individual differences in ovarian steroid
profiles during therapy are discussed below and in section 5.3.5 and
illustrated in figures 5.5.1 - 5.5.3.
Following the administration of the last depot, 15 of the 17 women who
completed 6 months therapy resumed menstruation within 80 days (median
72 days, range 62-80 days), with a delay to 95 days in one subject and
5 months in another aged 44 years who subsequently developed post¬
menopausal levels of gonadotrophins and became amenorrhoeic. The two
stopping after 3 and 5 months resumed ovulatory menstruation within 65
days. Recovery of ovarian activity following the administration of
depot 6 is shown for 4 individual subjects in figure 5.6 and for the
group as a whole in figure 5.4.1. In the latter, results have been
standardised around day 1 of menstruation. Two of the women recorded
episodes of spotting 32 and 36 days respectively after depot 6 and in
one there was a transient rise in urinary pregnanediol. The first
post-treatment menstruation was anovular in one case and preceded by a
short luteal phase in 2 others. Some of these individual differences
are illustrated in figures 5.5 - 5.6.
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Figure 5.5.1
Ovarian steroid metabolites, uterine volume and menstrual bleeding in
two subjects who commenced therapy in the early follicular phase of






0J I I 1 I I I I
BLEEDING











Ovarian steroid metabolites, uterine volume and menstrual bleeding
in two subjects who commenced therapy in the luteal phase of the
pretreatment cycle, showing marked differences in oestrogen









































































































Recovery of urinary ovarian steroid metabolites and return of
menstruation after administration of depot 6 in 4 subjects. In one
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5.3.3 - Biochemical and haematological results
No changes in biochemical and haematological parameters were seen
during therapy and the Cortisol response to Synacthen was not impaired
at the end of treatment. Beneficial effects on haemoglobin were seen
in two subjects who were mildly anaemic at its commencement. The
unfortunate subject with prolapse of a submucous fibroid required
transfusion because of an acute fall in haemoglobin concentration
secondary to haemorrhage.
5.3.4 - Clinical response to therapy
Menstrual pain and pressure symptoms secondary to the presence of
uterine fibroids were relieved completely during therapy. Bleeding
during treatment cycle 1 was more prolonged than normal although with
a normal or less than normal flow. In those subjects starting therapy
during the luteal phase, bleeding occurred around or just after the
time of expected menstruation (figure 5.5.2). When therapy was
initiated in the early follicular phase, further bleeding occurred 3-
21 days after the depot and corresponded to oestrogen withdrawal
although there was evidence of luteinisation in some cases (figure
5.4.2; 5.5.1). The duration of first cycle bleeding was not
significantly different, regardless of whether the treatment had been
started in the luteal (median 11.5 days, range 4-24 days) or the
follicular phase (median 8.5 days, range 5-26 days). There were 7
episodes of bleeding in 4 subjects after the completion of treatment
cycle 1. Four of these episodes were very scant, lasting 3 days or
less and were not associated with any changes in oestrogen excretion
(see table 5.5). The fifth subject had three episodes of bleeding
lasting 9, 4 and 11 days respectively, associated with
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oestrogen excretion in the mid-follicular phase range. This subject
showed lack of LH suppression during therapy and a poor fibroid
response (figure 5.5.3).
5.3.5 - Fibroid response
All the subjects with fibroids showed reduction of uterine volume
during therapy (figure 5.7). The individual response varied between
84% and 38% reduction at the end of therapy, with an overall reduction
of 55%. The reduction was statistically significant (p<0.01 by
repeated measure analysis of variance). The greatest reduction
occurred during the first treatment cycle (table 5.4), lessening
towards the end of therapy, although there was considerable individual
variation. In the subject illustrated in figure 5.5.2a, suppression
of oestrogen excretion into the castrate range was accompanied by an
84% reduction of uterine volume while the subject in figure 5.5.2b
showed resumption of ovarian follicular activity accompanied by loss
of fibroid response after depot 3. The subject described above who
showed an overall poor response to therapy is illustrated in figure
5.5.3. There was no significant difference in fibroid response during
the first cycle between those subjects where therapy was initiated in
the early follicular phase and those who had started in the mid luteal
phase. In the subject illustrated in figure 5.5.1a a 22% reduction in
uterine volume had occurred in the first cycle despite marked initial
oestrogen stimulation. Excluding the first treatment cycle, there was
a highly significant inverse correlation between the percentage
reduction in uterine volume and mean urinary oestrone




Serial ultrasound measurements of uterine volume in individual
subjects before, during and after completion of 6 months therapy with





































Changes in uterine volume during and 3 months after therapy with
Zoladex depot (n=12)
CYCLE volume (cm3) % reduction % pretreatment
(mean SD) per cycle volume
Pre 360 + 225 100
1 253 + 146 30.0 70
2 220 + 126 13.0 61
3 199 + 120 10.0 55
4 167 + 115 16.0 47
5 154 + 102 8.1 43
6 162 + 100 -5.8 45
Post 367 + 100 102
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Three months after the cessation of therapy, fibroid volume had
returned to pretreatment values (figure 5.7; table 5.4). Some
regrowth was seen even in those subjects where ovulatory menstruation
had not yet resumed (figure 5.5.2b).
5.3.6 - Other effects and side effects of therapy
The effect of therapy with Zoladex depot on menstrual bleeding has
been outlined in section 5.3.4. The occurrence of dysfunctional
bleeding and side effects associated with oestrogen suppression,
namely vasomotor symptoms and vaginal dryness is summarised in table
5.5. Here the incidence and severity of these problems is shown for
all treatment cycles with the exclusion of treatment cycles 1.
All but two of the subjects reported hot flushes on direct questioning
although the degree of associated distress was variable. There was a
significant negative correlation (r=-0.545, p<0.03) between mean
urinary oestrogen level (cycles 2-6) and overall severity of flushes
for the corresponding treatment cycles. Eight subjects reported
vaginal dryness at some time during therapy and in two of these there
was associated dyspareunia which in both cases was transient. The
vaginal symptoms tended to peak during treatment cycles 2, 3 and 4 and
resolve towards the end of therapy. Only one of the subjects
complained of lack of libido and she later withdrew from therapy prior
to its completion, although not primarily because of this problem (see
section 6.3.3). All were questioned monthly about the occurrence of
headaches but only in one case did these appear to be more frequently
present than prior to therapy. None of the subjects gained weight
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Table 5.5
SIDE EFFECTS OF THERAPY WITH ZOLADEX DEPOT
Treatment cycles excluding cycle 1 (n=90)
Dysfunctional bleeding:
Amenorrhoea 83 (92%)
Scanty 3 days or less 4 (4%)
Longer (range 4-11 days) 3 (3%)
Hot flushes:
None 12 (13%)





Associated dyspareunia 4 (4%)
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during therapy and no problems were encountered with the injection
sites.
Four subjects reported onset of symptoms of depression and/or anxiety
soon after the commencement of therapy (see section 6.3.3). All four
had reported cyclical mood changes prior to therapy although only one
presented with these as her primary complaint and she later withdrew
from the study. In the other three, who had presented with fibroids,




The administration of Zoladex depot resulted in sustained suppression
of pituitary-ovarian function in these 19 premenopausal subjects. The
subcutaneous depot produces a more reproducible response than that
seen with the intranasal route of administration (Hardt & Schmidt-
Gollwitzer, 1983; Lemay et al, 1984) and is more convenient than
frequent subcutaneous bolus administration (Maheux et al, 1985) or a
subcutaneous infusion (Healey et al, 1986). Inadequate endocrine
response was seen in only one subject although oestrogens did not
usually reach the castrate range. Some of the individual differences
in urinary oestrogen excretion may be attributable to oestrogen
derived from peripheral conversion of adrenal androgens. The latter
pathway is not affected by pituitary-ovarian suppression (Couzinet et
al, 1986) and this oestrogen contributes to the urinary metabolite
measured by our assay.
Our finding that mean oestrogen levels remain within the early
follicular phase range are in contrast with the results of some other
groups, where suppression to post-menopausal levels or to the castrate
range have been reported (eg. Meldrum et al, 1982; Muse et al, 1984;
Coddington et al, 1986; Walker et al, 1986). The urinary results
include oestrogens derived from adrenal sources but we also found that
mean plasma oestradiol concentrations were maintained within or just
below those obtained in the early follicular phase of the cycle. It
is possible that the constant plasma levels of the agonist obtained
with a depot, preparation enabled this less than complete degree of
suppression to be maintained while intermittent dosage regimes must
exert a more profound suppression for the effect to be sustained. As
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yet there is limited data from other groups on the effects of depot
administration. The only other published report of the use of Zoladex
in premenopausal women, in this case women with advanced breast cancer
(Walker et al, 1986), did show greater ovarian suppression than that
observed in the present study.
A dissociation between the effect of therapy on LH and FSH was seen,
with prolonged suppression of LH while FSH returned to the pre-
treatment range. This is the reverse of the dissociation of response
reported during short term therapy, where sustained elevation of LH
was observed with an acute rise following individual bolus doses
(Meldrum et al, 1982; Lemay et al, 1985), while suppression of FSH and
loss of acute response occurred at an early stage. There was no
relationship between the degree of oestrogen suppression and FSH
levels and the mechanism of this dissociation of gonadotrophin
response is unclear. However a similar observation was made by Walker
et al (1986) using Zoladex depot.
Marked differences in endocrine profiles were seen when therapy was
commenced in the luteal phase of the cycle, compared with its
initiation in the early follicular phase as has been the usual
practice in the majority of published studies. The latter timing has
the advantage of convenience, particular if cycles are irregular and
avoids the possibility of commencing therapy during early pregnancy in
potentially fertile women. However ovarian stimulation lasting up to
4 weeks or longer has been reported in these other studies (eg Hardt &
Schmidt-Gollwitzer, 1983; Shaw et al, 1983; Muse et al, 1984). Our
results showed a variable effect when therapy was initiated in the
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early follicular phase, with prolonged stimulation in about half the
subjects and minimal stimulation in the others. A more consistent
response was seen where therapy was initiated in the luteal phase with
the advantage of no additional menstruation after the expected bleed,
although the latter was invariably prolonged. However the duration of
first cycle bleeding did not significantly differ between the two
groups. It was also interesting that fibroid response during the
first cycle did not differ between the groups starting treatment in
the two cycle phases. In practice then, the luteal phase start would
not seem to confer any particular advantages despite the more uniform
endocrine response. Timing of initiation of therapy in relation to
other symptoms is discussed in the next chapter.
Ovarian function recovered rapidly after cessation of therapy,
allowing for the fact that the duration of action of each depot is at
least 30 days. The more prolonged recovery seen in two subjects may
be attributable to their age. The median delay of 72 days to onset of
first menses, when corrected to 42 days (by subtracting 30 days), is
equivalent to the mean of 47 days following intranasal nafarelin for
treatment of endometriosis (Schriock et al, 1985) and 43 days when
used for contraception (Gudmundsson et al, 1986). However shorter
recovery intervals have been reported by others using buserelin
(Bergquist et al, 1982; Lemay et al, 1984). Recovery was shorter
following a single depot of Zoladex (Thomas et al, 1986), where menses
returned between 61 and 71 days after administration. Thus, in women
wishing to preserve childbearing potential, the depot route of
administration appears entirely reversible.
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The reversibility of the effect of the agonist is seen in relation to
one target organ, namely the uterus, although it had been hoped that a
more sustained benefit on the fibroids would have been evident. The
oestrogen-dependent nature of this tissue is very clearly demonstrated
with a significant positive correlation between volume reduction and
mean urinary oestrogen. Oestrogen receptors have been identified in
fibroid tissue and their content found to vary during the menstrual
cycle (Soules & McCarty, 1982; M. Lumsden, personal communication,
Edinburgh 1987). The reduction in uterine volume seen in all the
subjects during therapy is consistent with the reduction of
circulating oestradiol and loss of ovarian cyclicity. The method of
measurement of the fibroids included the volume of the uterus itself
and thus a reduction of 100% was not anticipated although complete
fibroid regression was obtained in at least two of the subjects,
including the one illustrated in figure 5.5.2a. However, cessation of
therapy after 6 months was accompanied by rapid return of uterine
volume to pretreatment values in parallel with the return of ovulatory
menstruation. A more sustained benefit was reported in some or all of
the subjects in the other published series (Maheux et al, 1985;
Coddington et al, 1986; Healey et al, 1986). The reason for this
difference in outcome is not clear but more information is needed in
larger numbers of women. Our results are based on only 6 months
therapy with incomplete ovarian suppression in some of the subjects
and the effect of more prolonged agonist administration has yet to be
determined. However, for reasons mentioned below, prolonged and
profound ovarian suppression may carry disadvantages for premenopausal
women unless they are being treated for a malignant condition where
the benefits outweigh the disadvantages.
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In addition to ovarian oestrogen suppression, a significant reduction
of circulating testosterone was seen compared with mid-luteal phase
pre-treatment control values. Other workers have not examined this
aspect of ovarian function, except in women suffering from polycystic
ovarian disease (Chang et al, 1983; Couzinet el al, 1986). The
developing follicle and corpus luteum are both an important source of
androgens (McNatty et al, 1976) and thus the ovarian component of
circulating testosterone can be expected to fall during therapy.
Peripheral conversion of androstenedione also contributes
significantly to circulating testosterone (Horton & Tait, 1966) and as
this is also derived from the ovary it is surprising that a similar
degree of suppression of androstenedione was not observed during
therapy with the agonist. This may in part reflect its continuing
production from small and atretic follicles (McNatty et al, 1979) as
well as the normal adrenal production (Baird et al, 1969). It is also
possible that conversion of androstenedione to testosterone is
gonadotrophin dependent so that this pathway is active post-
menopausally when gonadotrophin levels are high but not when
gonadotrophins are suppressed during agonist therapy. However the
latter statement is purely speculative. It is presumably the parallel
reduction in both ovarian oestrogens and testosterone which resulted
in the lack of overall change in SHBG levels, as these two steroids
exert a counterbalancing effect (Anderson, 1974).
These observations on androgen levels during agonist therapy may have
important metabolic implications. The relatively hypo-oestrogenic
state induced by therapy with LHRH agonists has been referred to as
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'medical oophorectomy' (Meldrum et al, 1982) and has certain
similarities to the post-menopausal state. Both these situations are
associated with alterations in serum lipids (Oliver & Boyd, 1959;
Patterson et al, 1979) and an increased risk of ischaemic heart
disease (Gordon et al, 1978) although the latter association has been
challenged (Lapidus et al, 1985). However in contrast to the post-
oophorectomy situation (Vermulen, 1976), normal levels of
androstenedione are available during Zoladex therapy for peripheral
conversion to oestrone (Grodin et al, 1973) and in some cases
continuing low levels of oestradiol production are maintained.
Endocrine profiles are also different following the natural menopause
where continuing ovarian production of testosterone (Longcope et al,
1980) occurs in the stroma and appears to be dependent on the elevated
gonadotrophins (McNatty et al, 1979). This state of relative
androgen-dominance (Judd, 1976) may also be important in the aetiology
of the rising incidence of cardiovascular morbidity seen following the
menopause. It is unlikely to be of relevance in women receiving
therapy with LHRH agonists although results of studies on plasma lipid
profiles are awaited. The effects of exogenously administered
androgens and related steroids in relation to lipids and
cardiovascular morbidity is also discussed in another section of this
thesis (section 4.4).
Oestrogen suppression has other potentially important consequences in
premenopausal women. One of the major considerations is the effect on
bone density, which is known to be oestrogen-dependent (Nordin, 1971;
Lindsay et al, 1976). Studies of bone density during LHRH agonist
therapy are still in progress so it is too early to reach definite
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conclusions. However currently the use of these agents seems likely
to be restricted to short term or intermittent therapy, such as for
the management of endometriosis. They may also be of value for
preoperative shrinkage of fibroids (Lumsden et al, 1987) and in the
management of women with fibroids who are nearing the age of the
natural menopause.
The clinical application of LHRH agonists is also likely to be limited
by the occurrence of side effects associated with reduced circulating
oestrogens, namely hot flushes and atrophic vaginitis. However, these
problems did not result in any of the subjects presented above
withdrawing from the study. Partial oestrogen suppression with lower
intranasal doses of agonist, such as those investigated for
contraception (section 5.1.2) are not associated with these side
effects but here irregular bleeding becomes a problem, together with
the potential hazard of the effect of unopposed oestrogen on the
endometrium. One therapeutic strategy, which we are currently
investigating in relation to the management of fibroids, is to combine
an LHRH agonist in the dose and regime described above, with an
oestrogen receptor blocker in order to counteract the effect of the
remaining circulating oestrogen on its target tissue. One such agent
is the antioestrogen tamoxifen, already used widely in the management
of oestrogen-dependent breast cancer. An alternative strategy would
be the combination of an LHRH agonist with a pure progestogen, such as
medroxyprogesterone acetate. The latter reduces the frequency of
menopausal flushes when given orally (Albrecht et al, 1981) or by
depot (Bullock et al, 1975). Progestogens may also exert a protective
effect against bone loss (Lindsay et al, 1978).
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In conclusion, Zoladex depot produces reproducible and reversible
suppression of pituitary-ovarian activity in premenopausal women.
Although oestrogen levels are maintained just above the postmenopausal
range, symptoms of oestrogen deficiency are frequent and the long term
effects of therapy have yet to be clarified. While Zoladex produces
shrinkage of uterine fibroids and relief of associated symptoms during
therapy, rapid regrowth after its cessation limits its usefulness as a
single agent in clinical management at the present time. However,
further investigation of the use of the depot in other oestrogen-
dependent conditions is indicated and its potential role in the




A DESCRIPTIVE STUDY OF THE EFFECT OF ZOLADEX DEPOT (GOSERELIN) ON
CYCLICAL MENTAL AND PHYSICAL SYMPTOMS
6.1 - Introduction
The relationship between cyclical changes in ovarian steroids and
menstrual cycle related symptoms remains unresolved (see chapter 3).
Attempts to abolish cyclical symptoms by hormonal suppression of
ovulation with progestogens have yielded largely negative results
(chapter 4), complicated by variable cycle control and possibly by
direct effects of the steroids themselves. An alternative strategy is
the use of LHRH agonists which suppress ovarian function by pituitary
desensitisation (see chapter 5) and have no steroid-like action of
their own. Three groups have published the results of such
investigations, one using daily subcutaneous injections (Muse et al,
1984), and the others with intranasal spray (Backstrom, 1986; Bancroft
et al, 1987). The results of these studies are discussed in greater
detail later in this chapter but both these methods of administration
have disadvantages in terms of reproducibility of endocrine response
and patient acceptability (see section 5.1.2). The more recently
developed subcutaneous depot, described in chapter 5, has the
advantage of convenience for patients and a more consistent endocrine
response. The aim of the present study was to investigate the effect
of pituitary-ovarian suppression with the LHRH agonist Zoladex depot
(goserelin) on cyclical mood and physical symptoms in women with
premenstrual complaints. The endocrine and clinical effects of
therapy have already been described in detail in chapter 5.
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6.2 - SUBJECTS AND METHODS
6.2.1 - Subjects
Of the 20 subjects recruited for therapy with Zoladex depot (section
5.2.1), 7 had presented primarily with premenstrual problems. They
had been initially assessed by daily completion of a set of visual
analogue scales to establish the relationship of their symptoms to the
premenstrual phase of the cycle (see section 2.2.2). The other 13 had
presented with various menstrual-cycle related symptoms and were
subsequently found to have uterine fibroids. The women in this latter
group were also asked about the presence of premenstrual problems.
Six of the 13 claimed to experience such symptoms, later confirmed by
daily recording in four of the six. Indeed, in two, these problems
had contributed to their initial presentation. The data later
presented in this chapter will be concerned with the effects of
therapy in the 11 women experiencing cyclical symptom prior to
therapy, either as their principal complaint or in association with
uterine fibroids.
6.2.2 - Therapy
The dose and administration of Zoladex depot is described in section
5.2.2.
6.2.3 - Assessment of response
The subjects with cyclical symptoms were asked to complete a daily
symptom chart, starting at least one complete menstrual cycle prior to
administration of the initial depot, continuing for the duration of
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therapy and after its completion until the second post-treatment
menstrul bleed. The chart used has been described in sections 1.10.2
and 2.6.2 and is shown in figure 1.4. All symptoms were subjectively
scored from 0 (none) to 3 (severe). The subjects were also
interviewed monthly and asked about their response to therapy as well
as any side effects (see section 5.3.6).
6.2.4 - Data analysis
The data from the daily symptom records were initially plotted out for
each individual subject together with the results of twice weekly
urinary endocrine monitoring (see sections 5.2.3 and 5.2.7 for
methods). Symptom profiles for the group as a whole were obtained by
calculating the total daily scores for individual symptoms,
standardising results for treatment cycles around the day of
administration of individual depots and for pre and post-treatment
cycles around the first day of menstruation. Data from treatment
cycle 1 was also standardised around day 1 of menstruation to allow
for the different timing of administration of the initial depot
(luteal phase in some subjects and early follicular phase in the
remainder). Total daily scores were used in preference to median
daily scores for greater sensitivity as median daily scores during the
treatment months were generally zero (see section 6.3.3).
Symptom scores for each treatment cycle were calculated by adding the
daily scores for individual symptoms for each 28 day interval between
depot injections. Pre and post-treatment cycles were standardised to
28 days to allow for differences in cycle length so that each included
the first 5 days of menstruation, the preceding 14 premenstrual days
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and 9 'intermenstrual' days. Results were expressed as the median and
interquartile range of the individual scores. Statistical differences
between pretreatment and treatment cycles were calculated using the
Friedman non-parametric two-way analysis of variance for related
samples. P values for the Friedman test were obtained from tables of
the Chi-squared distribution using the method described by Colquhoun
(1971).
6.3 - RESULTS
6.3.1 - Patient characteristics and compliance
Of the eleven women whose pre-treatment assessment confirmed the
presence of premenstrual problems, seven had presented with these as
their primary complaint (group A) and four had been recruited for
therapy on account of uterine fibroids (group B). All eleven subjects
completed daily symptom charts for the duration of therapy although
two subjects from group A withdrew before its scheduled completion
(see section 6.3.3). Table 6.1 summarises the pre-treatment
characteristics of the women in groups A and B. The premenstrual mood
and physical symptom scores and degrees of relief following
menstruation were derived from analysis of data from one complete pre-
treatment cycle using the 4-point symptom scales and the methods
described in section 2.2.3). The mood scores are the mean of
depression and irritability and the physical scores the mean of
swelling and breast discomfort. The table also indicates whether the











































































None of these women had a past history of psychiatric problems or
treatment and all were physically healthy.
6.3.2 - Overall effects of therapy on mental and physical symptoms
Complete data over 6 months from the daily charts was available from
five women in group A and from all four in group B. The median
symptom scores for the pre-treatment cycle, all six treatment cycles
and the first full post-treatment cycle are shown for these nine
subjects in figure 6.1. All symptoms were significantly improved
during therapy, as calculated by Friedman's analysis of variance,
although this method determines only overall significance and does not
distinguish between individual cycles. Physical symptoms appear to
have been more completely suppressed than mental symptoms. Not
surprisingly, improvement was not seen during the first treatment
cycle because of initial endocrine stimulation prior to onset of
suppression (see section 5.3.2) although no overall worsening of
symptoms was apparent. When the data was included from the two
subjects in group A who withdrew before completion of therapy (figure
6.2), median symptom scores for depression failed to show a
significant improvement over the initial three treatment cycles,
although the other symptoms were significantly improved. Two other
subjects from group B, who failed to complete the charts, claimed
relief from cyclical symptoms during therapy.
Total daily symptom scores from those nine subjects with complete data
over six treatment cycles (figure 6.3) showed loss of the cyclical
pattern after the initial treatment cycle. Thereafter, the persisting





















































































































Effect of Zoladex depot on daily symptom profiles (total scores)
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individual depots. After cessation of therapy there was a prompt
recurrence of symptoms (see figures 6.1 & 6.3) with the exception of
breast discomfort where the effect of therapy appeared to be sustained
for at least the initial post-treatment cycle. The return of symptoms
appeared to coincide with or actually predate the time of the first
post-treatment ovulation (see figure 5.4.1).
The response to therapy shown by the women in group A and those in
group B are compared in figure 6.4, which is based on those completing
six months treatment. In view of small numbers in the two groups a
statistical comparison has not been attempted. However overall
profiles appear similar, apart from an apparent worsening of all
symptoms in the initial treatment cycle of those in group B and a
comparative delay in improvement of the emotional symptoms compared
with those in group A. The median pretreatment scores were, not
surprisingly, lower in the group B subjects with the exception of
pelvic pain.
6.3.3 - Relationship of individual symptom and endocrine profiles
The results of twice weekly assay of urinary ovarian steroids (see
section 5.3.2c) in the individual subjects were compared with the
daily symptom profiles. Subjects 1 & 7 from group A showed marked
symptom relief during therapy (figure 6.5), with urinary oestrogen
excretion maintained in or below the early follicular phase range. By
contrast, subject 3 (figure 6.6a) showed oestrogen suppression into
the castrate range associated with almost complete relief of the
sensation of swelling but intermittent episodes of irritability at
least as severe as those present prior to therapy and totally
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Figure 6.5
Urinary steroid excretion, symptoms and menstrual bleeding patterns
(expressed on 4-point scale) in (a) subject 1 and (b) subject 7
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Urinary steroid excretion, symptoms and menstrual bleeding patterns
(expressed on 4-point scale) in (a) subject 3 and (b) subject 2
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unrelated to endocrine activity. She later described these symptoms
as 'the way I feel when my period is due'. Similarly, subject 2
(figure 6.6b) also recorded intermittent episodes of swelling and
irritability, one of which may have been triggered by an episode of
follicular activity but with no apparent endocrine basis for the
others. Subject 2 always marked her chart with a large red cross to
indicate when her period would have been due, to which she related the
symptomatic episodes.
Subject 4 (figure 6.7a) whose pretreatment records indicated
incomplete post menstrual mood relief (38% - see table 6.1) also
recorded prolonged symptomatic episodes of swelling and, to a lesser
extent, irritability which were unrelated to ovarian activity and
apparently more severe than those normally present premenstrually.
However the last of these episodes coincided with the post-ovulation
phase of the first post-therapy menstrual cycle. The other subject
with incomplete post-menstrual mental relief prior to therapy (subject
5 - 45%) also recorded recurrent symptomatic episodes while on therapy
(not illustrated) and withdrew from the study after completion of the
fourth cycle.
Three of the subjects, two from group B and one from group A, recorded
episodes of depression early on during therapy and worse than any
similar symptom normally present premenstrually. A similar problem
was reported by a fourth subject, one of those who complained of
premenstrual problems prior to therapy, but did not consistently
complete the symptom charts. The group A subject (subject 6) later
withdrew from therapy after completion of treatment cycle 3. The
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Figure 6.7
(a) Recurrence of symptoms prior to cessation of therapy in subject 4
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depression is illustrated in figure 6.7b (subject 9) and to a lesser
extent in figure 6.8 (subject 10). Onset of depression occurred after
administration of depot 2 and when oestrogen concentrations were
already suppressed. However resolution occurred with continued
duration of therapy in both these subjects.
In the majority of the examples illustrated, therapy was commenced in
the luteal phase. The numbers are too small to permit a comparison of
the effect of timing of depot 1 on cycle-related symptoms. None of
the subjects recorded a marked worsening of symptoms in cycle 1,
although overall symptoms were unchanged during the initial cycle, in
keeping with the delay in onset of ovarian suppression (figures 5.4.1
-2). In figure 6.5b, the marked initial oestrogen stimulation after
early follicular phase administration of depot 1 (subject 7) was not
associated with any adverse symptoms.
These individual profiles illustrate differences in the recurrence of
symptoms after cessation of therapy. In subject 1 (figure 6.5a) where
breast discomfort was the predominant pretreatment complaint,
the symptomatic improvement was sustained over three post-treatment
cycles. By contrast, in the subjects illustrated in figures 6.5b,
6.6b and 6.7a, recurrence of symptoms actually predated or paralleled
the first mid-cycle oestrogen surge.
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6.4 - DISCUSSION
The results presented in this chapter and in chapter 5 show rapid and
effective suppression of pituitary-ovarian function during treatment
with Zoladex depot. After completion of treatment cycle 1, follicular
activity was minimal in the majority of cycles studied with consistent
inhibition of ovulation. It is thus not surprising that an overall
significant reduction of cycle-related symptomatology was seen.
Physical symptoms were usually more completely abolished than were
psychological ones, consistent with the findings during progestogen
therapy (chapter 4) although the latter did not produce significant
improvement of swelling, as compared with breast discomfort. Results
from individual subjects however showed differences in the degree of
symptom relief. Although the numbers are too small to permit
definitive conclusions, the two subjects with the lowest pretreatment
relief of their mental symptoms following menstruation (subjects 4 & 5
in table 6.1) both showed a poor response to therapy, supporting the
importance of pretreatment assessment of symptom profiles as discussed
in chapter 2. The results from one of these subjects (illustrated in
figure 6.7a), who continued to record symptomatic episodes and where
severe bloating was a predominant problem, suggest the alternative
diagnosis of cyclical oedema (see section 1.8.5) rather than a
premenstrual problem. The problem of preconditioning (see section
1.7) is illustrated by subject 2 who continued to record cyclical
symptoms in the absence of menstrual or ovarian cyclicity.
The results presented are based on two different groups of subjects
with cyclical symptoms, group A where these were the primary complaint
and group B where they were associated with another presenting
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problem, uterine fibroids. The reason for inclusion of both groups
was in part because of limits on the recruitment of subjects (see
section 5.1.3). It was also in order to compare the effects of
therapy in the two groups, as their expectations are likely to be
different. The results do not however show any marked differences
between the two groups although the numbers are too small for a
statistical comparison to be made. Apart from differences in
magnitude of premenstrual symptom scores prior to treatment, the
characteristics of the two groups were similar. It is however
possible that some of the benefits of therapy in group B were
secondary to relief of menstrual discomfort and heavy menstrual flow
associated with the fibroids. In this context, it is thus interesting
that pretreatment pain scores were not higher in the group with
fibroids.
The results clearly show recurrence of symptoms around the time of the
first post-treatment ovulation. It is difficult to explain this other
than by a true endocrine effect as none of the subjects, or indeed the
investigators knew how soon ovarian activity would return after
cessation of therapy. It is also interesting that in some cases
recurrence of symptoms appeared to coincide with the 'mid-cycle'
oestrogen surge whereas the earlier prospective study showed the
increase in adverse symptoms to occur later in the cycle (chapter 2).
The sustained improvement in breast discomfort seen after completion
of therapy is in contrast with the recurrence of the other symptoms,
including swelling and requires further investigation. It also
contrasts with the lack of sustained effect on uterine fibroid volume
after stopping LHRH agonist therapy (chapter 5).
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It is impossible to assess the extent to which the improvement seen
during therapy would have also been present with a placebo and a
placebo-controlled study is in progress. This is important because
the results from an investigation of the use of oestradiol implants in
the management of premenstrual problems (Magos et al, 1986) suggest
that the placebo effect may be particularly high where a 'surgical'
approach to therapy is used. However the design of a placebo
controlled study involving an LHRH agonist depot poses problems
because of the amenorrhoea associated with active therapy and such a
study would not be truly double-blind. It is unlikely that the
response seen over six months in the present study is entirely
attributable to a placebo effect as the latter response has been shown
to be most marked in the initial treatment cycle (Sampson, 1979) and
to decline over the first three months (Magos et al, 1986; Watts et
al, 1987). The results illustrated in figure 6.1 are consistent with
slight loss of a placebo response for depression and irritability
during treatment cycles 5 and 6 compared with the sustained
improvement in physical symptoms.
There have been two published placebo-controlled studies of the use of
LHRH agonists in women with premenstrual tension. The first of these
(Muse et al, 1984) was a 6 month cross-over study of 8 subjects who
self-administered the agonist by daily subcutaneous injection. With
the exception of the initial treatment cycle, where the expected
ovarian stimulation was seen with the agonist, cyclical symptoms were
abolished during agonist therapy but not during placebo
administration. A preliminary report of the second, a cross-over
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study of 26 subjects given 400 meg of buserelin daily by the
intranasal route (Backstrom, 1986) confirmed the beneficial findings
of the first study.
Less successful results were reported by Bancroft et al (1987) from an
open study. Most of the 20 subjects received 600 meg of buserelin
intranasally in three divided daily doses starting in the early
follicular phase. Half the women stopped treatment after a mean of 7
weeks because of a worsening of their pretreatment symptoms or because
of side effects. Aggravation of both mental symptoms and swelling was
reported by some subjects during the early stages of treatment,
corresponding to the more prolonged ovarian stimulation seen with the
intranasal route of administration (section 5.1.2). Symptomatic
improvement increased with longer duration of therapy although
follicular activity was less well suppressed than with the depot and a
proportion of the women continued to menstruate irregularly without
ovulation. These anovular bleeds were preceded by recurrence of
physical symptoms although the mental symptoms lost their relationship
to menstruation. In keeping with the results of the present study,
these authors found return of symptoms to predate ovulation after
cessation of therapy.
It was interesting that four of the subjects in the present study
(section 6.2.3; figures 6.7b & 6.8) experienced a worsening of
symptoms of anxiety and/or depression early on during treatment
although this problem lessened with duration of therapy in the three
who continued the study. All four had reported cyclical mood changes
prior to therapy although only one, the one who subsequently withdrew,
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had this as her presenting problem. In all four, the problem started
after oestrogen levels were suppressed. In other words, it was not
related to any initial ovarian stimulation and appears to have been
triggered by oestrogen withdrawal. This might support the theory that
oestrogen withdrawal is involved as an initiating factor in some cases
of emotional disturbance occuring during the the menopause (Coppen &
Wood, 1978) and in the early puerperium (Nott et al, 1976). In an
extensive review, Greene (1984) concluded that depression during the
menopause is a consequence of increased vulnerability to minor life
events and is not relieved by oestrogen therapy. Sherwin & Gelfand
(1985) studied women randomised to treatment with hormone replacement
therapy or with placebo following oophorectomy. The surgical
menopause is comparable to initiation of Zoladex therapy because
hormone withdrawal is abrupt, unlike the gradual changes of the
natural menopause. They found greater adverse psychological symptoms
and reduced well-being among those given a placebo. Their results
however indicated that androgen withdrawal contributed more to loss of
well-being than did withdrawal of oestrogen alone.
The sudden withdrawal of placental steroids following childbirth (West
& McNeilly, 1979) is another clear-cut endocrine event. Increased
emotional lability is common in the early days of the puerperium
(Pitt, 1973; Kendell et al, 1981), the so-called postnatal 'blues'.
In a study, based on daily visual analogue scale recordings for the
first 21 days after childbirth (Kendell et al, 1984), we found a
significant association between the fifth day blues and neuroticism,
measured antenatally by the Eysenck Personality Questionnaire. This
complex interaction between environmental factors, personality and
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endocrine change is similar to that which may operate both
premenstrually and during the natural menopause. Oestrogen
suppression by LHRH agonists offers an interesting model for the study
of the effect of oestrogen withdrawal on mood as it is dissociated
from the emotional and psychosocial components of childbirth or the
menopause.
Adverse physical effects of oestrogen withdrawal in the form of hot
flushes were experienced by the majority of the women treated with
Zoladex depot (section 5.3.6) and their reported severity was
associated with the degree of oestrogen suppression. It is possible
that their severity and the associated sleep disturbance may have
triggered or aggravated other mental symptoms such as irritability and
depression (Campbell & Whitehead, 1977) although none of the subjects
reported awareness of such a relationship. In practice however they
will limit the acceptability of therapy. Vaginal dryness, although
much less frequent was another consequence of ovarian suppression in
some subjects. The influence of ovarian steroids on other aspects of
human sexuality is still unclear. A direct relationship is in doubt
(Utian, 1975; Campbell & Whitehead, 1977; Dow et al, 1983) and only
one of this group of women reported reduced libido. She differed from
the others in being in the early stages of a new relationship.
Patient compliance during the study was extremely good and only two
out of 13 women with cyclical symptoms failed to fully complete the
daily assessment charts. This compares very favourably with the
progestogen study (section 4.3.1) where non-compliance was much higher
as was the drop-out rate from therapy. This may reflect the nature of
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the therapy, the frequency of follow-up or patient selection. In
particular, the group being treated for uterine fibroids may have been
particularly motivated to continue therapy in order to avoid
hysterectomy. The use of the simpler daily charts may have reduced
the sensitivity of symptom recording (see section 2.6.4) and had
disadvantages in terms of statistical analysis because of the need to
use non-parametric methods (section 1.10.2). However they had the
advantage of simplicity in comparison with the visual analogue scales
which may not have been completed so consistently over the nine month
period of the study.
The future role of LHRH analogues in the management of women with
severe cyclical problems has yet to be defined. As discussed in
section 5.4, more information is required about their long-term
effects before their therapeutic use can be widely advocated in young
premenopausal women. However these results indicate ways in which
LHRH agonists can be used in the investigation and research into this
difficult clinical problem. The observation that menstrual cycle
related symptoms persist in some individuals after ovarian suppression
confirms the importance of other factors in their aetiology. It
illustrates a potentially useful role of LHRH agonists in establishing
the association between such symptoms and ovarian activity in women
who present difficulties in assessment or management. In particular,
LHRH agonists might be used to predict the likely success of ovarian
suppression as an approach to therapy. LHRH depots may also be used
in conjunction with various doses of exogenous oestrogen and
progestogens to study the effect of the latter on mood and physical
state. This would go a long way towards clarifying the role of
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ovarian steroids in the aetiology of cycle-related symptoms, where the
literature is still very confused (see chapter 3). Combined therapy
is also a therapeutic possibility in women with cyclical symptoms or
indeed those with other menstrual problems. Inhibition of endogenous
pituitary-ovarian activity by LHRH agonist depots could be accompanied
by low dose 'hormone replacement therapy' which would prevent the
symptoms and consequences of prolonged oestrogen suppression while
avoiding the possible metabolic consequences of the larger doses of
exogenous ovarian steroids required for inhibition of ovulation (see
section 4.4).
6.5 - Conclusions
This preliminary investigation of the effect of the LHRH agonist depot
goserelin (Zoladex), has demonstrated its effectiveness in ovarian
suppression. Abolishing the menstrual cycle substantially improves
cyclical symptoms, in particular physical symptoms but the effect on
mental symptoms is less predictable and the benefits are rapidly
reversed after cessation of therapy. The presence of symptomatic
episodes in some of the women studied, in the absence of alterations
in ovarian activity, confirms doubts about the precise relationship
between mood and the menstrual cycle. However the results also
demonstrate that endocrine changes can trigger symptoms in individuals
so predisposed. Although the use of these agonists as a long term
therapy for premenstrual problems remains to be established, there are
clearly a number of areas in which their use will facilitate clinical
management and act as a useful research tool.
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CHAPTER 7
THE ROLE OF ENDOGENOUS OPIOID PEPTIDES IN MENSTRUAL CYCLE
SYMPTOMATOLOGY - INVESTIGATION OF THE EFFECT OF AN ORAL OPIATE
ANTAGONIST
7.1 - Introduction
7.1.1.- Endogenous opioid peptides and neuroendocrine control
Opiate alkaloids such as morphine are known to have a wide range of
actions in addition to analgesia (Jaffe & Martin, 1980), including an
inhibitory effect on ovulation (Packman & Rothchild, 1976).
Investigation of these actions and the evidence for the presence of
specific opiate receptors has led to the identification of a group of
endogenous opioid peptides (EOP) which are present within the central
nervous system and in certain peripheral sites such as the
gastrointestinal tract (see reviews by Grossman, 1983; Cicero, 1986).
They include the enkephalins, which are thought to act as
neurotransmitters, the dynorphins and the endorphins. The most potent
of the latter group is beta-endorphin which appears to be located
predominantly in the arcuate nucleus of the hypothalamus and thus is
likely to be involved in the control of secretion of the hypothalamic
releasing factors (see section 1.2.2).
Much of our current knowledge about EOPs has been obtained from animal
studies (Cicero, 1986). Two main approaches have been used in human
subjects, one involving the study of the effects of administration of
opioids, the other by the use of specific opiate antagonists, in
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particular naloxone. There is currently evidence for an inhibitory
effect of opioids on release of ACTH and gonadotrophins with possible
stimulatory effects on TSH, growth hormone and, in particular,
prolactin (Stubbs, 1978; Reid et al, 1981), the latter by inhibition
of dopaminergic pathways. Control appears to be at the hypothalamic
level and to involve several different receptor types (Grossman,
1983), characterised by differences in sensitivity to antagonism by
naloxone. Thus high doses of naloxone are required to overcome the
inhibitory effect on ACTH while small doses will cause an elevation of
basal LH (Grossman et al, 1986). Plasma prolactin concentration was
not altered by naloxone administration (Martin et al, 1979).
7.1.2 - Opioid peptides and the menstrual cycle
In women, studies of the effect of administration of naloxone during
different phases of the menstrual cycle have indicated that opioid
inhibition of gonadotrophin release is greatest during the late
follicular and luteal phases and minimal during the early follicular
phase (Quigley & Yen, 1980) as well as following the menopause (Reid
et al, 1983). Opiate antagonism is accompanied by an increase in the
frequency (Moult et al, 1981) and amplitude (Blankstein et al, 1981;
Ellingboe et al, 1982) of LH pulses. In postmenopausal women,
administration of oestrogen and/or progestogen is followed by a return
of the LH response to naloxone (Casper & Alopin-Rabilloutz, 1985;
Shoupe et al, 1985). It is thus possible that feedback of ovarian
steroids may, in part, act via opioid-mediated mechanisms although
opioids do not appear to be involved in the genesis of the LH surge
(Grossman et al, 1981). They may be involved in some disorders of the
hypothalamo-pituitary ovarian axis (Quigley et al, 1980; Blankstein et
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al, 1981). The opioid most likely to be involved in modulation of
LHRH release is thought to be beta-endorphin but it is currently
uncertain whether its effect is a direct one or whether it is exerted
via catecholamine neurotransmitters (Vane, 1987). In primates, direct
sampling of hypophyseal portal blood (Wehrenberg et al, 1982) has
confirmed a cyclical alteration in the level of beta-endorphin, which
is undetectable at menstruation and during the early follicular phase
of the cycle but high during the remainder of the cycle. It is
undetectable following oophorectomy but restored by hormone
replacement (Wardlaw et al, 1982).
The observation that EOP inhibition of LHRH is highest during the
luteal phase and falls prior to menstruation has led to speculation
that these peptides may be involved in premenstrual symptomatology
(Reid, 1983). Further evidence for a role in disorders of mood is
provided by a report of adverse symptoms provoked in healthy adult
males given large doses of naloxone, some of which were similar to
symptoms associated with premenstrual tension (Cohen et al, 1981).
One way of testing this theory would be by administration of an opiate
antagonist to symptomatic women in order to study the effects of
modification of the normal cyclical pattern of opioid inhibition and
its release. Use of an antagonist such as naloxone which needs to be
administered parenterally and has a very short half life has obvious
disadvantages because effective plasma concentrations can only be
maintained by intravenous infusion or by very frequent bolus
injections. The recent availability of an opiate antagonist which may
be administered orally made such a study feasible.
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7.1.3 - Nalmefene - an orally active opiate antagonist
Nalmefene is a new narcotic antagonist structurally similar to
naloxone and naltrexone but with greater potency and a longer duration
of action. After oral administration peak plasma concentrations are
seen after one and a half hours and its plasma half life is ten hours.
Preliminary animal studies showed no evidence that tolerance developed
over a seven day period and a lack of toxicity. Unpublished data
(Nalmefene - Information for Physicians, 1984) from healthy male
volunteers showed the drug to be well tolerated at oral doses of up to
100 mg with no evidence of any agonist actions. Obese
hyperinsulinaemic women have been shown to have elevation of EOP
levels (Givens et al, 1980). In a pilot study, five such women were
treated with an oral dose of 20 mg nalmefene twice daily for five days
with reduction in both fasting insulin concentrations and the insulin
response to an oral glucose load, when compared with placebo therapy.
Circulating concentrations of gonadotropins, prolactin, Cortisol,
growth hormone, androgens and urinary catecholamine outputs were
apparently unchanged (Nalmefene - Information for Physicians, 1984).
However mild side effects of fatigue, dizziness and nausea were
reported by all five subjects on the active therapy which was
interpreted as being confirmatory of elevated levels of EOP in this
group of women.
7.1.4 - Aims and objectives of the current study
The hypothesis to be tested was that premenstrual symptoms involve
excessive endogenous opioid activity during the early to mid luteal
phase of the cycle followed by withdrawal in the late luteal phase
(Reid, 1983). If so, then blockade of opiate receptors by a specific
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antagonist throughout the luteal phase of the cycle may modify these
symptoms. An initial pilot study was planned in which therapy would
be commenced in the early luteal phase and continue until the onset of
menstruation using an initial dosage of 10 mg nalmefene twice daily
(the dose recommended for clinical trials), with the option of
altering the dose or the duration of therapy depending on the clinical
effects. As an additional assessment of opiate inhibition, the effect
of therapy on LH pulse frequency during the mid luteal phase would be
measured in all the subjects. A maximum of six subjects would be
studied initially. To act as a control, placebo tablets would be
administered for 10 days prior to the introduction of the active
therapy. Ethical committee approval for this pilot study was
obtained.
7.2 - SUBJECTS AND METHODS
7.2.1 - Subjects
The subjects were recruited from those presenting with premenstrual
problems (see section 2.2.1, who had already completed two months
preliminary assessment. Only those who showed symptom relief of 50%
or more postmenstrually were considered suitable for the study. All
were in good physical health, none had a history of current or past
psychiatric treatment and none were receiving any chronic medication
prior to or during the study, with the exception of occasional simple
analgesia in one case for a back problem. All were using non-hormonal
methods of contraception. The nature and purpose of the study was
explained to all the subjects and written consent obtained.
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7.2.2 - Therapy
Therapy was administered over two consecutive menstrual cycles.
According to the initial protocol, placebo tablets were started on day
7 of the cycle and continued twice daily for 10 days when (day 17)
nalmefene 10 mg twice daily was commenced for 12 days. This was
repeated during the second treatment cycle. As described in the
results section, severe effects attributed to opiate withdrawal were
experienced by the three subjects initially recruited to the study.
The regime was therefore modified so that active treatment was
commenced on day 8 of the cycle when endogenous opioid activity should
be less marked (see section 7.1.2), testing the effect both of a
reduced daily dosage (5 mg twice daily) or a more gradual introduction
of active therapy over three days, building up to a dose of 10 mg bd.
Placebo tablets were taken between days 1 and 7 of the cycle
inclusively.
7.2.3 - Assessment of response
Daily self-assessment of mood and physical symptoms was by means of
the visual analogue scales described in earlier sections of this
thesis (1.10.1 and 2.2.2). All the subjects also completed these
charts for at least two pretreatment assessment cycles prior to their
inclusion in the study. The data was analysed descriptively by
plotting out individual symptom profiles for each subject and also by
comparison of the mean mental and physical symptom scores for the
different cycle phases in individual subjects before and during
therapy. A mean of the scores for tension, irritability and
depression was calculated for the mental symptoms and of breast
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tenderness and swelling for the physical symptoms. Lethargy was
excluded because of its prominence as a side effect of therapy (see
below). The postmenstrual phase was taken from days 6-12 inclusive,
'midcycle' from days 13-20, premenstrual from days 21-28 and menstrual
from days 1-5 inclusive.
7.2.4 - Endocrine measurements
The subjects were asked to collect twice weekly early morning samples
of urine for measurement of oestrone glucuronide and pregnanediol as
described in section 5.2.7, both metabolites being expressed as the
steroid:creatinine ratio. In addition, the effect of therapy on
pulsatile LH secretion was assessed by sampling peripheral venous
blood via an in-dwelling cannula every 15 minutes over four to six
hours during the mid-luteal phase of the pretreatment and the initial
treatment cycle. LH was measured by double antibody radioimmunoassay
as described in section 5.2.7. A pulse was defined as occurring when
the hormone concentration of two consecutive samples was greater than
that of the mean of the two previous samples, providing that the value
of at least one of the peak samples exceeded the mean of the two basal
samples by more than twice the coefficient of variation of the assay
(Baird et al, 1977).
7.3 - RESULTS
7.3.1 - Compliance
Three subjects were initially recruited to the study, commencing










































































All experienced adverse effects on the day of onset of active
treatment (see below and table 7.2) and only one of the three
completed two treatment cycles, one withdrawing during the initial
treatment cycle and one during cycle 2. The protocol was thus altered
as above with initiation of placebo therapy on day 1 of the cycle
and active therapy on day 8. One subject taking the reduced dose of
nalmefene (5 mg bd) completed the study. The other withdrew because
of adverse effects experienced after the onset of active therapy.
Details of the subjects who entered the study, together with the
severity of their premenstrual mental symptoms and the degree of
postmenstrual mood relief, based on two control cycles, are given in
table 7.1, which also shows the dose and duration of placebo and
active therapy.
7.3.2 - Adverse effects of therapy
All the subjects documented side effects of treatment in the space
provided at the bottom of the visual analogue scale charts. All five
experienced adverse symptoms at or soon after the onset of active
therapy, leading to withdrawal from the study in three of the five as
above. Full details of these effects and their timing are given in
table 7.2. All three who commenced active therapy on day 17 of the
cycle reported the sudden onset of adverse effects very soon after the
first tablet had been taken. In the other two, onset of adverse
effects was apparently less sudden, particularly in subject 5 where
active therapy was introduced gradually over 3 days (days 8-10. Only
one woman (subject 4) recorded any adverse effects while on placebo
tablets, in this case headaches. Dizziness, lightheadedness and
weakness were the symptoms most frequently reported, with nausea,
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TABLE 7.2
SIDE EFFECTS OF NALMEFENE AND PLACEBO
Subject Cycle Day of Symptoms Comments
& cycle day of therapy
onset (active)
1.1 17 10 (1) Dizziness, weakness, lasted 5
blurred vision days
12 (3) nausea, lethargy,
thirst
1.2 17 10 (1) Lightheadedness, lasted 6
nausea, weakness days






















8 (1) Thirst lasted 7


















thirst and mental symptoms also documented. These effects were least
marked in subject 4 who took the reduced dosage of nalmefene.
7.3.3 - Effect on cyclical mental and physical symptoms
The effect of therapy on individual symptoms assessed by daily visual
analogue scales is shown in figures 7.1 and 7.2. In subjects 1
(figure 7.1a) and 2 (figure 7.2a), it is apparent that mental symptoms
of irritability and tension reached a peak in the early luteal phase
of treated cycles, corresponding to the onset of active therapy, with
improvement in the late luteal phase. Similarly, onset of active
therapy in the follicular phase in subject 5 (figure 7.2b) was
accompanied by a peak of tension which resolved once therapy was
discontinued but a premenstrual build up of symptoms occurred later in
the cycle. However subject 4 (figure 7.1b) recorded an apparent
improvement in her normal cyclical pattern of irritability in
treatment cycle 1 which was not sustained during cycle 2.
In figure 7.3, the effect of therapy on both mental and physical
symptoms by cycle phase in individual subjects is illustrated. Loss
of the normal cyclical pattern of mental symptoms was seen in subjects
1 and 2, who started active therapy on day 17, with maximal intensity
between days 13-20. In subject 4, where a lower dose of nalmefene was
started in the follicular phase, the cyclical pattern of both mental
and physical symptoms appears to have been maintained, with reduced
symptom intensity. The peak of mental symptoms at the onset of
















































































































































































































Mean mental and physical symptom scores in each cycle phase before and
during nalmefene therapy in subjects 1 & 2 who commenced active
therapy on day 17 and subjects 4 & 5 who commenced active therapy on
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7.3.4 - Effect on urinary ovarian steroid excretion and LH
pulsatilitv
As seen in figures 7.1 and 7.2, nalmefene therapy produced no
consistent alteration of urinary ovarian steroid excretion although
only the initial treatment cycles were monitored. All treated cycles
were of normal length and no breakthrough bleeding occurred. There
was no apparent effect of therapy on LH pulse frequency or amplitude
(figure 7.4) in the three subjects who continued therapy for long
enough to enable the sampling to be completed.
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Figure 7.4
Luteal phase plasma LH concentrations (15 min samples) in a control
cycle and during treatment with nalmefene lOmg bd (subjects 1 & 2) and
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The numbers of subjects treated with nalmefene in this small pilot
study were too few to permit any meaningful conclusions about the role
of opiate antagonists in the management of premenstrual tension.
However some consistent findings are apparent and are worthy of
discussion. All the subjects given nalmefene 10 mg bd experienced
unpleasant symptoms very soon after the onset of active therapy, with
some of the symptoms resembling those experienced premenstrually and
accompanied by others classically associated with opiate withdrawal
(Jaffe, 1980). Such effects were unexpected with the doses of
nalmefene selected and may support the theory that endogenous opioids
are involved in the aetiology of premenstrual mental changes. No
associated physical changes of swelling or breast discomfort were
evoked, supporting a different mechanism for the latter. In view of
the limited experience of the use of nalmefene it is not possible to
exclude a dose-related opioid withdrawal effect similar to that
reported in normal male volunteers given very large (2-4 mg/kg)
intravenous doses of naloxone (Cohen et al, 1981). For reversal of
the effects of exogenous opiates, an intravenous dose of around 0.05
mg/kg of naloxone is normally used and at these doses effects on mood
have not been observed (Grevert & Goldstein, 1978). Compared with
naloxone, nalmefene appears to have approximately 5-fold greater
potency. The oral equivalent of nalmefene for opiate reversal would
appear to be around 0.25 mg/kg. However male volunteers given much
larger doses in preliminary studies (section 7.1.3) tolerated five¬
fold higher doses that those used in the present study before effects
attributable to opioid withdrawal became apparent. In one small
study of the use of nalmefene in dementia, one out of five women
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experienced side effects of nausea, headaches and dysphoria at a
dosage of 10 mg twice daily (Weiss, 1987) but none apparently suffered
the severe symptoms reported by the subjects in the present study.
Opioid-withdrawal effects were rapid in onset and severe in the three
women who commenced therapy in the luteal phase when the inhibitory
effects of endogenous opioids on hypothalamic release of LHRH are
presumed to be greatest (see section 7.1.2). When therapy was
continued until the end of the cycle, subsequent 'premenstrual'
symptoms appeared to be improved possibly suggesting that the opiate
antagonist had shifted an opioid withdrawal phase to an earlier stage
in the cycle. However further placebo-controlled studies would be
required to confirm this. Only two subjects in the current study had
therapy initiated during the follicular phase and effects became
severe by day 11. in subject 5, corresponding to the time when therapy
had reached full dosage. Milder and less specific symptoms were noted
at the same stage in subject 4 with a smaller daily dosage and here
the subsequent premenstrual build up of symptoms appears to have been
retained. It would be of interest to study the effect of initiating
therapy even earlier in the follicular phase when EOP inhibition has
been shown to be minimal (section 7.1.2). More information about the
effects of oral nalmefene in different phases of the menstrual cycle
is needed in normal women before reaching any firm conclusions from
the above results. However they do appear to support a role for
endogenous opioids in the aetiology of cyclical mood changes.
Two groups have studied concentrations of beta-endorphin in peripheral
plasma in premenstrual tension sufferers, in comparison with normal
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control subjects. Chuong et al (1985) sampled their subjects twice
during the menstrual cycle and found the symptomatic women to have
significantly lower concentrations on day 25 of the cycle, with no
difference between the groups on day 7. Faccinetti et al (1987) also
reported that circulating concentrations of beta-endorphin were
significantly lower 0-6 days prior to the onset of menstruation in
patients with premenstrual symptoms compared with asymptomatic
volunteers, with no differences during the remainder of the cycle.
Cyclical variations were not seen in the normal control group, unlike
results of direct hypophyseal blood sampling in primates (Wehrenberg
et al, 1982) and a study of daily peripheral venous blood samples in
normal women (Vrbicky et al, 1982). Shoupe et al (1985) found
peripheral levels of beta-endorphin to be a poor indicator of central
opioid activity and thus only limited conclusions may be drawn from
the above studies. Perhaps of more significance is the finding of
Faccinetti et al (1987) that the LH response to a 4 mg IV bolus of
naloxone was significantly lower during the late luteal phase in the
patients than in the controls, while the response during the mid
luteal phase was similar in both groups. They concluded that adverse
premenstrual symptoms are a consequence of opioid withdrawal during
the late luteal phase of the cycle. This would be compatible with the
pattern of symptoms identified in the subjects described in chapter 2.
However they do not confirm the hypothesis that abnormally high opioid
activity is present earlier in the cycle. Neither this report or that
of Reid et al (1986) in which a naloxone infusion was given to women
with premenstrual symptoms associated with 1hypoglycaemia', mentioned
any adverse side effects provoked by naloxone but doses used were
relatively low.
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Nalmefene in the doses and regimens used above produced no obvious
alteration of cycle length or ovarian function although more detailed
endocrine monitoring would be required to confirm this observation.
In addition, there was no effect on the pulsatile release of LH, even
when this was tested in the early luteal phase. As described above
(section 7.1.2,) single intravenous doses or infusions of naloxone
cause a prompt increase in the frequency and amplitude of LH pulses
during the luteal phase of the cycle in healthy volunteer subjects.
The lack of such an effect with chronic oral therapy may reflect the
development of tolerance to the opiate antagonist, as demonstrated by
Owens & Cicero (1981) in rats given repeated injections of naloxone.
This could be clarified by studies of LH pulse frequency and amplitude
before and after single oral doses of nalmefene.
If opioids are involved in the aetiology of premenstrual
symptomatology, it is not clear why tissue concentrations should
differ from those of asymptomatic women. They may be affected by
ovarian steroid feedback (see section 7.1.2) but it is more likely
that any small differences in circulating steroids which may be
present in symptomatic women (section 3.2) are a consequence rather
than a cause of abnormalities in the central control of the cycle. An
attractive hypothesis would be that the entire syndrome is stress-
related and that symptomatic women experience differences in their
response to either normal or abnormal levels of environmental stress
during the premenstrual phase of the cycle. Endogenous opioids are
known to inhibit the response to certain well defined stressful
stimuli, for example the catecholamine response to insulin induced
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hypoglycaemia (Bouloux et al, 1985a) and the cold pressor test
(Bouloux et al, 1985b). Similarly, opioid antagonists have been used
in states of severe shock to assist resuscitation by removing opioid
mediated inhibition of the stress response (Faden, 1984) and have been
shown to enhance adrenal medullary catecholamine release (Critchley et
al, 1988). It is much more difficult to objectively study responses
to mental stress because of difficulties in defining or quantifying
such stresses. Symptoms of anxiety are, in part, attributed to
increased activity of the sympathetic nervous system, both
peripherally and centrally. Thus, in states of chronic emotional
stress opioids may modulate the activity of the sympathetic nervous
system. The degree of inhibition may vary with menstrual cycle phase,
cyclical opiate withdrawal resulting in rebound hyperactivity of
adrenergic neurones (Llorens et al, 1978). It has been suggested that
many of the symptoms of opiate withdrawal are due to hyperactivity in
the locus coeruleus, a noradrenergic centre in the midbrain. It is
involved in feelings of alarm, fear and anxiety (see Jaffe, 1980) and
is considered to be inhibited by alpha-adrenergic neurones and
endogenous opioids (Gold et al, 1978). It is also postulated that
this centre, which has hypothalamic connections via noradrenergic
neurones, is involved in the genesis of the LH surge (see Reichlin,
1985), which may explain the inhibitory effect of opiates and
emotional stress on ovulation.
There is evidence that noradrenergic activity varies with menstrual
cycle phase in normal women. A study based on daily sampling of
volunteers showed venous plasma and urinary noradrenaline
concentrations to be significantly higher during the luteal phase of
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the cycle, compared with the follicular phase, concentrations
increasing prior to ovulation and reaching a peak in the mid to late
luteal phase (Goldstein et al, 1983). Premenstrual symptoms may be
attributable to the balance between the activity of the sympathetic
nervous system and the degree of endogenous opioid inhibition (see
above). To date, no studies of catecholamine concentrations in
premenstrual tension sufferers have been reported although studies
based on peripheral venous catecholamine estimations must be
interpreted with caution because of rapid reuptake of plasma
catecholamines by the tissues (Critchley & West, 1977).
The above theory most readily explains the adverse symptoms in those
women whose premenstrual and menstrual problems represent an
exacerbation of symptoms present throughout the cycle and where
environmental and personal stress factors can frequently be identified
(see chapter 2). A similar mechanism may exist in women with
premenstrual exacerbation of an underlying depression. There is
believed to be an abnormality of catecholamine activity in depressive
states (Rose, 1985) although the exact mechanisms involved have not
been clarified. In addition, some patients with endogenous depression
show elevation of circulating ACTH, Cortisol and CSF Cortisol with
impaired Cortisol response to dexamethasone suppression, reflecting
lack of inhibition of the hypothalamo-pituitary-adrenal axis (Carroll
et al, 1976; Rubin et al, 1987). Opioids are known to have an
inhibitory effect on the HPA axis (Grossman et al, 1982; Taylor et al,
1983) in addition to their modulating effect on adrenergic systems.
While the role of endogenous opioids in the aetiology of chronic
depressive states has not been clarified, it is possible that changing
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activity in opioid-mediated pathways is involved in the aetiology of
menstrual cycle related depressive symptoms.
The above theory must remain purely speculative and does not offer
such a plausible explanation for those in whom stress factors are not
apparent. Such women may be excessively sensitive to the normal
fluctuations in endogenous opioid peptides which occur during the
menstrual cycle. This might explain the sensitivity of the subjects
in the present study to relatively small doses of nalmefene. It is
evident that the factors which influence central control of the
menstrual cycle are highly complex but the link between the menstrual
cycle and mood is more readily explained by consideration of these
mechanisms than by simple study of peripheral ovarian steroid
concentrations or excretion. However, the methodological difficulties
involved in clarifying these central mechanisms are considerable.
In summary, all five women in this pilot study developed marked
adverse effects on commencement of therapy with an oral opiate
antagonist at doses well below those tolerated without ill effect by
healthy volunteers. These effects are attributable to opiate
withdrawal and suggest that these women either had abnormally high
endogenous opioid peptide activity or increased sensitivity to the
normal fluctuations in activity. In the women who continued therapy,
the usual premenstrual peak of adverse mood symptoms was reduced.
These findings give indirect support for an involvement, of endogenous
opioid peptides in the aetiology of menstrual cycle related disorders
of mood. No alteration in LH pulse frequency and amplitude during
chronic oral administration of the opiate antagonist was detected, in
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contrast with the results of acute intravenous administration,
presumably reflecting the development of tolerance to the effects of
the antagonist.
Because of organisational changes in the pharmaceutical company
supporting the above pilot study, it was not continued beyond the
initial stages described here. Further investigations of opiate
antagonists in women with premenstrual problems and in healthy
control subjects appear to be justified along the lines discussed
above although additional caution in terms of dose and duration of
therapy will be required in view of the adverse effects encountered.
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